<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">FEMS Microbiol Rev</journal-id><journal-id journal-id-type="iso-abbrev">FEMS Microbiol. Rev</journal-id><journal-id journal-id-type="pmc-domain-id">2714</journal-id><journal-id journal-id-type="pmc-domain">femsmr</journal-id><journal-id journal-id-type="publisher-id">femsre</journal-id><journal-title-group><journal-title>FEMS Microbiology Reviews</journal-title></journal-title-group><issn pub-type="ppub">0168-6445</issn><issn pub-type="epub">1574-6976</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5995208</article-id><article-id pub-id-type="pmcid-ver">PMC5995208.1</article-id><article-id pub-id-type="pmcaid">5995208</article-id><article-id pub-id-type="pmcaiid">5995208</article-id><article-id pub-id-type="pmid">29547971</article-id><article-id pub-id-type="doi">10.1093/femsre/fuy011</article-id><article-id pub-id-type="publisher-id">fuy011</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Potential targets for next generation antimicrobial glycoconjugate vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Micoli</surname><given-names initials="F">Francesca</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Costantino</surname><given-names initials="P">Paolo</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Adamo</surname><given-names initials="R">Roberto</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label>GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena</aff><aff id="aff2"><label>2</label>GSK, Via Fiorentina 1, 53100 Siena</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> GSK, Research Centre, Via Fiorentina 1 bldg. 10, 53100, Siena, Italy. Tel: +39 0577539393; E-mail: <email>roberto.x.adamo@gsk.com</email></corresp></author-notes><pub-date pub-type="epub" iso-8601-date="2018-03-14"><day>14</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2018</year></pub-date><volume>42</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">314973</issue-id><fpage>388</fpage><lpage>423</lpage><history><date date-type="accepted"><day>13</day><month>3</month><year>2018</year></date><date date-type="received"><day>14</day><month>12</month><year>2017</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>03</month><year>2018</year></date></event><event event-type="pmc-live"><date><day>15</day><month>06</month><year>2018</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-17 23:25:17.423"><day>17</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; FEMS 2018.</copyright-statement><copyright-year>2018</copyright-year><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fuy011.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fuy011.pdf"/><abstract><title>Abstract</title><p>Cell surface carbohydrates have been proven optimal targets for vaccine development. Conjugation of polysaccharides to a carrier protein triggers a T-cell-dependent immune response to the glycan moiety. Licensed glycoconjugate vaccines are produced by chemical conjugation of capsular polysaccharides to prevent meningitis caused by meningococcus, pneumococcus and <italic toggle="yes">Haemophilus influenzae</italic> type b. However, other classes of carbohydrates (O-antigens, exopolysaccharides, wall/teichoic acids) represent attractive targets for developing vaccines. Recent analysis from WHO/CHO underpins alarming concern toward antibiotic-resistant bacteria, such as the so called ESKAPE pathogens (<italic toggle="yes">Enterococcus faecium</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Acinetobacter baumannii</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Enterobacter</italic> spp.) and additional pathogens such as <italic toggle="yes">Clostridium difficile</italic> and Group A <italic toggle="yes">Streptococcus</italic>. Fungal infections are also becoming increasingly invasive for immunocompromised patients or hospitalized individuals. Other emergencies could derive from bacteria which spread during environmental calamities (<italic toggle="yes">Vibrio cholerae</italic>) or with potential as bioterrorism weapons (<italic toggle="yes">Burkholderia pseudomallei</italic> and <italic toggle="yes">mallei</italic>, <italic toggle="yes">Francisella tularensis</italic>). Vaccination could aid reducing the use of broad-spectrum antibiotics and provide protection by herd immunity also to individuals who are not vaccinated.</p><p>This review analyzes structural and functional differences of the polysaccharides exposed on the surface of emerging pathogenic bacteria, combined with medical need and technological feasibility of corresponding glycoconjugate vaccines.</p></abstract><abstract abstract-type="teaser"><p>This review is intended to analyze structural and functional differences of surface-exposed polysaccharides from emerging pathogenic bacteria and, combined with epidemiological, medical need and technological considerations, identify potential targets for glycoconjugate vaccines in the near future. How advances in the field of glycoconjugate vaccine production (conjugation of natural polysaccharides, chemo-enzymatic approaches, glycoengineering) can support the development of efficacious novel well-defined vaccines is also discussed.</p></abstract><kwd-group kwd-group-type="keywords"><kwd>carbohydrates</kwd><kwd>glycoconjugates</kwd><kwd>vaccines</kwd><kwd>glycoengineering</kwd><kwd>antimicrobial resistance</kwd></kwd-group><counts><page-count count="36"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>INTRODUCTION</title><p>Surface carbohydrates, particularly capsular polysaccharides (CPS), have been proven optimal targets for bacterial vaccines development. Polysaccharide-based vaccines against meningococcus, pneumococcus and <italic toggle="yes">Haemophilus influenzae</italic> type b were licensed between the 1970s and the early 1980s. Due to their T-cell independent character, they are efficacious in adults, but fail to elicit adequate protection in high-risk groups, such as infants and children under 2 years of age (Peltola <italic toggle="yes">et&#160;al.</italic><xref rid="bib281" ref-type="bibr">1977a</xref>,<xref rid="bib282" ref-type="bibr">b</xref>).</p><p>This limitation of polysaccharide vaccines can be overcome by conjugation to a carrier protein, which triggers a T-cell-dependent immune response to the carbohydrate moiety (Costantino, Rappuoli and Berti <xref rid="bib69" ref-type="bibr">2011</xref>) and assures efficacious vaccination of children and elderly.</p><p>Glycoconjugate vaccines have been used to control a variety of bacterial infections in recent years, and more vaccines are either under development at preclinical level or in clinical trials (Costantino, Rappuoli and Berti <xref rid="bib69" ref-type="bibr">2011</xref>).</p><p>The glycoconjugate vaccines licensed so far are obtained from CPS or derived fragments (Table&#160;<xref ref-type="table" rid="tbl1">1</xref>). However, pathogenic bacteria also display other classes of carbohydrates that might represent good candidates for vaccine development, especially when the pathogen does not produce a capsule (e.g. most of the <italic toggle="yes">Shigella</italic> species or <italic toggle="yes">Vibrio cholerae</italic>) or the capsule mimics self-structures (e.g. &#945;-(2&#8594;8) polysialic acid capsule of <italic toggle="yes">Neisseria meningitidis</italic> serogroup B, and the polyhyaluronic acid capsule of Group A <italic toggle="yes">Streptococcus</italic>) or the pathogen has a high number of strains with different CPS, making vaccine formulation development very complicated.</p><table-wrap id="tbl1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Examples of glycoconjugate vaccines in the market or in development.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Type of glycan</th><th align="left" rowspan="1" colspan="1">Organism (WHO/CDC category of AMR top T high H medium M)</th><th align="left" rowspan="1" colspan="1">Manufacturer (licensed :L) (clinical:C) (discovery: D)</th><th align="left" rowspan="1" colspan="1">Saccharide</th><th align="left" rowspan="1" colspan="1">Approach<xref ref-type="table-fn" rid="tb1fn1"><sup>a</sup></xref></th><th align="left" rowspan="1" colspan="1">Carrier</th><th align="left" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Hib (M)</td><td rowspan="1" colspan="1">GSK (L)</td><td rowspan="1" colspan="1">PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">CDC (<xref rid="bib48" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Sanofi (L)</td><td rowspan="1" colspan="1">PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Zou and Jennings (<xref rid="bib413" ref-type="bibr">2009</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GSK (L)</td><td rowspan="1" colspan="1">Oligo</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Costantino, Rappuoli and Berti (<xref rid="bib69" ref-type="bibr">2011</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Merck (L)</td><td rowspan="1" colspan="1">Size reduced PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">OMPC</td><td rowspan="1" colspan="1">Marburg <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib244" ref-type="bibr">1986</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Pfizer(L)</td><td rowspan="1" colspan="1">Oligo</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Anderson <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib11" ref-type="bibr">1986</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">SIIL (L)</td><td rowspan="1" colspan="1">PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Sharma <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib333" ref-type="bibr">2012</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">CIGB (L)</td><td rowspan="1" colspan="1">Oligo</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Verez-Bencomo <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib372" ref-type="bibr">2004</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Hilleman Lab (D)</td><td rowspan="1" colspan="1">Size reduced PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Laferriere <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib205" ref-type="bibr">2011</xref>; Rana <italic toggle="yes">et&#160;al.</italic><xref rid="bib297a" ref-type="bibr">2015</xref>; Schneerson <italic toggle="yes">et&#160;al.</italic><xref rid="bib324" ref-type="bibr">1980</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Bionet-Asia</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Hia</td><td rowspan="1" colspan="1">NRC Canada (D)</td><td rowspan="1" colspan="1">Size reduced PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub> and Protein D</td><td rowspan="1" colspan="1">Cox <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib71" ref-type="bibr">2017</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Meningococcus</td><td rowspan="1" colspan="1">GSK (L)</td><td rowspan="1" colspan="1">Oligo MenC</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Costantino, Rappuoli and Berti (<xref rid="bib69" ref-type="bibr">2011</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Pfizer (Nuron) (L)</td><td rowspan="1" colspan="1">MenC size reduced PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Ravenscroft, Wheeler and Jones (<xref rid="bib301" ref-type="bibr">2010</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Baxter (L)</td><td rowspan="1" colspan="1">MenC PS De-OAc Size reduced</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Ravenscroft, Wheeler and Jones (<xref rid="bib301" ref-type="bibr">2010</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Hilleman Lab (D)</td><td rowspan="1" colspan="1">MenX</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Harale <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib148" ref-type="bibr">2015</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">SIIL (L)</td><td rowspan="1" colspan="1">MenA Size reduced PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Ravenscroft, Wheeler and Jones (<xref rid="bib301" ref-type="bibr">2010</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GSK (D)</td><td rowspan="1" colspan="1">MenX Ps size reduced</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Fiebig <italic toggle="yes">et&#160;al.</italic> (2017); Micoli et al. (2013)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GSK (L)</td><td rowspan="1" colspan="1">MenACWY Oligos</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Broker <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib35" ref-type="bibr">2009</xref>)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Capsular polysaccharide</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Pfizer (L) formerly GSK</td><td rowspan="1" colspan="1">MenACWY size reduced PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Broker, Berti and Costantino (<xref rid="bib32" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Sanofi (L)</td><td rowspan="1" colspan="1">MenACWY size reduced PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">DT</td><td rowspan="1" colspan="1">Ravenscroft, Wheeler and Jones (<xref rid="bib301" ref-type="bibr">2010</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Sanofi (C)</td><td rowspan="1" colspan="1">MenACWY</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">McVernon <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib235" ref-type="bibr">2012</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">SIIL (C)</td><td rowspan="1" colspan="1">MenACWYX PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT, CRM<sub>197</sub></td><td rowspan="1" colspan="1">LaForce (<xref rid="bib206" ref-type="bibr">2017</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Pneumococcus (M/H)</td><td rowspan="1" colspan="1">Pfizer (L)</td><td rowspan="1" colspan="1">4, 6B, 9V, 14, 18C, 19F, 23F, PS except 18C size reduced</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Ravenscroft <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib299" ref-type="bibr">2015</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Pfizer (L)</td><td rowspan="1" colspan="1">1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F PS except 18C size reduced</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Ravenscroft <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib299" ref-type="bibr">2015</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GSK (L)</td><td rowspan="1" colspan="1">1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F PS except 23F size reduced</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">Protein D, TT(18C), DT (19F)</td><td rowspan="1" colspan="1">Dhillon and Pace (<xref rid="bib91" ref-type="bibr">2017</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Limmatech Biologics (D)</td><td rowspan="1" colspan="1">Multivalent</td><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">rEPA</td><td rowspan="1" colspan="1">Ravenscroft <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib300" ref-type="bibr">2017</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Merck (C)</td><td rowspan="1" colspan="1">15 valent</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">McFetridge <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib230" ref-type="bibr">2015</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">CIGB (C)</td><td rowspan="1" colspan="1">1, 5, 6B, 14, 18C, 19F, 23F</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Linares-Perez <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib218" ref-type="bibr">2017</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GBS (na/M)</td><td rowspan="1" colspan="1">GSK (C )</td><td rowspan="1" colspan="1">Ia, Ib, III PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Madhi <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib236" ref-type="bibr">2013</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GSK (D)</td><td rowspan="1" colspan="1">Ia, Ib, II, III, V PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Kobayashi <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib198" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Various (D or C)</td><td rowspan="1" colspan="1">Ia, Ib, II, III, IV, V, VI, VII and VIII Ps</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT and CRM<sub>197</sub></td><td rowspan="1" colspan="1">Heath (<xref rid="bib150" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Pfizer (C )</td><td rowspan="1" colspan="1">Multivalent</td><td rowspan="1" colspan="1">Platform developed for pneumo conjugates</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Kobayashi <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib198" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic> (H)</td><td rowspan="1" colspan="1">GSK (C)</td><td rowspan="1" colspan="1">Type 5 and 8 PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Levy <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib213" ref-type="bibr">2015</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Pfizer (C )</td><td rowspan="1" colspan="1">Type 5 and 8 PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Nissen <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib269" ref-type="bibr">2015</xref>); Frenck <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib119" ref-type="bibr">2017</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GlycoVaxyn ( now Limmatech Biologics) (D)</td><td rowspan="1" colspan="1">Type 5 and 8 PS</td><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">rEPA</td><td rowspan="1" colspan="1">Wacker <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib381" ref-type="bibr">2014</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Salmonella</italic> Typhi (H/M)</td><td rowspan="1" colspan="1">NIH (C), GVGH/Biological E (C), Biomed (L), Barath Biotech (L)</td><td rowspan="1" colspan="1">Vi PS and Fragments</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub>, TT, DT, rEPA</td><td rowspan="1" colspan="1">MacLennan, Martin and Micoli (<xref rid="bib234" ref-type="bibr">2014</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Burkholderia pseudomallei</italic>
</td><td rowspan="1" colspan="1">DSTL (D)</td><td rowspan="1" colspan="1">Oligo</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">TetHc</td><td rowspan="1" colspan="1">Scott <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib327" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Klebsiella pneumoniae</italic> (T/T)</td><td rowspan="1" colspan="1">Max Plank Institute (D)</td><td rowspan="1" colspan="1">CPS repeating unit</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Seeberger <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib329" ref-type="bibr">2017</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Shigella</italic> (M/H)</td><td rowspan="1" colspan="1">Limmatech Biologics (C )</td><td rowspan="1" colspan="1">
<italic toggle="yes">Sh. dysenteriae</italic> type 1 PS</td><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">rEPA</td><td rowspan="1" colspan="1">Hatz <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib149" ref-type="bibr">2015</xref>); Riddle <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib307" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Sh. flexneri</italic> 2a PS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">NICHHD (C )</td><td rowspan="1" colspan="1">
<italic toggle="yes">S. sonnei</italic> and <italic toggle="yes">Sh. flexneri</italic> 2a PS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">rEPA</td><td rowspan="1" colspan="1">Ashkenazi <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib14" ref-type="bibr">1999</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Institute Pasteur (C )</td><td rowspan="1" colspan="1">
<italic toggle="yes">Sh. flexneri</italic> 2a oligo</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">van der Put <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib365" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1">
<bold>O-Antigen</bold>
</td><td rowspan="1" colspan="1">
<italic toggle="yes">Escherichia coli</italic>
</td><td rowspan="1" colspan="1">Limmatech Biologics/J&amp;J (C)</td><td rowspan="1" colspan="1">O1, O2, O6, O25 Expec</td><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">rEPA</td><td rowspan="1" colspan="1">van den Dobbelsteen <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib364" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Salmonella</italic> Paratyphi A and non-typhoidal <italic toggle="yes">Salmonella</italic> (H/M)</td><td rowspan="1" colspan="1">NVGH (D), NIH (C ), IVI (D)</td><td rowspan="1" colspan="1">O2 <italic toggle="yes">S.</italic> Parathyphi A, O9 <italic toggle="yes">S.</italic> Enteritidis, O4,5 <italic toggle="yes">S.</italic> Typhimurium</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT, CRM<sub>197</sub>, DT</td><td rowspan="1" colspan="1">MacLennan, Martin and Micoli (<xref rid="bib234" ref-type="bibr">2014</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic> (T/H)</td><td rowspan="1" colspan="1">SSVI/WRAIR (C ) program stopped</td><td rowspan="1" colspan="1">O1,2,3,4,5,6,11,12</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">EPA</td><td rowspan="1" colspan="1">Cryz <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib74" ref-type="bibr">1987</xref>, <xref rid="bib76" ref-type="bibr">1989</xref>); Lang <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib207" ref-type="bibr">2004</xref>); Schaad <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib323" ref-type="bibr">1991</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Klebsiella pneumoniae</italic> (T/T)</td><td rowspan="1" colspan="1">University Maryland (D)</td><td rowspan="1" colspan="1">O1, O2a, O2a,c, O3, O4, O5, O7, O8, O12</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">PA flagellin</td><td rowspan="1" colspan="1">Simon, Cross and Tennant (<xref rid="bib338" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Vibrio cholerae</italic>
</td><td rowspan="1" colspan="1">NIH, Institut Pasteur (D)</td><td rowspan="1" colspan="1">O1 (Inaba and Ogawa), O139</td><td rowspan="1" colspan="1">SS; ST</td><td rowspan="1" colspan="1">BSA, rEPA, TThc</td><td rowspan="1" colspan="1">Gupta <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib143" ref-type="bibr">1998</xref>); Boutonnier <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib27" ref-type="bibr">2001</xref>); Chernyak <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib59" ref-type="bibr">2002</xref>); Wade <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib382" ref-type="bibr">2006</xref>); Rollenhagen <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib309" ref-type="bibr">2009</xref>); Alam <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib8" ref-type="bibr">2014</xref>); Sayeed <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib322" ref-type="bibr">2015</xref>); Soliman and Kovac (<xref rid="bib341" ref-type="bibr">2016</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Francisella tularensis</italic>
</td><td rowspan="1" colspan="1">CCRC-NRCC and DSTL (D)</td><td rowspan="1" colspan="1">O-Ag</td><td rowspan="1" colspan="1">ST; B</td><td rowspan="1" colspan="1">KLH; rEPA</td><td rowspan="1" colspan="1">Boltje <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib23" ref-type="bibr">2012</xref>); Cuccui <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib79" ref-type="bibr">2013</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Burkholderia pseudomallei</italic>
</td><td rowspan="1" colspan="1">Academic (D)</td><td rowspan="1" colspan="1">OPSII</td><td rowspan="1" colspan="1">B; ST</td><td rowspan="1" colspan="1">AcrA;</td><td rowspan="1" colspan="1">Garcia-Quintanilla <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib123" ref-type="bibr">2014</xref>); Kenfack <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib190" ref-type="bibr">2017</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Moraxella catarrhalis</italic>
</td><td rowspan="1" colspan="1">NRC Canada (D)</td><td rowspan="1" colspan="1">Truncated LPS</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Cox <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib70a" ref-type="bibr">2011</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">NDCD/NIH (D)</td><td rowspan="1" colspan="1">Detox LPS serotype A, B and C</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">TT, NTHi HMP, UspA, CD, CRM<sub>197</sub></td><td rowspan="1" colspan="1">Gu <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib135" ref-type="bibr">1998</xref>); Hu <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib165" ref-type="bibr">2004</xref>); Yu and Gu (<xref rid="bib408" ref-type="bibr">2005</xref>, <xref rid="bib409" ref-type="bibr">2007</xref>)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Teichoic</bold>
<bold>acids</bold>
</td><td rowspan="1" colspan="1">
<italic toggle="yes">Enterococcus faecalis</italic> (H/H)</td><td rowspan="1" colspan="1">UML/Leiden University (D)</td><td rowspan="1" colspan="1">LTA</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">BSA</td><td rowspan="1" colspan="1">Laverde <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib209" ref-type="bibr">2014</xref>)</td></tr><tr><td rowspan="1" colspan="1">
<bold>PNAG</bold>
</td><td rowspan="1" colspan="1">
<italic toggle="yes">Acinetobacter baumannii</italic> (T/H) and other pathogens</td><td rowspan="1" colspan="1">Harvard Medical School, Alopexx (D)</td><td rowspan="1" colspan="1">&#946;-(1&#8594;6)-oligo glucosamine</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Cywes-Bentley <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib82" ref-type="bibr">2013</xref>); Gening <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib82a" ref-type="bibr">2009</xref>)</td></tr><tr><td rowspan="1" colspan="1">
<bold>ExoPS</bold>
</td><td rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic> (T/H)</td><td rowspan="1" colspan="1">Harvard Medical School (C and D)</td><td rowspan="1" colspan="1">Polymannuronic acid; alginate</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">ExoA, Flagellin; TT, KLH, OMV, synthetic peptides</td><td rowspan="1" colspan="1">Campodonico <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib42" ref-type="bibr">2011</xref>); Doring and Pier (<xref rid="bib95" ref-type="bibr">2008</xref>); Farjah <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib105" ref-type="bibr">2015</xref>); Farjah <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib104" ref-type="bibr">2014</xref>); Kashef <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib189" ref-type="bibr">2006</xref>); Theilacker <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib352" ref-type="bibr">2003</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Clostridium difficile</italic>
</td><td rowspan="1" colspan="1">Guelph University, Max Planck Institute (D)</td><td rowspan="1" colspan="1">PS-I</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Broecker <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib30" ref-type="bibr">2016a</xref>); Martin <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib246" ref-type="bibr">2013b</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GSK, Guelph University, Max Planck Institute (D)</td><td rowspan="1" colspan="1">PS-II</td><td rowspan="1" colspan="1">ST; SS</td><td rowspan="1" colspan="1">CRM<sub>197</sub>, <italic toggle="yes">Clostridiumdifficile</italic> rToxins,</td><td rowspan="1" colspan="1">Adamo <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib4" ref-type="bibr">2012</xref>); Bertolo <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib19" ref-type="bibr">2012</xref>); Romano <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib310" ref-type="bibr">2014</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Max Planck Institute (D)</td><td rowspan="1" colspan="1">PS-III</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Broecker <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib31" ref-type="bibr">2016b</xref>); Cox <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib70" ref-type="bibr">2013</xref>); Martin <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib245" ref-type="bibr">2013a</xref>)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Cell Wall PS</bold>
</td><td rowspan="1" colspan="1">Group A Streptococcus (GAS) (M/M)</td><td rowspan="1" colspan="1">GSK (D)</td><td rowspan="1" colspan="1">GAC fragments</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Kabanova <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib184" ref-type="bibr">2010</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Rockefeller University</td><td rowspan="1" colspan="1">PS</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1">Sabharwal <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib316" ref-type="bibr">2006</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Various Academic Institutions (D)</td><td rowspan="1" colspan="1">GlcNAc deficient PS</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">Sp0435</td><td rowspan="1" colspan="1">van Sorge <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib366" ref-type="bibr">2014</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Aspergillus fumigatus</italic>
</td><td rowspan="1" colspan="1">Zelinsky Inst. Org. Chem./Institute Pasteur (D)</td><td rowspan="1" colspan="1">&#945;-(1&#8594;3)-glucans</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">BSA</td><td rowspan="1" colspan="1">Komarova <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib200" ref-type="bibr">2015</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Candida albicans</italic> (na/M)</td><td rowspan="1" colspan="1">GSK, CCRC (D)</td><td rowspan="1" colspan="1">&#946;-(1&#8594;3)/&#946;-(1&#8594;6)-glucans</td><td rowspan="1" colspan="1">SS; ST</td><td rowspan="1" colspan="1">CRM<sub>197</sub></td><td rowspan="1" colspan="1">Adamo <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib5" ref-type="bibr">2011</xref>, <xref rid="bib2" ref-type="bibr">2014</xref>); Bromuro <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib36" ref-type="bibr">2010</xref>); Liao <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib215" ref-type="bibr">2015</xref>, <xref rid="bib216" ref-type="bibr">2016</xref>); Torosantucci <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib358" ref-type="bibr">2005</xref>)</td></tr><tr><td rowspan="1" colspan="1">Fungal glycans</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Alberta University/ Theracarb/Novadigm (D)</td><td rowspan="1" colspan="1">&#946;-(1&#8594;2)-mannotriose</td><td rowspan="1" colspan="1">ST</td><td rowspan="1" colspan="1">TT, <italic toggle="yes">Candida</italic> peptides</td><td rowspan="1" colspan="1">Johnson and Bundle (<xref rid="bib180" ref-type="bibr">2013</xref>); Xin <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib404" ref-type="bibr">2008</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">Cryptococcus neoformans</italic>
</td><td rowspan="1" colspan="1">Dublin University/J. Hopkins Bloomberg SPH (D)</td><td rowspan="1" colspan="1">GXM PS and oligosaccharides</td><td rowspan="1" colspan="1">SS; ST</td><td rowspan="1" colspan="1">HSA</td><td rowspan="1" colspan="1">Casadevall <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib44" ref-type="bibr">1992</xref>); Devi (<xref rid="bib89" ref-type="bibr">1996</xref>); Guazzelli, McCabe and Oscarson (<xref rid="bib137" ref-type="bibr">2016</xref>); Nakouzi <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib264" ref-type="bibr">2009</xref>)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Mycobacterial</bold>
<bold>glycans</bold>
</td><td rowspan="1" colspan="1">
<italic toggle="yes">Mycobacterium tubercolosis</italic> (H)</td><td rowspan="1" colspan="1">Uppsala University/Eurocine AB (D)</td><td rowspan="1" colspan="1">AM</td><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">Ag85B, TT</td><td rowspan="1" colspan="1">Hamasur <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib146" ref-type="bibr">2003</xref>); Kallenius, Pawlowski and Hamasur (<xref rid="bib186" ref-type="bibr">2008</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="tb1fn1"><label>a</label><p>Semisynthetic conjugates from natural carbohydrates: SS; Conjugates synthetic carbohydrates: ST; Bioconjugates: B; not available: na.</p></fn></table-wrap-foot></table-wrap><p>In these cases, other glycans, such as the O-antigen portion of lipopolysaccharide (LPS) molecules in Gram-negative or cell wall-associated glycans in Gram-positive bacteria, can be sufficiently accessible to the immune system to be taken into consideration as vaccine candidates. Notable examples are <italic toggle="yes">V. cholerae</italic> (Sayeed <italic toggle="yes">et&#160;al.</italic><xref rid="bib322" ref-type="bibr">2015</xref>), <italic toggle="yes">Shigella</italic> species (Mani, Wierzba and Walker <xref rid="bib242" ref-type="bibr">2016</xref>) and <italic toggle="yes">Escherichia coli</italic> (Huttner <italic toggle="yes">et&#160;al.</italic><xref rid="bib172" ref-type="bibr">2017</xref>).</p><p>The emerging of antimicrobial resistance (AMR) for some pathogens including, among others, <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Acinetobacter baumannii</italic> and <italic toggle="yes">Clostridium difficile</italic>, which are currently not treated by vaccination, is rendering the identification of future candidates more urgent (Garcia-Quintanilla <italic toggle="yes">et&#160;al.</italic><xref rid="bib124" ref-type="bibr">2016</xref>). In fact, vaccination could aid reducing the use of broad spectrum antibiotics and provide protection (herd immunity) also for individuals who are not vaccinated (Lipsitch and Siber <xref rid="bib221" ref-type="bibr">2016</xref>).</p><p>This review is intended to analyze structural and functional differences of surface-exposed polysaccharides from emerging pathogenic bacteria and, combined with epidemiological, medical need and technological considerations, identify potential targets for glycoconjugate vaccines in the near future. How advances in the field of glycoconjugate vaccine production (conjugation of natural polysaccharides, chemo-enzymatic approaches, glycoengineering) can support the development of efficacious novel well-defined vaccines is also discussed.</p></sec><sec id="sec2"><title>THE SURFACE CARBOHYDRATE STRUCTURES OF BACTERIA AND FUNGI</title><p>The bacterial cell envelope is surrounded by a dense layer of fibrous polysaccharides and glycoproteins, named <italic toggle="yes">glycocalyx</italic>. This structure helps bacteria to survive in unpredictable and often hostile environment, while it allows the selective passage of nutrients from the outside and waste products from the inside.</p><p>Generally, the capsule is the outermost surface polysaccharide of both Gram-negative and Gram-positive bacteria (Hendrickx <italic toggle="yes">et&#160;al.</italic><xref rid="bib152" ref-type="bibr">2011</xref>; Brown <italic toggle="yes">et&#160;al.</italic><xref rid="bib37" ref-type="bibr">2015</xref>; Filloux and Whitfield <xref rid="bib112" ref-type="bibr">2016</xref>). A given bacterial species might have strains with structurally different CPS resulting in different serogroups or serotypes. Immediately below the capsule, Gram-negative bacteria are characterized by an outer membrane (OM) from which anchored LPS, CPS and membrane proteins protrude. A thin peptidoglycan cell wall is sandwiched between OM and the inner cytoplasmic cell membrane. In contrast, Gram-positive bacteria lack an OM, and are surrounded by a much thicker layer of peptidoglycans compared to Gram-negatives (Fig.&#160;<xref ref-type="fig" rid="fig1">1</xref>). Carbohydrates, like &#946;-glucans, mannans, and others, are predominant components of the surface of fungal species (Gow, Latge and Munro <xref rid="bib131" ref-type="bibr">2017</xref>). Furthermore, glycosylphosphatidylinositol molecules, which are present on the surface of virtually all eukaryotic cells serving as surface protein anchors, occur at relatively high levels and with specific structures in parasitic protozoa, such as <italic toggle="yes">Plasmodium falciparum</italic> (Gowda, Gupta and Davidson <xref rid="bib132" ref-type="bibr">1997</xref>). The use of parasite carbohydrates as potential vaccine antigens has been recently reviewed and will not be in the scope of the present work (Jaurigue and Seeberger <xref rid="bib177" ref-type="bibr">2017</xref>).</p><fig id="fig1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Structures of the cell walls of Gram-negative and Gram-positive bacteria. Both classes of bacteria can produce a capsule (CPS). Gram-negative bacteria express lipopolysaccharide (LPS) or lipooligosaccharide (LOS). Unlike Gram-negative bacteria which possess an outer membrane with an outmost layer rich of phospholipids and LPS molecules, Gram-positive bacteria lack of the outer membrane and possess lipoteichoic acids (LTA) and the more exposed wall teichoic acids (WTA).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fuy011fig1.jpg"/></fig><p>A general description of the different glycans present in bacteria and fungi is given below, and structures of glycans with potential of being used to extend the coverage of licensed glycoconjugate vaccines or for the development of future vaccines are given in Table&#160;<xref ref-type="table" rid="tbl2">2</xref>.</p><table-wrap id="tbl2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Structures of some surface microbial carbohydrates tested as vaccine antigens in preclinical studies or in early clinical phase.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fuy011tab1a.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fuy011tab1b.jpg"/></table-wrap><sec id="sec2-1"><title>Polysaccharide capsule</title><p>CPS are typically made of negatively charged and highly hydrophilic long-chain polysaccharides, firmly anchored to the cell membrane.</p><p>CPS are well-established virulence factors, and they can interfere with innate immunity preventing the activation of the alternate complement pathway. Their hydrophilic character protects microorganisms from desiccation, thus facilitating host-to-host transmission, and their chemical structure sometimes mimics molecules produced by human cells so that the pathogen is not recognized as foreign by the immune system.</p><p>A paradigm of the remarkable structural diversity in CPS is embodied by almost 80 capsular serotypes in <italic toggle="yes">E. coli</italic>, more than 90 in <italic toggle="yes">Streptococcus pneumoniae</italic> and about 70 capsular serotypes in <italic toggle="yes">K. pneumoniae</italic> (Willis and Whitfield <xref rid="bib398" ref-type="bibr">2013</xref>). The most studied system for the biosynthesis of CPS is <italic toggle="yes">E. coli</italic> (Whitfield <xref rid="bib391" ref-type="bibr">2006</xref>). Its CPS are classified into four groups, numbered from 1 to 4 on the basis of genetic and biosynthetic criteria. In terms of biosynthesis three main pathways have been identified (Fig.&#160;<xref ref-type="fig" rid="fig2">2</xref>): Wzx/Wzy, ATP-binding cassette (ABC) transporter and synthase dependent (Cuthbertson, Kos and Whitfield <xref rid="bib80" ref-type="bibr">2010</xref>; Willis and Whitfield <xref rid="bib398" ref-type="bibr">2013</xref>). The Wzx/Wzy- and ABC transporter-dependent pathways share some similarities: the polysaccharide is built on a lipid acceptor, usually undecaprenol diphosphate (UndPP), starting from activated building blocks, that are typically cytosolic sugar nucleotides (Fig.&#160;<xref ref-type="fig" rid="fig2">2A</xref>). Glycosyltransferase reactions transfer sugars to UndPP, at the cytoplasmic face of the membrane. The final lipid-linked polysaccharide is located outside the cytoplasmic membrane. In the Wzx/Wzy-dependent pathway, the individual repeating units are first assembled and then exported across the membrane by a flippase Wzx protein. The exported UndPP-linked glycans are finally polymerized by a Wzy polymerase, which extends the growing chain one repeat unit at a time at the periplasmic face of the cytoplasmic membrane. A polysaccharide copolymerase controls the polymerization process. Groups 1 and 4 CPS are synthesized according to Wzy-dependent processes. These types of CPS are found in isolates causing intestinal infections, including enteropathogenic, enterotoxigenic and enterohemorrhagic <italic toggle="yes">E. coli</italic>, and other relevant pathogens, comprising <italic toggle="yes">St. pneumoniae</italic> and <italic toggle="yes">S. aureus</italic> (Yother <xref rid="bib406" ref-type="bibr">2011</xref>).</p><fig id="fig2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Mechanisms for polysaccharide biosynthesis in bacteria. (<bold>A</bold>) In the Wzx/Wzy-dependent pathway, the polysaccharide is built on a undecaprenol diphosphate (UndPP) acceptor, on which cytosolic sugar nucleotides are attached by glycosyltransferase (GT) catalyzed reactions an then exported across the membrane by a flippase Wzx protein for final polymerization by a Wzy polymerase, under the control of a polysaccharide copolymerase (PCP). (<bold>B</bold>) In the ABC transport-dependent pathway, the polysaccharide is built up at the cytoplasmic face of the inner membrane by GTs, and then exported by the ABC transporter. (<bold>C</bold>) In the synthase-dependent pathway, the polysaccharide is assembled at the cytoplasmic face of the inner membrane by a synthase that is also involved in its transportation across the membrane.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fuy011fig2.jpg"/></fig><p>In the ABC transport-dependent pathway, the polysaccharide is completed at the cytoplasmic face of the inner membrane (IM), and then exported by the ABC transporter (Fig.&#160;<xref ref-type="fig" rid="fig2">2B</xref>). Group 2 and 3 capsules, generally found in isolates causing extra intestinal infections, are both assembled via this pathway. Their structural features vary extensively and seem reminiscent of <italic toggle="yes">N. meningitidis</italic> and <italic toggle="yes">H. influenzae</italic> CPS (Whitfield <xref rid="bib391" ref-type="bibr">2006</xref>).</p><p>In the synthase-dependent pathway (Fig.&#160;<xref ref-type="fig" rid="fig2">2C</xref>), which is the less known of the three mechanisms, a polymerizing glycosyltransferase (the synthase) assembles the polysaccharide at the cytoplasmic face of the IM and is also believed to be involved in its export across the IM (Willis and Whitfield <xref rid="bib398" ref-type="bibr">2013</xref>). Serotypes 3 and 37 of <italic toggle="yes">St. pneumoniae</italic> are known to follow the synthase-dependent pathway for their CPS biosynthesis (Yother <xref rid="bib406" ref-type="bibr">2011</xref>).</p><p>Unlike the CPS biosynthesis, structure and biochemical pathway for the anchor to the cell membrane is less known. In <italic toggle="yes">E. coli</italic>, <italic toggle="yes">N. meningitidis, H. influenzae</italic> and other Gram-negative pathogens, this anchor is made of (lyso)phoshatidylglycerol moiety to which CPS is attached via an oligosaccharide of five to nine &#946;-linked 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) residues (Fig.&#160;<xref ref-type="fig" rid="fig3">3A</xref>) (Willis <italic toggle="yes">et&#160;al.</italic><xref rid="bib397" ref-type="bibr">2013</xref>). The CPS of <italic toggle="yes">Salmonella</italic> Typhi (Vi antigen) has a unique lipid terminus composed of a reducing terminal HexNAc residue modified with two &#946;-hydroxy fatty acids that resembles one half of lipid A structure (Liston, Ovchinnikova and Whitfield <xref rid="bib224" ref-type="bibr">2016</xref>). Some bacteria, in addition to the LPS molecules carrying the serological O-antigen, produce a CPS linked to a lipid A core, and therefore termed K<sub>LPS</sub> or K antigen (Whitfield <xref rid="bib391" ref-type="bibr">2006</xref>).</p><fig id="fig3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>General structures of bacterial surface polysaccharides. (<bold>A</bold>) Capsules are homopolymeric or heteropolymeric carbohydrate chains inserted into the membrane. (<bold>B</bold>) LPS is made of three components: lipid A, core-oligosaccharide and O-polysaccharide or O-antigen. LPS lacking of the O-antigen is termed LOS. (<bold>C</bold>) Teichoic acids are differentiated into lipoteichoic acids (LTA) and wall teichoic acids (WTA).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fuy011fig3.jpg"/></fig><p>In most of capsule-forming Gram-positive bacteria, the majority of the polymers is covalently linked to the peptidoglycans or to membrane components, although some may be released from the cell (Yother <xref rid="bib406" ref-type="bibr">2011</xref>). There are exceptions, such as <italic toggle="yes">St. pneumoniae</italic> type 3, where the CPS is bound to the membrane through a phosphatidylglycerol anchor (Cartee, Forsee and Yother <xref rid="bib43" ref-type="bibr">2005</xref>).</p></sec><sec id="sec2-2"><title>Glycans associated to Gram-negative bacteria OM</title><p>The OM is a distinguishing feature of Gram-negative bacteria. Unlike most biological membranes, the OM is an asymmetrical lipid bilayer. Typically, the inner leaflet is composed predominantly of phospholipids and the outer leaflet of LPS (Raetz and Whitfield <xref rid="bib296" ref-type="bibr">2002</xref>; Filloux and Whitfield <xref rid="bib112" ref-type="bibr">2016</xref>).</p><p>The human innate immune system is sensitized to LPS which is generally an indicator of infection. LPS is responsible for the endotoxic shock associated with the septicemia caused by Gram-negative organisms (Raetz and Whitfield <xref rid="bib296" ref-type="bibr">2002</xref>). LPS is made of three components (Fig.&#160;<xref ref-type="fig" rid="fig3">3B</xref>): lipid A, core-oligosaccharide and O-polysaccharide (O-PS) or O-antigen (O-Ag). The OM generally contains a complex mixture of LPS molecules, including molecules with only the lipid A and core-oligosaccharide (rough LPS), as well as molecules capped with O-PS (smooth LPS) (Knirel <italic toggle="yes">et&#160;al.</italic><xref rid="bib196" ref-type="bibr">2001</xref>).</p><p>The typical lipid A structure consists of a glucosamine disaccharide, substituted with fatty acids (Raetz and Whitfield <xref rid="bib296" ref-type="bibr">2002</xref>). The acyl chains are largely saturated and facilitate tight packing of OM, playing a critical role in the barrier function of the OM. The core-oligosaccharide is divided into two regions: the inner core consisting of Kdo and L-glycero-D-manno-heptose residues that is highly conserved, and the outer core, which displays limited structural diversity and consists mainly of hexose sugars. The O-Ag domain is made up of repeating units of one or more sugar residues and exhibits remarkable structural diversity. Variations in its composition are often the basis for serotyping classification by serological methods. Although not essential for growth in laboratory culture, O-Ag helps the bacterium to resist certain antimicrobial molecules, the complement system, and environmental stresses in its natural environment (Raetz and Whitfield <xref rid="bib296" ref-type="bibr">2002</xref>; Greenfield and Whitfield <xref rid="bib133" ref-type="bibr">2012</xref>).</p><p>Some Gram-negative bacteria, such as <italic toggle="yes">Neisseria</italic> spp., <italic toggle="yes">Haemophilus</italic> spp. and <italic toggle="yes">Bordetella pertussis</italic>, and in general mucosal pathogens are unable to synthesize O-Ag and produce instead a LPS form called lipooligosaccharide (LOS) that contains the inner core from which one or more mono- or oligosaccharide branches (which determine serological specificity) extend. <italic toggle="yes">Pseudomonas aeruginosa</italic> can produce a rough LPS, once colonization has been established (Knirel <italic toggle="yes">et&#160;al.</italic><xref rid="bib196" ref-type="bibr">2001</xref>).</p><p>Biosynthesis of the lipid A is a highly conserved process among Gram-negative species, which occurs partly in the cytoplasm, and partly at the inner leaflet of the IM (Greenfield and Whitfield <xref rid="bib133" ref-type="bibr">2012</xref>). The O-Ag is assembled following the same pathways than the CPS, except that the ABC transporter-dependent mechanism of O-Ag biosynthesis seems the most widespread (Fig.&#160;<xref ref-type="fig" rid="fig2">2</xref>). The completed O-Ag is transferred from the UndPP linked intermediate and ligated to the lipid A-core in the periplasmic face of the IM. Very seldom the synthase-dependent mechanism is involved.</p></sec><sec id="sec2-3"><title>Glycans associated to Gram-positive bacterial cell wall</title><sec id="sec2-3-1"><title>Peptidoglycan</title><p>Peptidoglycan (PG) is made up of repeating units of the disaccharide N-acetyl glucosamine-N-acetyl muramic acid, which are cross-linked by pentapeptide side chains (Vollmer, Blanot and de Pedro <xref rid="bib377" ref-type="bibr">2008</xref>). The PG sacculus is a very large polymer that, because of its rigidity, determines cell shape. The PG layer is much thicker in Gram-positive than in Gram-negative bacteria.</p></sec><sec id="sec2-3-2"><title>Teichoic and lipoteichoic acids</title><p>In Gram-positive bacteria, threading through the layer of peptidoglycans, there are teichoic acids (TA), zwitterionic glycopolymers containing phosphodiester-linked polyol repeat units (Armstrong <italic toggle="yes">et&#160;al.</italic><xref rid="bib13" ref-type="bibr">1958</xref>). TA play crucial roles in cell shape determination, regulation of cell division and other fundamental aspects of Gram-positive bacterial physiology. They are divided into lipoteichoic acids (LTA), which are anchored in the bacterial membrane via a glycolipid, and wall teichoic acids (WTA), which are covalently attached to peptidoglycans (Fig.&#160;<xref ref-type="fig" rid="fig1">1</xref>) (Brown, Santa Maria and Walker <xref rid="bib38" ref-type="bibr">2013</xref>; Sewell and Brown <xref rid="bib331" ref-type="bibr">2014</xref>).</p><p>Fully extended membrane-linked LTA may not be able to completely penetrate the PG layer and only reach the bacterial surface once released from the membrane (Reichmann and Grundling <xref rid="bib302" ref-type="bibr">2011</xref>). WTA extend through and beyond the cell surface more than LTA do (Silhavy, Kahne and Walker <xref rid="bib336" ref-type="bibr">2010</xref>), as confirmed by cryo-EM images for <italic toggle="yes">S. aureus</italic>. WTA are highly abundant modifications of Gram-positive cell walls (Brown, Santa Maria and Walker <xref rid="bib38" ref-type="bibr">2013</xref>): in <italic toggle="yes">Bacillus subtilis</italic> and <italic toggle="yes">S. aureus</italic>, for instance, they represent up to 60% of the cell wall (Xia, Kohler and Peschel <xref rid="bib402" ref-type="bibr">2010</xref>). WTA are made by two components (Fig.&#160;<xref ref-type="fig" rid="fig3">3C</xref>): a disaccharide unit that is highly conserved across bacterial species and a main chain polymer composed of phosphodiester-linked polyol repeating units, generally composed of 1,5-D-ribitol-phosphate (RibP) or (1&#8594;3)-L-&#945;-glycerol-phosphate (GroP) (Endl <italic toggle="yes">et&#160;al.</italic><xref rid="bib101" ref-type="bibr">1983</xref>; Neuhaus and Baddiley <xref rid="bib266" ref-type="bibr">2003</xref>).</p><p>Structural diversity of WTA can derive from the presence or absence of substituents attached to the backbone (Fig.&#160;<xref ref-type="fig" rid="fig2">2</xref>), including cationic D-alanine esters and a variety of mono- or oligosaccharides, commonly Glc or GlcNAc (Collins <italic toggle="yes">et&#160;al.</italic><xref rid="bib65" ref-type="bibr">2002</xref>).</p><p>LTA has a simpler and more conserved structure that typically consists of a polyglycerolphosphate (PGP) chain (Fischer, Koch and Haas <xref rid="bib114" ref-type="bibr">1983</xref>; Fischer <italic toggle="yes">et&#160;al.</italic><xref rid="bib113" ref-type="bibr">1993</xref>) (Fig.&#160;<xref ref-type="fig" rid="fig3">3C</xref>). Similarly to WTA, the PGP backbone chain of LTA is modified with D-alanine residues, and in many bacteria with additional glycosyl groups.</p></sec></sec><sec id="sec2-4"><title>Other glycans</title><p>Another polysaccharide structure found in many species is the poly-&#946;-D-(1&#8594;6)-N-acetylglucosamine (PNAG), a polymer with partial <italic toggle="yes">N</italic>-deacetylation and <italic toggle="yes">O</italic>-succinyl substituents which is one of the major component of biofilms <italic toggle="yes">in S. epidermidis</italic> and <italic toggle="yes">S. aureus</italic> (Joyce <italic toggle="yes">et&#160;al.</italic><xref rid="bib183" ref-type="bibr">2003</xref>). Besides cell-to-cell adherence, PNAG also acts as an important virulence factor and protects bacteria against innate host defenses (Little <italic toggle="yes">et&#160;al.</italic><xref rid="bib225" ref-type="bibr">2014</xref>).</p><p>Synthesis of PNAG in <italic toggle="yes">Staphylococci</italic> is controlled by an operon, icaADBC, codifying for four proteins responsible of biosynthesis and transport across the IM. A similar operon, pgaABCD, has been found in <italic toggle="yes">A. baumannii</italic> as well as in the genomes of a number of Gram-negative bacteria, including <italic toggle="yes">Yersinia pestis</italic>, <italic toggle="yes">Y. enterocolitica</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">B. pertussis</italic>, <italic toggle="yes">B. parapertussis</italic>, <italic toggle="yes">B. bronchiseptica</italic>, <italic toggle="yes">Burkholderia cepacia</italic>, <italic toggle="yes">P. fluorescens</italic>, <italic toggle="yes">Actinobacillus pleuropneumoniae</italic> and <italic toggle="yes">Aggregatibacter actinomycetemcomitans</italic> (Wang, Preston and Romeo <xref rid="bib383" ref-type="bibr">2004</xref>; Tiwary <italic toggle="yes">et&#160;al.</italic><xref rid="bib356" ref-type="bibr">2016</xref>), indicating that PNAG is ubiquitous in a number of species.</p></sec><sec id="sec2-5"><title>Mycobacteria and fungal glycans</title><p>The architecture of Gram-positive bacteria shares some similarities with mycobacteria and fungi, since they all possess a thick wall outside of their cellular membrane. The cell walls of mycobacteria consist of thin internal layers of peptidoglycans and arabinogalactans, surrounded by a thick layer of micolic acids, glycolipids and cell membrane anchored lipoarabinomannans protruding on the surface. The cell wall of fungi is instead dominated by polysaccharides like mannans (in the form of mannoproteins) and &#946;-(1&#8594;3) and &#946;-(1&#8594;6) glucans, while a chitin layer is located below (Masuoka <xref rid="bib248" ref-type="bibr">2004</xref>; Brown <italic toggle="yes">et&#160;al.</italic><xref rid="bib37" ref-type="bibr">2015</xref>; Gow, Latge and Munro <xref rid="bib131" ref-type="bibr">2017</xref>).</p><p>A particular case is encountered in <italic toggle="yes">Cryptococcus neoformans</italic>, an important cause of meningitis in Africa especially in those categories who are immunocompromised as a consequence of underlying disease like AIDS. <italic toggle="yes">Cryptococcus neoformans</italic> displays a polysaccharide capsule which is essential for its virulence and is composed primarily of glucuronoxylomannan and galactoxylomannan (McFadden, De Jesus and Casadevall <xref rid="bib229" ref-type="bibr">2006</xref>).</p></sec></sec><sec id="sec3"><title>APPROACHES FOR PRODUCTION OF GLYCOCONJUGATE VACCINES</title><p>There are a number of methods to prepare glycococonjugate vaccines: some of them are well established and used in licensed products, others are emerging and increasingly applied to vaccines under development. They are mainly based on covalent linkage between CPS and carrier protein; however, it is worth to mention strategies for non-covalent interaction based on CPS biotinylation followed by association to carrier proteins fused with avidin like peptides (Zhang <italic toggle="yes">et&#160;al.</italic><xref rid="bib411a" ref-type="bibr">2013</xref>), CPS entrapped in cross-linked protein (Thanawastien <italic toggle="yes">et&#160;al.</italic><xref rid="bib351" ref-type="bibr">2015</xref>), and liposomal encapsulation of CPS and proteins (Jones <italic toggle="yes">et&#160;al.</italic><xref rid="bib182a" ref-type="bibr">2017</xref>). Historical attempts to develop glycoconjugate vaccines based on non-covalent association of CPS with proteins, although promising in animal models, have failed in humans (Anderson <italic toggle="yes">et&#160;al.</italic><xref rid="bib10" ref-type="bibr">1985</xref>), thus anticipating an intense validation effort for these new attempts. Below the main approaches for glycoconjugate vaccines are discussed, and some examples are schematically reported in Fig.&#160;<xref ref-type="fig" rid="fig4">4</xref>.</p><fig id="fig4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Approaches for the production of glycoconjugate vaccines include (<bold>A</bold>) engineering of <italic toggle="yes">E. coli</italic> for expression of carbohydrate, carrier protein and <italic toggle="yes">in vivo</italic> conjugation, resulting in glycans radially oriented relative to protein; (B) polysaccharides activation of sugar residues along the chain and conjugation to the carrier protein, resulting in cross-linked structures; (C) polysaccharide fragmentation (hydrolysis or other methods discussed in the text), sizing and conjugation via end terminal residues, resulting in glycans radially oriented relative to protein; (D) construction of the oligosaccharide from appropriate building blocks with an in-built linker for conjugation, also resulting in glycans radially oriented relative to protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fuy011fig4.jpg"/></fig><sec id="sec3-1"><title>Semisynthesis: extraction of polysaccharide and carrier protein moieties from bacteria</title><p>The classical approach used for glycoconjugate vaccines is based on polysaccharide extraction from bacterial fermentation, subsequent purification and chemical modification to install a covalent linkage between the saccharide and the carrier protein (Costantino, Rappuoli and Berti <xref rid="bib69" ref-type="bibr">2011</xref>; Ravenscroft <italic toggle="yes">et&#160;al.</italic><xref rid="bib299" ref-type="bibr">2015</xref>; Khatun <italic toggle="yes">et&#160;al.</italic><xref rid="bib191" ref-type="bibr">2017</xref>). The carrier protein is also derived from bacteria by fermentation and subsequent purification and, depending on the chemistry used, it can be conjugated via its functional groups or alternatively derivatized before polysaccharide linkage. Adequate linkers are often used to facilitate the conjugation, reducing steric hindrance between protein and saccharide.</p><p>In some cases specific chemical moieties of the polysaccharide, such as the carboxyl group of sialic acid residues, are randomly derivatized and subsequently conjugated to the carrier protein. In some other cases, cis-diols present on the saccharide chain can be modified by NaIO<sub>4</sub> oxidation in order to generate aldehydes (Fig.&#160;<xref ref-type="fig" rid="fig4">4B</xref>). These chemical groups can be directly linked to the &#949;-amine of the protein lysine residues by reductive amination, or further derivatized before linkage to the protein (Anderson <italic toggle="yes">et&#160;al.</italic><xref rid="bib11" ref-type="bibr">1986</xref>; Marburg <italic toggle="yes">et&#160;al.</italic><xref rid="bib244" ref-type="bibr">1986</xref>; Zou and Jennings <xref rid="bib413" ref-type="bibr">2009</xref>; CDC <xref rid="bib48" ref-type="bibr">2016</xref>). Alternatively, the polysaccharides can be fragmented, for example, by acid treatment, and subsequently sized, by means of chromatography or ultrafiltration, to obtain more defined oligosaccharide populations for protein conjugation (Costantino <italic toggle="yes">et&#160;al.</italic><xref rid="bib68" ref-type="bibr">1999</xref>; Broker, Berti and Costantino <xref rid="bib32" ref-type="bibr">2016</xref>). In this case the protein coupling is generally carried out using the end reducing sugar which can be modified with a spacer bearing appropriate functional group reacting with the protein (Fig.&#160;<xref ref-type="fig" rid="fig4">4C</xref>).</p><p>Depending on the polysaccharide structure (e.g. <italic toggle="yes">H. influenzae</italic> type b CPS), NaIO<sub>4</sub> oxidation results in simultaneous fragmentation and generation of terminal aldehyde groups available for conjugation. Similarly, treatment of polysialic acids (e.g. <italic toggle="yes">N. meningitidis</italic> serogroup C) with hydrogen peroxide results in depolymerization and concomitant activation through introduction of carbonyl groups (Ryall <xref rid="bib315" ref-type="bibr">2003</xref>; Neyra, Paladino and Le Borgne <xref rid="bib267" ref-type="bibr">2015</xref>). Hydrogen peroxide has been used also for depolymerization of <italic toggle="yes">Salmonella</italic> Typhi (Vi CPS) (Arcuri <italic toggle="yes">et&#160;al.</italic><xref rid="bib12" ref-type="bibr">2017</xref>).</p><p>Many licensed glycoconjugate vaccines to prevent <italic toggle="yes">St. pneumoniae</italic>, <italic toggle="yes">N. meningitidis</italic> and <italic toggle="yes">H. influenzae</italic> caused infections are prepared based on these approaches. Five carrier proteins have been used in these vaccines: tetanus toxoid (TT), diptheria toxoid (DT), CRM<sub>197</sub>, the outer membrane protein complex of meningococcus B (OMPC) and Protein D from <italic toggle="yes">H. influenzae.</italic> For a more technical discussion on this topic, we refer the reader to other reviews (Broker <italic toggle="yes">et&#160;al.</italic><xref rid="bib34" ref-type="bibr">2011</xref>, <xref rid="bib33" ref-type="bibr">2017</xref>; Costantino, Rappuoli and Berti <xref rid="bib69" ref-type="bibr">2011</xref>).</p><p>Often the polysaccharides are attached to multiple points of the carrier proteins in a random fashion (Adamo <italic toggle="yes">et&#160;al.</italic><xref rid="bib3" ref-type="bibr">2013</xref>). However, recently the possibility to chemically conjugate the glycan at predetermined sites of the carrier protein is emerging (Nilo <italic toggle="yes">et&#160;al.</italic><xref rid="bib268" ref-type="bibr">2015</xref>; Stefanetti <italic toggle="yes">et&#160;al.</italic><xref rid="bib344" ref-type="bibr">2015</xref>). Also, by means of recombinant techniques, unnatural amino acids with side chains suitable for specific conjugation to the polysaccharide can be inserted in specific regions of the protein sequence (Hu, Berti and Adamo <xref rid="bib164" ref-type="bibr">2016</xref>; Kapoor <italic toggle="yes">et&#160;al.</italic><xref rid="bib188" ref-type="bibr">2018</xref>). These approaches render the conjugation procedures more selective, allowing for a more rational design of the vaccine and preservation of the key protein epitopes.</p><p>Recently, an alternative glycoconjugation method based on dry glycation following periodate oxidation of pneumococcal CPS has been reported (Turner <italic toggle="yes">et&#160;al.</italic><xref rid="bib359" ref-type="bibr">2017</xref>).</p></sec><sec id="sec3-2"><title>Synthetic approach: production of the saccharide moiety by means of organic synthesis</title><p>The immense progress in the chemical synthesis of carbohydrates seen over the last decades has led to developing protocols for the preparation of a variety of complex bacterial oligosaccharides (Smoot and Demchenko <xref rid="bib340" ref-type="bibr">2009</xref>; Morelli, Poletti and Lay <xref rid="bib257" ref-type="bibr">2011</xref>) (Fig.&#160;<xref ref-type="fig" rid="fig4">4D</xref>).</p><p>The climax of this approach has been the development and introduction in Cuban routine vaccination schedule of a conjugate vaccine against <italic toggle="yes">H. influenzae</italic> type b, where the carbohydrate moiety has been obtained by large-scale synthesis of the capsular oligosaccharide (Verez-Bencomo <italic toggle="yes">et&#160;al.</italic><xref rid="bib372" ref-type="bibr">2004</xref>). A glycoconjugate based on synthetic carbohydrate of <italic toggle="yes">Sh. flexneri</italic> type 2a has recently entered clinical trials (van der Put <italic toggle="yes">et&#160;al.</italic><xref rid="bib365" ref-type="bibr">2016</xref>). Synthetic oligosaccharides are generally prepared with a built-in spacer for conjugation at the downstream end, and offer advantages including the avoidance of handling pathogens, lack of bacterial impurities, minimal batch-to-batch variability and higher quality control standards during process manufacturing (Adamo <xref rid="bib1" ref-type="bibr">2017</xref>).</p><p>The introduction of methods for solid phase automated oligosaccharides synthesis (Seeberger <xref rid="bib328" ref-type="bibr">2015</xref>; Hahm <italic toggle="yes">et&#160;al.</italic><xref rid="bib145" ref-type="bibr">2017</xref>) and automated polymer supported by HPLC-assisted flow chemistry (Ganesh <italic toggle="yes">et&#160;al.</italic><xref rid="bib120" ref-type="bibr">2012</xref>) could simplify and accelerate large-scale production of oligosaccharides. A study of the database &#8216;glycoscience.de&#8217; showed that a minimal set of 36 monosaccharide building blocks would be sufficient to construct 75% of the catalogued 3299 mammalian oligosaccharides (Werz <italic toggle="yes">et&#160;al.</italic><xref rid="bib388" ref-type="bibr">2007</xref>). Despite bacterial glycans are generally characterized by more complex structures than mammalian ones, with numerous branchings and substituents, like acetyl or phosphate groups, this approach has been proven applicable for the fast production of a variety of carbohydrates (Schumann <italic toggle="yes">et&#160;al.</italic><xref rid="bib325" ref-type="bibr">2017</xref>).</p><p>In addition, other methods, including one-pot protocols (Huang <italic toggle="yes">et&#160;al.</italic><xref rid="bib167" ref-type="bibr">2004</xref>; Wu <italic toggle="yes">et&#160;al.</italic><xref rid="bib401" ref-type="bibr">2017</xref>) and chemo-enymatic approaches (Wang <italic toggle="yes">et&#160;al.</italic><xref rid="bib385" ref-type="bibr">2013</xref>; Fiebig <italic toggle="yes">et&#160;al.</italic><xref rid="bib111" ref-type="bibr">2016</xref>; Li and Wang <xref rid="bib214" ref-type="bibr">2016</xref>), are accelerating the production of synthetic saccharides rendering their use increasingly attractive, particularly when the polysaccharide is difficult to be purified at high yields, or for the production of more stable sugar mimics (Gao <italic toggle="yes">et&#160;al.</italic><xref rid="bib122" ref-type="bibr">2013</xref>).</p></sec><sec id="sec3-3"><title>Bioconjugation approach: engineering <italic toggle="yes">E. coli</italic> for <italic toggle="yes">in vivo</italic> glycoconjugate production</title><p>The <italic toggle="yes">in vivo</italic> production of glycoproteins has recently found application in the delivery of a series of glycoconjugate vaccine candidates (Wacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib380" ref-type="bibr">2002</xref>). <italic toggle="yes">Escherichia coli</italic> is engineered with genome integrated pathogen glycan clusters, with an oligosaccharyl transferase (PglB) from <italic toggle="yes">Campylobacter jejuni</italic>, integrated in the genome or plasmid encoded, and with a plasmid encoding for the carrier protein with N-glycosylation consensus sequences Asp/Glu-Asn-X-Ser/Thr (where X can be any amino acid except proline) in selected sites (Feldman <italic toggle="yes">et&#160;al.</italic><xref rid="bib109" ref-type="bibr">2005</xref>; Kowarik <italic toggle="yes">et&#160;al.</italic><xref rid="bib202" ref-type="bibr">2006</xref>; Wacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib379" ref-type="bibr">2006</xref>) (Fig.&#160;<xref ref-type="fig" rid="fig4">4A</xref>). In detail, pathogen glycans repeating units are expressed in the cytoplasm, assembled onto the <italic toggle="yes">E. coli</italic> lipid carrier UndPP and then flipped across the cytoplasmic membrane. The repeats are polymerized by a polymerase in the periplasmic space, where PglB enables the transfer of the resulting lipid linked oligosaccharides to asparagine residues of the N-glycosylation consensus sequences of the carrier protein.</p><p>Biosynthesis of glycoproteins from a number of bacterial polysaccharides, including <italic toggle="yes">Salmonella enterica, Shigella</italic> spp<italic toggle="yes">, E. coli</italic> LPS and <italic toggle="yes">S. aureus</italic> serotype 5 or 8 CPS and <italic toggle="yes">St. pneumoniae</italic> CPS has been achieved through this technology (Wetter <italic toggle="yes">et&#160;al.</italic><xref rid="bib389" ref-type="bibr">2012</xref>, <xref rid="bib390" ref-type="bibr">2013</xref>; Wacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib381" ref-type="bibr">2014</xref>; van den Dobbelsteen <italic toggle="yes">et&#160;al.</italic><xref rid="bib364" ref-type="bibr">2016</xref>; Ravenscroft <italic toggle="yes">et&#160;al.</italic><xref rid="bib300" ref-type="bibr">2017</xref>). Selective glycosylation allows for a better exploitation of proteins with the dual carrier/antigen role, as demonstrated for <italic toggle="yes">S. aureus</italic> &#945; toxin Hla used as carrier for type 5 and 8 CPS (Wacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib381" ref-type="bibr">2014</xref>). Phase-1 trials of monovalent vaccines against <italic toggle="yes">Shigella dysenteriae</italic> O1 and <italic toggle="yes">Sh. flexneri</italic> 2a (Hatz <italic toggle="yes">et&#160;al.</italic><xref rid="bib149" ref-type="bibr">2015</xref>), and a tetravalent anti-extra intestinal pathogenic <italic toggle="yes">E. coli</italic> (ExPEC) vaccine have been successfully completed (Huttner <italic toggle="yes">et&#160;al.</italic><xref rid="bib172" ref-type="bibr">2017</xref>).</p><p>Recently, glycoengineering of outer membrane vescicles (geOMVs) for expression of heterologous polysaccharides attached to O-Ag negative lipid A core has been proposed as a novel platform for polysaccharide vaccines (Chen <italic toggle="yes">et&#160;al.</italic><xref rid="bib54" ref-type="bibr">2016</xref>; Price <italic toggle="yes">et&#160;al.</italic><xref rid="bib293" ref-type="bibr">2016</xref>; Valguarnera and Feldman <xref rid="bib363" ref-type="bibr">2017</xref>). OMVs combine antigen presentation with optimal size for immune stimulation and proper adjuvant properties for the presence of Toll-like receptors (TLR) 2 and 4. Price <italic toggle="yes">et&#160;al.</italic> (<xref rid="bib293" ref-type="bibr">2016</xref>) showed the efficacy of geOMVs as vaccines against <italic toggle="yes">St. pneumoniae</italic> in mice, and <italic toggle="yes">Ca. jejuni</italic> in chicken. In another study, <italic toggle="yes">Francisella tularensis</italic> O-Ag expressed on <italic toggle="yes">E. coli</italic> OMVs provided protection against <italic toggle="yes">F. tularensis</italic> (Chen <italic toggle="yes">et&#160;al.</italic><xref rid="bib54" ref-type="bibr">2016</xref>).</p></sec><sec id="sec3-4"><title>Cell surface glycans as target for glycoconjugate vaccines</title><p>The currently licensed glycoconjugate vaccines (Table&#160;<xref ref-type="table" rid="tbl1">1</xref>) were developed based on the epidemiology of bacterial infectious diseases, which registered in the past decades a high incidence of bacterial meningitis caused by <italic toggle="yes">N. meningitidis</italic>, <italic toggle="yes">H. influenzae</italic> type b and <italic toggle="yes">St. pneumoniae</italic> (Pace and Pollard <xref rid="bib275" ref-type="bibr">2007</xref>; Pace <xref rid="bib274" ref-type="bibr">2013</xref>; Vella and Pace <xref rid="bib370" ref-type="bibr">2015</xref>). A number of new glycoconjugate vaccines are being advanced building up on the success of this first generation. Some of them address new pathogens, while others can be considered an extension of current ones to cover additional emerging serotypes.</p><p>For example, with the evolving of the pneumococcal epidemiology, non-vaccine serotypes are emerging. Therefore, extension from the current 10- and 13-valent conjugate vaccines (Geno <italic toggle="yes">et&#160;al.</italic><xref rid="bib127" ref-type="bibr">2015</xref>; Delgleize <italic toggle="yes">et&#160;al.</italic><xref rid="bib85" ref-type="bibr">2016</xref>) up to a 15-valent using CRM<sub>197</sub> as carrier is under development (McFetridge <italic toggle="yes">et&#160;al.</italic><xref rid="bib230" ref-type="bibr">2015</xref>) (Table&#160;<xref ref-type="table" rid="tbl1">1</xref>). The increasing medical need in elderly population and the additional emergence of non-vaccine-serotype disease is expected to driving the development of even higher valence vaccines.</p><p>Recent outbreaks in Africa (Boisier <italic toggle="yes">et&#160;al.</italic><xref rid="bib21" ref-type="bibr">2007</xref>) have highlighted the need for an anti serogroup X meningococcal vaccine (Xie <italic toggle="yes">et&#160;al.</italic><xref rid="bib403" ref-type="bibr">2013</xref>), in addition to the already available A, C, W and Y. Conjugates of CPS X (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) (Bundle, Smith and Jennings <xref rid="bib39" ref-type="bibr">1974</xref>) were immunogenic and induced bactericidal antibodies in mice (Micoli <italic toggle="yes">et&#160;al.</italic><xref rid="bib252" ref-type="bibr">2013a</xref>). Oligomers of various lengths have also been produced by enzymatic and synthetic methods (Morelli <italic toggle="yes">et&#160;al.</italic><xref rid="bib256" ref-type="bibr">2014</xref>; Harale <italic toggle="yes">et&#160;al.</italic><xref rid="bib148" ref-type="bibr">2015</xref>; Fiebig <italic toggle="yes">et&#160;al.</italic><xref rid="bib111" ref-type="bibr">2016</xref>).</p><p>Among the novel targets, a recent analysis from WHO (WHO <xref rid="bib396" ref-type="bibr">2017</xref>) and CDC (CDC <xref rid="bib46" ref-type="bibr">2013a</xref>) highlights bacteria that are increasingly developing resistance to current antimicrobial therapies and are considered an emerging and serious threat for the public health (Garcia-Quintanilla <italic toggle="yes">et&#160;al.</italic><xref rid="bib124" ref-type="bibr">2016</xref>). Most of the resistant bacteria belong to the category of nosocomial pathogens, but there are also examples in the community acquired infectious diseases.</p><p>In addition to the CPS, other cell surface glycans are being taken into consideration in the development of novel conjugate vaccines. Moreover, along with the classical semisynthetic chemistry, other approaches, including the use of synthetic carbohydrates or <italic toggle="yes">E. coli</italic> glycoprotein expression, are increasingly taking place.</p><p>Table&#160;<xref ref-type="table" rid="tbl1">1</xref> reports a list of glycoconjugate vaccines which are at different stage: licensed (L), in clinical trials (C) or discovery (D). Proposed surface glycan antigens and utilized approaches are also included.</p><p>Below we describe the more relevant pathogens for which a medical need has been identified and the different classes of microbial glycans (CPS, O-Ag and other surface carbohydrates) that have been targeted for vaccine development.</p><sec id="sec3-5"><title>Capsular polysaccharides</title><sec id="sec3-5-1"><title>Acinetobacter baumannii</title><p>The Gram-negative bacterium <italic toggle="yes">A. baumannii</italic> is the major cause of nosocomial infections and it has frequently been reported in times of war and natural disasters (Fournier and Richet <xref rid="bib118" ref-type="bibr">2006</xref>). It affects different human organs, particularly the lungs, causing ventilator-associated pneumonia (VAP) which usually develops to septicemia in intensive care unit residents. Patients at risk are immunocompromised, elderly, premature neonates and patients undergoing surgeries, and its danger has increased due to emerging antibiotic resistance (Peleg, Seifert and Paterson <xref rid="bib280" ref-type="bibr">2008</xref>). Recently, a monoclonal antibody against <italic toggle="yes">A. baumannii</italic> K1 capsule was produced and shown protective in a rat challenge model (Russo <italic toggle="yes">et&#160;al.</italic><xref rid="bib313" ref-type="bibr">2013</xref>). The K1 CPS (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) was also demonstrated as a potential vaccine antigen via passive immunization. However, an anti K1 CPS monoclonal antibody (mAb) recognized only 13% of the tested strains, and there is little information on the prevalence in clinical isolates (antigen epidemiology) of the nearly 40 serovars identified so far, which complicate the development of a CPS-based vaccine (Chen <xref rid="bib56" ref-type="bibr">2015</xref>).</p></sec><sec id="sec3-5-2"><title>Burkholderia pseudomallei <roman toggle="no">and</roman> mallei</title><p>
<italic toggle="yes">Burkholderia pseudomallei</italic> (Bp) is a Gram-negative saprophyte that causes melioidosis. It is highly resistant to harsh environmental pressures, and it is classified as a potential class B bioterrorism weapon due to its high infectivity when aerosolized (Silva and Dow <xref rid="bib337" ref-type="bibr">2013</xref>; Peacock <italic toggle="yes">et&#160;al.</italic><xref rid="bib279" ref-type="bibr">2012</xref>). The intrinsically high resistance of Bp to several different classes of antibiotics increases the potential danger of this organism. Melioidosis is acquired by skin inoculation, inhalation and ingestion, with pneumonia being the most common clinical presentation. This disease is prevalent in South-East Asia and Northern Australia, and persons with open skin wounds and those with diabetes or chronic renal disease are at increased risk for this infection, particularly among individuals performing agricultural work without health care standard protections.</p><p>Bp possesses a CPS (named O-polysaccharide I, OPSI) which was originally identified as an LPS (Knirel <italic toggle="yes">et&#160;al.</italic><xref rid="bib197" ref-type="bibr">1992</xref>). OPSI is composed of linear (1&#8594;3)-linked 2-O-acetyl-6-deoxy-&#946;-D-manno-heptopyranose residues with O-acetylation at position 2 (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>), and it is required for serum resistance and virulence (Perry <italic toggle="yes">et&#160;al.</italic><xref rid="bib286" ref-type="bibr">1995</xref>). Similarly to Bp, <italic toggle="yes">B. mallei</italic> (Bm), the causative agent of glanders, expresses only this single serotype of capsule (DeShazer, Brett and Woods <xref rid="bib87" ref-type="bibr">1998</xref>; DeShazer <italic toggle="yes">et&#160;al.</italic><xref rid="bib88" ref-type="bibr">2001</xref>; Nelson <italic toggle="yes">et&#160;al.</italic><xref rid="bib265" ref-type="bibr">2004</xref>). Therefore, a CPS-based vaccine would potentially offer cross-protection against both pathogens (Scott <italic toggle="yes">et&#160;al.</italic><xref rid="bib326" ref-type="bibr">2014</xref>). CPS-BSA conjugates were immunogenic in mice and elicited antibodies protective against infection and opsonic (Nelson <italic toggle="yes">et&#160;al.</italic><xref rid="bib265" ref-type="bibr">2004</xref>). A synthetic hexasaccharide of Bp capsule coupled to the Hc domain of TT elicited anti-CPS antibodies in mice that were protective against Bp infection (Scott <italic toggle="yes">et&#160;al.</italic><xref rid="bib327" ref-type="bibr">2016</xref>).</p></sec><sec id="sec3-5-3"><title>
<italic toggle="yes">Enterococcus faecalis</italic>
<roman toggle="no">and</roman>
<italic toggle="yes">faecium</italic>
</title><p>Until the late 1970s, Gram-positive enterococci were considered a relatively inoffensive group of pathogens against which effective antibiotics were readily available. Emergence of antibiotic resistance and increased isolation from hospitalized patients, where they account for 11% of nosocomial bloodstream isolates, have pointed out the relevance of Enterococci as nosocomial pathogens (Theilacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib354" ref-type="bibr">2004</xref>), overtaken in terms of epidemiology only by <italic toggle="yes">S. aureus</italic>. It is estimated that in the USA about 66 000 enterococcal infections occur each year, and about 20 000 of these are due to multiple-drug-resistant strains, with about 1300 deaths per year (Reyes, Bardossy and Zervos <xref rid="bib304" ref-type="bibr">2016</xref>).</p><p>Initially, a CPS with an LTA-like structure composed of &#945;-D-Glc<italic toggle="yes">p</italic>-(1&#8594;2)-&#945;-D-Glc<italic toggle="yes">p</italic>-(1&#8594;2)-Gro-3P (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) was isolated in <italic toggle="yes">En. faecalis</italic> (Huebner <italic toggle="yes">et&#160;al.</italic><xref rid="bib169" ref-type="bibr">1999</xref>; Wang <italic toggle="yes">et&#160;al.</italic><xref rid="bib384" ref-type="bibr">1999</xref>). A different surface-exposed polysaccharide composed of glucose, galactose, glycerol and phosphate in a 4:1:1:2 ratio was also reported (Hancock and Gilmore <xref rid="bib147" ref-type="bibr">2002</xref>). Based on the analysis of the biosynthetic CPS locus, four serotypes A-D were later described (Hufnagel <italic toggle="yes">et&#160;al.</italic><xref rid="bib171" ref-type="bibr">2004</xref>). A recent analysis of clinical <italic toggle="yes">En. faecalis</italic> isolates indicated that most pathogenic strains belong to serotype C. This suggested that a limited number of <italic toggle="yes">En. faecalis</italic> capsular serotypes would be needed for developing a broadly active immunotherapeutic agent. However, in another study, a collection of 157 isolates was examined, and only half of them could be typed to any of these four serotypes indicating that serotype diversity might be larger (Hufnagel <italic toggle="yes">et&#160;al.</italic><xref rid="bib170" ref-type="bibr">2006</xref>).</p><p>Early studies showed that purified CPS depleted the opsonic killing activity of immune rabbit sera, and elicited in rabbit high titers of antibodies mediating opsonic killing of bacteria (Huebner <italic toggle="yes">et&#160;al.</italic><xref rid="bib169" ref-type="bibr">1999</xref>, <xref rid="bib168" ref-type="bibr">2000</xref>). Approximately one-third of a sample of 15 <italic toggle="yes">En. faecalis</italic> strains and 7 vancomycin-resistant <italic toggle="yes">En. faecium</italic> strains were shown to possess shared CPS, target of opsonophagocytic antibodies. CPS also elicited protective antibodies in a mouse model of systemic enterococcal infection (Huebner <italic toggle="yes">et&#160;al.</italic><xref rid="bib168" ref-type="bibr">2000</xref>). Anti-CPS antibodies made in rabbits passively protected mice against serologically related enterococcal strains. Furthermore, capsule producing strains of serotype C and D resulted more resistant to complement-mediated opsonophagocytosis than unencapsulated strains (Thurlow <italic toggle="yes">et&#160;al.</italic><xref rid="bib355" ref-type="bibr">2009</xref>), supporting the role of the CPS as virulence factor and possible vaccine antigen.</p></sec></sec><sec id="sec3-6"><title>
<roman toggle="no">Group B</roman>
<italic toggle="yes">Streptococcus</italic>
</title><p>Group B <italic toggle="yes">Streptococcus</italic> (<italic toggle="yes">Streptococcus agalactiae</italic>; GBS) is an encapsulated Gram-positive &#946;-hemolytic pathogen, leading cause of neonatal sepsis and meningitis (Le Doare and Heath <xref rid="bib210" ref-type="bibr">2013</xref>). Risk factors for developing invasive GBS include maternal GBS vaginal-colonization, prematurity, prolonged rupture of membranes (&gt;18 h), chorioamnionitis, young maternal age, black race and having a previous infant with invasive GBS disease. Current strategy for prevention of GBS infection in newborns is centered on maternal vaccination with CPS conjugates (Heath <xref rid="bib150" ref-type="bibr">2016</xref>). Since, based on the structure of the CPS structure, 10 serotypes can be differentiated, 5 of which are responsible for the majority of the epidemiology, multiple polysaccharides are used for the development of conjugate vaccines. GSK has sponsored phase-1 and -2 trials of an investigational trivalent (Ia, Ib, III) CPS-CRM<sub>197</sub> conjugate vaccine, and is currently pursuing pre-clinical studies of a pentavalent (Ia, Ib, II, III, V) CPS-CRM<sub>197</sub> vaccine (Kobayashi <italic toggle="yes">et&#160;al.</italic><xref rid="bib198" ref-type="bibr">2016</xref>). Pfizer has recently announced to enter clinical trials with a multivalent formulation (Kobayashi <italic toggle="yes">et&#160;al.</italic><xref rid="bib198" ref-type="bibr">2016</xref>).</p></sec><sec id="sec3-7"><title>
<italic toggle="yes">Haemophilus influenzae</italic>
<roman toggle="no">type a</roman>
</title><p>Among the six different capsulated strains (a&#8211;f) of the Gram-negative <italic toggle="yes">H. influenzae</italic>, b and a are the most infective ones. Hib was the first pathogen against which a conjugated CPS vaccine was developed and introduced in vaccination schedules, with consequent significant decrease of incidence. In recent years, increasing rates of invasive infection due to Hia have been reported in Canada, Alaska, Aboriginal populations in southwestern USA and Australia, and in Brazil (Ribeiro <italic toggle="yes">et&#160;al.</italic><xref rid="bib305" ref-type="bibr">2003</xref>; Boisvert and Moore <xref rid="bib22" ref-type="bibr">2015</xref>). However, due to lack of comprehensive surveillance programs in many countries, the epidemiological data of Hia-associated diseases are neither complete nor accurately recorded, potentially underestimating the impact of Hia infection worldwide (Ulanova and Tsang <xref rid="bib360" ref-type="bibr">2014</xref>). Cases of non-Hib disease have been reported to exhibit AMR to commonly used therapeutic agents making treatment more challenging (Skaare <italic toggle="yes">et&#160;al.</italic><xref rid="bib339" ref-type="bibr">2014</xref>). Hia and Hib share a similar CPS structure (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>), but no cross-protection is afforded to type a by immunization with Hib conjugate vaccines (Jin <italic toggle="yes">et&#160;al.</italic><xref rid="bib179" ref-type="bibr">2007</xref>). Considering the similarity of the two CPS, a conjugate vaccine against Hia is likely to be effective and the development of a vaccine comparable to the current Hib conjugate appears reasonable (Boisvert and Moore <xref rid="bib22" ref-type="bibr">2015</xref>). This hypothesis was corroborated by recent conjugation of sized and activated Hia polysaccharide to CRM<sub>197</sub> and protein D as carriers (Cox <italic toggle="yes">et&#160;al.</italic><xref rid="bib71" ref-type="bibr">2017</xref>). The glycoconjugates were immunogenic in rabbits and elicited bactericidal antibodies.</p></sec><sec id="sec3-7-1"><title>Klebsiella pneumoniae</title><p>
<italic toggle="yes">Klebsiella pneumoniae</italic> is a Gram-negative pathogen belonging to the family of <italic toggle="yes">Enterobacteriaceae</italic>, implicated in severe infections and outbreaks with high mortality especially for multidrug-resistant infections (Brady <italic toggle="yes">et&#160;al.</italic><xref rid="bib28" ref-type="bibr">2016</xref>). In 2013, it was reported among the top five causes of hospital-acquired infection in EU (Suetens <italic toggle="yes">et&#160;al.</italic><xref rid="bib346" ref-type="bibr">2013</xref>) and the second leading cause of Gram-negative blood stream infection. Depending on the type of infection and the mode of infectivity, cells of <italic toggle="yes">Klebsiella</italic> spp. may adhere and attack upper respiratory tract epithelial cells, cells in gastrointestinal tract, endothelial cells or uroepithelial cells, followed by colonization of mucosal membranes. Common underlying conditions include alcoholism, diabetes mellitus, chronic liver disease (cirrhosis), chronic renal failure, cancer, transplants, burns and/or use of catheters. <italic toggle="yes">Klebsiella</italic> spp. can be transmitted through skin contact with environmentally contaminated surfaces and/or objects, and less frequently by fecal transmission (Janda and Abbott <xref rid="bib174" ref-type="bibr">2006</xref>). Seventy-eight capsular antigens (K antigens), leading to different serogroups, have been identified, although about 24/25 were reported to cover about 70% of epidemiology (Podschun and Ullmann <xref rid="bib291" ref-type="bibr">1998</xref>). The role of the capsule as virulent factor was demonstrated by pioneering studies by Cryz <italic toggle="yes">et&#160;al.</italic> (Cryz <xref rid="bib73" ref-type="bibr">1983</xref>; Cryz, Furer and Germanier <xref rid="bib75" ref-type="bibr">1984</xref>). Strains with capsular serotypes K1 and K2 (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) have been identified as the predominant virulent strains, and their virulence has been confirmed in mouse models (Struve <italic toggle="yes">et&#160;al.</italic><xref rid="bib345" ref-type="bibr">2015</xref>).</p><p>The capsules of <italic toggle="yes">K. pneumoniae</italic> are complex acidic polysaccharides (CPS) consisting of repeating units composed of four to six sugars, one of which is often an uronic acid (Corsaro <italic toggle="yes">et&#160;al.</italic><xref rid="bib67" ref-type="bibr">2005</xref>). The synthetic hexasaccharide repeating unit of the capsule from carbapenem-resistant strains belonging to the sequence type 258 (ST258), found in some isolates in the USA and Israel (Diago-Navarro <italic toggle="yes">et&#160;al.</italic><xref rid="bib92" ref-type="bibr">2014</xref>), has recently been demonstrated to bind a specific mAb and to promote, after conjugation, the production of phagocytic antibodies (Seeberger <italic toggle="yes">et&#160;al.</italic><xref rid="bib329" ref-type="bibr">2017</xref>).</p><p>A 24-valent CPS-based vaccine passed phase 1 in human trials, but the maximum protection coverage never exceeded 70% of the <italic toggle="yes">K. pneumoniae</italic> strains (Ahmad <italic toggle="yes">et&#160;al.</italic><xref rid="bib6" ref-type="bibr">2012a</xref>). Consequently, attention has been addressed to other surface polysaccharides, particularly the O-Ag, which will be discussed later.</p></sec><sec id="sec3-8"><title>
<italic toggle="yes">Salmonella</italic>
<roman toggle="no">species</roman>
</title><p>
<italic toggle="yes">Salmonella enterica</italic> serovar Typhi (<italic toggle="yes">S</italic>. Typhi), which causes the so-called typhoid fever, is still a major problem in low-income countries, such as South and South-East Asia, affecting millions of people each year (Mogasale <italic toggle="yes">et&#160;al.</italic><xref rid="bib255" ref-type="bibr">2014</xref>). Vi CPS (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) is currently licensed as a vaccine against typhoid fever (MacLennan, Martin and Micoli <xref rid="bib234" ref-type="bibr">2014</xref>). However, being an T-independent antigen, Vi is not immunogenic in infants and is only licensed for children over 2 years of age (Lebacq <xref rid="bib211" ref-type="bibr">2001</xref>). While a phase 3 study was reported more than 15 years ago demonstrating high protective efficacy of Vi CPS conjugated to <italic toggle="yes">r</italic>EPA (Lin <italic toggle="yes">et&#160;al.</italic><xref rid="bib217" ref-type="bibr">2001</xref>), only recently Vi-TT and Vi-<italic toggle="yes">r</italic>EPA conjugate vaccines were licensed in India and China (MacLennan, Martin and Micoli <xref rid="bib234" ref-type="bibr">2014</xref>). CPS-based glycoconjugate vaccines against <italic toggle="yes">S.</italic> Typhi are currently under development by a number of manufacturers (Table&#160;<xref ref-type="table" rid="tbl1">1</xref>).</p></sec><sec id="sec3-8-1"><title>Staphylococcus aureus</title><p>Among the Gram-positive bacteria, staphylococci account for a large proportion of hospital-acquired infections (Theilacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib354" ref-type="bibr">2004</xref>). High rates are observed for methicillin-resistant <italic toggle="yes">S. aureus</italic> infections (MRSA), which cause mostly pneumonia, skin-, wound-, bloodstream- and surgical site infections (Theilacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib354" ref-type="bibr">2004</xref>). In the USA, the annual incidence of <italic toggle="yes">S. aureus</italic> bacteremia is of 15&#8211;17 cases per 100 000 population, of which nearly half are due to MRSA (Hidron <italic toggle="yes">et&#160;al.</italic><xref rid="bib153" ref-type="bibr">2008</xref>), justifying the need for vaccination. Although there are at least 12 capsular types, CPS5 and 8 (Jones <xref rid="bib181" ref-type="bibr">2005</xref>) (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) comprise &#8764;85% of blood infections, and their use for vaccine development was explored (Robbins <italic toggle="yes">et&#160;al.</italic><xref rid="bib308" ref-type="bibr">2004</xref>). A single unadjuvanted dose of the bivalent vaccine composed of <italic toggle="yes">S. aureus</italic> CPS5 and 8, bound to <italic toggle="yes">r</italic>EPA, showed a trend of efficacy over the first 40 weeks postvaccination (Fattom <italic toggle="yes">et&#160;al.</italic><xref rid="bib106" ref-type="bibr">2004a</xref>,<xref rid="bib107" ref-type="bibr">b</xref>). However, the same vaccine did not show benefit compared to placebo when tested in further trials in end-stage renal disease patients as target population (Fattom <italic toggle="yes">et&#160;al.</italic><xref rid="bib108" ref-type="bibr">2015</xref>). CPS5 and 8 conjugated to TT, in combination with mutated detoxified alpha-toxin and clumping factor A (ClfA), with and without the adjuvant AS03B, were safe and induced a strong humoral response in a phase-1 clinical trial with healthy adults conducted by GSK (Levy <italic toggle="yes">et&#160;al.</italic><xref rid="bib213" ref-type="bibr">2015</xref>). Also CRM<sub>197</sub> conjugates of CPS5 and 8 in mixture with ClfA and manganese transporter C, without adjuvant, were well tolerated and immunogenic in a phase-1 clinical trial conducted by Pfizer (Nissen <italic toggle="yes">et&#160;al.</italic><xref rid="bib269" ref-type="bibr">2015</xref>; Frenck <italic toggle="yes">et&#160;al.</italic><xref rid="bib119" ref-type="bibr">2017</xref>).</p></sec></sec><sec id="sec3-9"><title>O-Antigens</title><p>O-Ag components of LPS molecules have been recognized as virulence factors and suggested as potential vaccine candidates for different pathogens.</p><sec id="sec3-9-1"><title>Burkhoderia pseudomallei <roman toggle="no">and</roman> mallei</title><p>LPS from Bp, generally referred as OPSII, is genetically related and structurally similar to the one from Bm. The O-Ag structure consists of a linear heteropolymer of a disaccharide composed of &#946;-D-glucopyranose (1&#8594;3)-linked to 6-deoxy-&#945;-L-talopyranose (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>). While some studies have focused on the OPSI capsule as unique antigen for a vaccine, others indicate OPSII to be required for serum resistance and virulence (DeShazer, Brett and Woods <xref rid="bib87" ref-type="bibr">1998</xref>; DeShazer <italic toggle="yes">et&#160;al.</italic><xref rid="bib88" ref-type="bibr">2001</xref>). LPS-specific monoclonal antibodies were proven passively protective in animal models of infection (Trevi&#241;o <xref rid="bib358a" ref-type="bibr">2006</xref>; AuCoin <xref rid="bib14a" ref-type="bibr">2012</xref>). Interspecies variations within the O-Ag lie in the different substitutions of the 6-deoxytalose residues, particularly O-acetylation at both C4 and C2 and O-methylation at C2 (Brett, Burtnick and Woods <xref rid="bib29" ref-type="bibr">2003</xref>). O-Acetylation at the C4 position has been detected in significant amounts in Bp, whereas it is absent in Bm strains (Heiss <italic toggle="yes">et&#160;al.</italic><xref rid="bib151" ref-type="bibr">2013</xref>). In a recent study, among a panel of seven disaccharides variably substituted, the disaccharide with a 2-O-acetylated-3-O-methylated 6d-Tal unit showed the best binding to a LPS-specific mAb, known to be passively protective in mouse models of melioidosis and glanders, and gave the highest anti-LPS immune response after conjugation to CRM<sub>197</sub> (Kenfack <italic toggle="yes">et&#160;al.</italic><xref rid="bib190" ref-type="bibr">2017</xref>). A bioconjugate of OPSII with a <italic toggle="yes">Campylobacter</italic> protein AcrA was shown to be immunogenic in mice and moderately increased protection of mice after intranasal challenge (Garcia-Quintanilla <italic toggle="yes">et&#160;al.</italic><xref rid="bib123" ref-type="bibr">2014</xref>).</p></sec><sec id="sec3-9-2"><title>Escherichia coli</title><p>
<italic toggle="yes">Escherichia coli</italic> is a Gram-negative bacterium that can be broadly classified as either diarrheagenic or extra-intestinal pathogenic <italic toggle="yes">E. coli</italic> (Croxen and Finlay <xref rid="bib72" ref-type="bibr">2009</xref>). ExPEC cause a broad variety of infections including urinary tract infections (UTI) and bacteremia, an increasing problem in the aging population (Russo and Johnson <xref rid="bib314" ref-type="bibr">2003</xref>). The emergence of antibiotic-resistant strains has resulted in increased numbers of hospitalizations for UTI, high risk of death in patients with bacteremia and intensified treatment costs (Zilberberg and Shorr <xref rid="bib412" ref-type="bibr">2013</xref>). O-Ag specific antibodies confer protection against <italic toggle="yes">E. coli</italic> infections (Sarkar <italic toggle="yes">et&#160;al.</italic><xref rid="bib320" ref-type="bibr">2014</xref>). The immunogenicity and safety of a tetravalent ExPEC vaccine produced by the process of bioconjugation, composed of the O1, O2, O6 and O25b antigens (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) linked to <italic toggle="yes">r</italic>EPA, showed good immunogenicity in animal models (van den Dobbelsteen <italic toggle="yes">et&#160;al.</italic><xref rid="bib364" ref-type="bibr">2016</xref>). This bioconjugate vaccine candidate, co-developed by Limmatech Biologics AG and Janssen Pharmaceuticals Inc., was well tolerated and elicited functional antibody responses against all vaccine serotypes in women with a history of recurrent UTI (Huttner <italic toggle="yes">et&#160;al.</italic><xref rid="bib172" ref-type="bibr">2017</xref>).</p></sec><sec id="sec3-9-3"><title>Francisella tularensis</title><p>
<italic toggle="yes">Francisella tularensis</italic> is a highly-infectious Gram-negative bacterium that causes the rapid, and often lethal disease, tularemia (Rowe and Huntley <xref rid="bib311" ref-type="bibr">2015</xref>). It has been classified by the Center for Disease Control and Prevention as a category A bioweapon (Dennis <italic toggle="yes">et&#160;al.</italic><xref rid="bib86" ref-type="bibr">2001</xref>). Humans can acquire this infection through several routes including a bite from an infected tick, deerfly or mosquito, contact with an infected animal or its dead body, drinking contaminated water and breathing contaminated dirt or aerosol. Clinical manifestation of the disease is dependent on the biotype, inoculum and port of entry (Ulu-Kilic and Doganay <xref rid="bib361" ref-type="bibr">2014</xref>).</p><p>A key factor in the biology of this bacterium is LPS, which poorly activates proinflammatory responses due to its lack of interaction with TLR4. LPS molecules can be modified by various carbohydrates, including Glc, Man and GalNAc, affecting various aspects of virulence. Mutants devoid of O-Ag (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) show reduced intracellular survival and mouse virulence. The inability of the LPS to alarm the immune system coupled with its frequent modification/alteration likely aid the success of this pathogen during human infection (Gunn and Ernst <xref rid="bib142" ref-type="bibr">2007</xref>). An OAg-<italic toggle="yes">r</italic>EPA bioconjugate was successfully produced (Cuccui <italic toggle="yes">et&#160;al.</italic><xref rid="bib79" ref-type="bibr">2013</xref>) and resulted able to boost IgG levels and significantly increase the time to death upon subsequent challenge with <italic toggle="yes">F. tularensis</italic>. The inner core region of the LPS of <italic toggle="yes">F. tularensis</italic> was synthesized and proved to be recognized by antiserum against LPS and a live vaccine strain, supporting to further explore this compound as a vaccine candidate (Boltje <italic toggle="yes">et&#160;al.</italic><xref rid="bib23" ref-type="bibr">2012</xref>). O-Ag displayed on OMVs from a hyperblebbing <italic toggle="yes">E. coli</italic> strain induced high levels of specific IgG titers, as well as vaginal and bronchoalveolar IgA antibodies, and provided protection against challenge with <italic toggle="yes">F. tularensis</italic> strain (Chen <italic toggle="yes">et&#160;al.</italic><xref rid="bib54" ref-type="bibr">2016</xref>).</p></sec><sec id="sec3-9-4"><title>Klebsiella pneumoniae</title><p>In contrast to the large number of capsular serotypes, <italic toggle="yes">K. pneumoniae</italic> has only nine LPS O groups, and in a recent study serotypes O1, O2 and O3 accounted for 80% of infections (Follador <italic toggle="yes">et&#160;al.</italic><xref rid="bib115" ref-type="bibr">2016</xref>). The O-Ag is accessible to antibodies in encapsulated strains (Rukavina <italic toggle="yes">et&#160;al.</italic><xref rid="bib312" ref-type="bibr">1997</xref>; Ahmad <italic toggle="yes">et&#160;al.</italic><xref rid="bib6" ref-type="bibr">2012a</xref>). However, it is unclear whether this is true for most of clinical isolates, since in some K serogroups O-Ag appears masked by CPS (Tom&#225;s <italic toggle="yes">et&#160;al.</italic><xref rid="bib357" ref-type="bibr">1991</xref>).</p><p>Conjugate vaccine of the O-Ag from <italic toggle="yes">K. pneumoniae</italic> M 10 and iron-regulated cell surface proteins of the same organism was found immunogenic and protective against challenge in a rat lobar pneumonia model (Chhibber and Bajaj <xref rid="bib60" ref-type="bibr">1995</xref>)<italic toggle="yes">.</italic> Immunization of rats with an O-Ag TT conjugate decreased bacterial colonization in lungs, and resulted in activation of alveolar macrophages capable of bacterial phagocytosis <italic toggle="yes">in vitro</italic> (Chhibber, Rani and Vanashree <xref rid="bib61" ref-type="bibr">2005</xref>).</p><p>The O1 O-Ag chemically linked to <italic toggle="yes">Klebsiella</italic> OM proteins elicited immunoglobulins against different <italic toggle="yes">Klebsiella</italic> infections, which were transferred via placenta to the offspring of the vaccinated rabbits (Ahmad <italic toggle="yes">et&#160;al.</italic><xref rid="bib7" ref-type="bibr">2012b</xref>). A non-toxic and immunogenic form of <italic toggle="yes">K. pneumoniae</italic> LPS was obtained by incorporation of the native preparation into liposomes (Chhibber, Wadhwa and Yadav <xref rid="bib62" ref-type="bibr">2004</xref>)<italic toggle="yes">.</italic></p><p>O1 and O2 O-Ag share a similar polygalactose structure, termed D-galactan-I, except that O1 is shielded by the outer repeating units (D-galactan-II, Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) (Whitfield <italic toggle="yes">et&#160;al.</italic><xref rid="bib393" ref-type="bibr">1991</xref>,<xref rid="bib392" ref-type="bibr">1992</xref>; Vinogradov <italic toggle="yes">et&#160;al.</italic><xref rid="bib374" ref-type="bibr">2002</xref>).</p><p>Recently, it was found that the vast majority of ST258 isolates, a globally disseminated drug-resistant nosocomial strain, express a modified D-galactan-I O-Ag, termed D-galactan-III (Szijarto <italic toggle="yes">et&#160;al.</italic><xref rid="bib348" ref-type="bibr">2016</xref>). Since 83% of the more than 200 ST258 draft genome sequences currently available carry the corresponding operon, these isolates are predicted to express D-galactan-III antigens. Accordingly, a D-galactan-III specific mAb was produced, showing to bind to extracted LPS from a panel of ST258 isolates, irrespective of the distinct capsular antigens expressed. Based on these data, the D-galactan-III antigen may represent an attractive target for immunization approaches against <italic toggle="yes">K. pneumoniae</italic> ST258.</p><p>Conjugates of polysaccharides from different serovars (Table&#160;<xref ref-type="table" rid="tbl1">1</xref>) to <italic toggle="yes">P. aeruginosa</italic> flagellin have been proven to induce protective antibodies (Simon, Cross and Tennant <xref rid="bib338" ref-type="bibr">2016</xref>). Attempts to target common motif in bacterial LPS such as the core tetrasaccharide Hep<sub>2</sub>Kdo<sub>2</sub> have been recently made. The structure was synthesized and covalently attached to DT. Rabbit serum elicited against the conjugate was reactive to <italic toggle="yes">N. meningitidis</italic> strains as well as <italic toggle="yes">E. coli</italic> strain St1052 (W3110) and <italic toggle="yes">P. aeruginosa</italic> serotype O6 reference strain (St4017). The serum enabled <italic toggle="yes">N. meningitidis</italic> bacterial killing, when combined to an inhibitor of CPS transport (Kong <italic toggle="yes">et&#160;al.</italic><xref rid="bib201" ref-type="bibr">2016</xref>).</p></sec><sec id="sec3-9-5"><title>Moraxella catarrhalis</title><p>
<italic toggle="yes">Moraxella catarrhalis</italic>, also known as <italic toggle="yes">Branhamella catarrhalis</italic>, and previously known as <italic toggle="yes">Neisseria catarrhalis</italic> or <italic toggle="yes">Micrococcus catarrhalis</italic>, is a Gram-negative, aerobic diplococcus, frequently found as a commensal of the upper respiratory tract, particularly in children.</p><p>Besides being recognized as the primary cause of acute otitis media after <italic toggle="yes">St. pneumoniae</italic> and <italic toggle="yes">H. influenzae</italic> (Enright and McKenzie <xref rid="bib102" ref-type="bibr">1997</xref>), <italic toggle="yes">M. catarrhalis</italic> is also implicated as a pathogen in bronchitis, sinusitis and laryngitis in adults and children and is a major cause of bronchopneumonia and exacerbation of existing chronic obstructive pulmonary disease (COPD) in elderly patients and long-term heavy smokers with chronic pulmonary disease (Sethi and Murphy <xref rid="bib330" ref-type="bibr">2001</xref>). It can also cause nosocomial infection, particularly in respiratory, pediatric and intensive-care units (Richards <italic toggle="yes">et&#160;al.</italic><xref rid="bib306" ref-type="bibr">1993</xref>). The clinical management of patients infected with <italic toggle="yes">M. catarrhalis</italic> relies predominantly on antimicrobial agents, and growing global emergence of &#946;-lactamase-producing strains (Verduin <italic toggle="yes">et&#160;al.</italic><xref rid="bib371" ref-type="bibr">2002</xref>) has highlighted the need for vaccination (Kaieda <italic toggle="yes">et&#160;al.</italic><xref rid="bib185" ref-type="bibr">2005</xref>).</p><p>The LPS from <italic toggle="yes">M. catarrhalis</italic> lacks of a full-length O chain, and therefore the LOS is a possible virulence factor in the pathogenesis of human infections (Fomsgaard <italic toggle="yes">et&#160;al.</italic><xref rid="bib116" ref-type="bibr">1991</xref>). Serological studies have identified three <italic toggle="yes">M. catarrhalis</italic> LOS types (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>): A, B and C, representing 61%, 29% and 5%, respectively, of the 95% of the total 302 isolates tested from different geographic locations (Vaneechoutte <italic toggle="yes">et&#160;al.</italic><xref rid="bib367" ref-type="bibr">1990</xref>). The inner core is conserved among the three serotypes, while the difference lies in the diversity of their oligosaccharide branches (Edebrink <italic toggle="yes">et&#160;al.</italic><xref rid="bib96" ref-type="bibr">1994</xref>, <xref rid="bib97" ref-type="bibr">1995</xref>, <xref rid="bib98" ref-type="bibr">1996</xref>). Therefore, this LOS might be a good candidate for a vaccine antigen (Verduin <italic toggle="yes">et&#160;al.</italic><xref rid="bib371" ref-type="bibr">2002</xref>). Sera from lower respiratory tract-infected patients recognized <italic toggle="yes">M. catarrhalis</italic> LOS (Rahman <italic toggle="yes">et&#160;al.</italic><xref rid="bib297" ref-type="bibr">1995</xref> ), and convalescent sera from COPD patients possessed IgA antibodies against this molecule (Murphy <italic toggle="yes">et&#160;al.</italic><xref rid="bib262" ref-type="bibr">2005</xref>).</p><p>Recent studies identified a mAb recognizing a common LOS epitope and facilitating complement killing of <italic toggle="yes">M. catarrhalis</italic> strains from all three major serotypes (Gergova <italic toggle="yes">et&#160;al.</italic><xref rid="bib129" ref-type="bibr">2007</xref>). Immunization with detoxified LOS A, B and C coupled to carrier proteins produced in mouse and rabbit models sera inducing complement-mediated bactericidal activity against homologous and some heterologous strains (Gu <italic toggle="yes">et&#160;al.</italic><xref rid="bib135" ref-type="bibr">1998</xref>; Yu and Gu <xref rid="bib408" ref-type="bibr">2005</xref>, <xref rid="bib409" ref-type="bibr">2007</xref>). Mouse antisera elicited by detoxified LOS conjugated to OMP CD or to UspA proteins showed high titers of specific anti-LOS antibodies, with complement-dependent bactericidal activity toward <italic toggle="yes">M. catarrhalis</italic>. In addition, mice immunized with both conjugates showed a significant enhancement of the clearance of <italic toggle="yes">M. catarrhalis</italic> from lungs compared with control mice (Hu <italic toggle="yes">et&#160;al.</italic><xref rid="bib166" ref-type="bibr">2000</xref>, <xref rid="bib165" ref-type="bibr">2004</xref>).</p></sec><sec id="sec3-9-6"><title>Neisseria gonorrhoeae</title><p>
<italic toggle="yes">Neisseria gonorrhoeae</italic> is the causative agent of the sexually transmitted disease gonorrhea. WHO reports an estimated global incidence of over 106 million cases per year, with a 21% increase in incidence having occurred between 2005 and 2008 (WHO <xref rid="bib395" ref-type="bibr">2012</xref>; Edwards <italic toggle="yes">et&#160;al.</italic><xref rid="bib99" ref-type="bibr">2016</xref>). A 11% increase in the number of cases has been reported in the USA from 2009 to 2013 (CDC <xref rid="bib47" ref-type="bibr">2013b</xref>) and a 90% increase in Australia from 2009 to 2014 (NNDSS <xref rid="bib270" ref-type="bibr">2015</xref>). Incidence is likely underestimated due to inadequate surveillance and diagnostics methods in many regions, as well as the high number of asymptomatic cases. Gonococcus has developed resistance to all classes of antibiotics used to treat it over the past seven decades, including the sulphonamides, penicillins, tetracyclines, macrolides and quinolones (Unemo <xref rid="bib362" ref-type="bibr">2015</xref>). As other <italic toggle="yes">Neisseria</italic> species, gonococcus biosynthesizes a core LPS pentasaccharide (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>), of which extensions from the LOS core heptoses (HepI and HepII) are phase variable. The mAb 2C7 which attenuates gonococcal burden in the mouse vaginal colonization model is directed to LOS. Sugar motifs responsible for total, partial or no complement-dependent killing by mAb 2C7 have been identified (Yamasaki <italic toggle="yes">et&#160;al.</italic><xref rid="bib405" ref-type="bibr">2010</xref>; Chakraborti <italic toggle="yes">et&#160;al.</italic><xref rid="bib52" ref-type="bibr">2016</xref>). Heptose-monophosphate (HMP) found in <italic toggle="yes">N. gonorrhoeae</italic> core LOS was found as the link between gonorrhea and HIV, since it activates CD4&#160;+&#160;T cells to invoke an NF-&#954;B&#8211;dependent transcriptional response that drives HIV-1 expression and viral production (Malott <italic toggle="yes">et&#160;al.</italic><xref rid="bib241" ref-type="bibr">2013</xref>). The 2C7 epitope is a conserved oligosaccharide (OS) structure expressed by 94% of gonococci that reside in the human genital tract and by 95% of first passaged isolates (Gulati <italic toggle="yes">et&#160;al.</italic><xref rid="bib140" ref-type="bibr">1996</xref>).</p><p>A peptide mimic (called PEP1) as an immunological surrogate of the 2C7-OS epitope and reconfigured into a multi-antigenic peptide (MAP1) was investigated. Mice immunized with MAP1 developed a Th1-biased anti-LOS IgG antibody response that was also bactericidal, resulting in reduction of the carriage length (Gulati <italic toggle="yes">et&#160;al.</italic><xref rid="bib141" ref-type="bibr">2013</xref>).</p></sec><sec id="sec3-9-7"><title>
<roman toggle="no">Non-typeable</roman> Haemophilus influenzae</title><p>Non-typeable <italic toggle="yes">Haemophilus influenzae</italic> (NHTi) strains lack the polysaccharide capsule, and their virulence is associated with multiple factors, including LOS. So far, the only known natural habitat of <italic toggle="yes">H. influenzae</italic> is the human respiratory tract. The hallmark of NTHi is heterogeneity, and this has been the major obstacle for developing a successful vaccine. <italic toggle="yes">H. influenzae</italic> cause a wide spectrum of diseases ranging from respiratory tract infections to severe invasive disease, such as meningitis, sepsis, bacteraemic pneumonia and epiglottitis (Cerquetti and Giufre <xref rid="bib51" ref-type="bibr">2016</xref>). After introduction of Hib vaccination, a marked change in the predominant invasive serotype from Hib to NTHi has taken place. Invasive NTHi disease occurs across all age groups and account for 77% of all notified invasive <italic toggle="yes">H. influenzae</italic> cases in Europe. NTHi is also the most frequently isolated bacterial pathogen in otitis media and sinusitis in children (Murphy, Bakaletz and Smeesters <xref rid="bib261" ref-type="bibr">2009</xref>). Acute exacerbations in COPD in adults are almost exclusively associated with NTHi isolates (Soriano and Lamprecht <xref rid="bib342" ref-type="bibr">2012</xref>). NTHi colonization/infection is also quite common in young children with cystic fibrosis (CF). In developing countries, NTHi is the major cause of hearing loss, affecting an estimated 65 million to 300 million people globally (Murphy <xref rid="bib260" ref-type="bibr">2015</xref>).</p><p>Vaccines to prevent otitis media and COPD will have a broad impact in reducing antimicrobial use and resistance (Murphy <xref rid="bib260" ref-type="bibr">2015</xref>).</p><p>NTHi LOS is structurally and antigenically heterogeneous. To date, 10 serotypes have been identified (Campagnari <italic toggle="yes">et&#160;al.</italic><xref rid="bib41" ref-type="bibr">1987</xref>; Patrick <italic toggle="yes">et&#160;al.</italic><xref rid="bib277" ref-type="bibr">1987</xref>). Detoxified LOS (dLOS) conjugated to proteins resulted immunogenic in mice and rabbits and conferred T-cell-dependent immunological protection against otitis media in chinchillas (Gu <italic toggle="yes">et&#160;al.</italic><xref rid="bib134" ref-type="bibr">1996</xref>, <xref rid="bib136" ref-type="bibr">1997</xref>; Sun <italic toggle="yes">et&#160;al.</italic><xref rid="bib347" ref-type="bibr">2000</xref>). Intranasal immunization with a dLOS-TT conjugate elicited LOS-specific mucosal and systemic immunity, which enhanced not only the homologous but also heterologous bacterial clearance in mouse nasopharynx (Hirano <italic toggle="yes">et&#160;al.</italic><xref rid="bib154" ref-type="bibr">2003</xref>). NTHi OM protein P6 was evaluated as carrier for dLOS, due to its conservation and potential to elicit bactericidal antibodies (Wu <italic toggle="yes">et&#160;al.</italic><xref rid="bib400" ref-type="bibr">2005</xref>). Animal studies revealed that P6 could serve as an effective carrier for dLOS.</p><p>Peptides that mimic NTHi LOS, conjugated to KLH, were able to induce anti-LOS antibodies in rabbits (Hou and Gu <xref rid="bib161" ref-type="bibr">2003</xref>; Balakrishnan <xref rid="bib15" ref-type="bibr">2017</xref>). Passive immunization with the anti-LOS sera resulted in enhanced pulmonary bacterial clearance in a mouse model that could be eliminated after pre-absorption of the sera with LOS.</p></sec><sec id="sec3-10-1"><title>Pseudomonas aeruginosa</title><p>
<italic toggle="yes">Pseudomonas aeruginosa</italic> (PA) is a Gram-negative, ubiquitous bacterium, capable of both aerobic and anaerobic growth that can survive on minimal nutritional requirements and tolerate harsh physical conditions, persisting in both community and hospital settings. Serious infections with PA are predominantly hospital acquired (Sharma, Krause and Worgall <xref rid="bib332" ref-type="bibr">2011</xref>) and PA has highest mortality rate (37%) of nosocomial infections (Klevens, Edwards and Gaynes <xref rid="bib193" ref-type="bibr">2008</xref>; Lister, Wolter and Hanson <xref rid="bib223" ref-type="bibr">2009</xref>).</p><p>PA may cause fulminant and acute VAP (Klompas <italic toggle="yes">et&#160;al.</italic><xref rid="bib194" ref-type="bibr">2011</xref>; Sandiumenge and Rello <xref rid="bib319" ref-type="bibr">2012</xref>), be a colonizer in COPD or cause a chronic infection in CF patients (Sharma, Krause and Worgall <xref rid="bib332" ref-type="bibr">2011</xref>), with slowly progressive deterioration of pulmonary function as well as non-CF bronchiectasis and COPD patients (Kraemer <italic toggle="yes">et&#160;al.</italic><xref rid="bib203" ref-type="bibr">2005</xref>; Veesenmeyer <italic toggle="yes">et&#160;al.</italic><xref rid="bib369" ref-type="bibr">2009</xref>).</p><p>Antibiotic resistance of PA is a major concern. Antibiotics can alter the bacterial flora in the upper respiratory tract, favoring colonization of resistant nosocomial pathogens and subsequent pneumonia. Treatment of infections can be very challenging, since most PA are resistant to at least one of the classes of antibiotics, and a few PA are resistant even to all of the antibiotics available (Talbot <italic toggle="yes">et&#160;al.</italic><xref rid="bib350" ref-type="bibr">2006</xref>; Pier <xref rid="bib289" ref-type="bibr">2007</xref>).</p><p>At least 20 different O-Ag structures can be distinguished, although only about 11 of these are expressed in the majority of clinical PA isolates. The lipid A shows variation from CF to bronchiectasis patients in the acylation pattern. Also O-Ag shows variability, as transition to chronic infections is correlated with changes in LPS from smooth (with O-Ag) to rough (with no O-Ag). The core structure seems to remain identical. The most commonly isolated serotypes in acute infection are O1, 6 and 11 (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>), yet there is a quote of isolates not expressing O-Ag (Jennings <italic toggle="yes">et&#160;al.</italic><xref rid="bib178" ref-type="bibr">2015</xref>).</p><p>A heptavalent vaccine prepared from LPS of seven different serotypes, called Pseudogen, showed efficacy in preventing fatal PA infections in non-randomized trials among adult cancer and burn patients, but these vaccines were limited by toxicity and showed no benefit moreover in studies with leukemia and CF patients (Alexander, Fisher and MacMillan <xref rid="bib9" ref-type="bibr">1971</xref>; Haghbin, Armstrong and Murphy <xref rid="bib144" ref-type="bibr">1973</xref>; Young, Meyer and Armstrong <xref rid="bib407" ref-type="bibr">1973</xref>; Pennington <italic toggle="yes">et&#160;al.</italic><xref rid="bib283" ref-type="bibr">1975</xref>; Hortobagyi <italic toggle="yes">et&#160;al.</italic><xref rid="bib160" ref-type="bibr">1978</xref>). When Pseudogen was tested in CF patients already infected with PA, the patients did clinically worse compared with non-vaccinated controls, perhaps due to exacerbation of inflammation engendered by vaccination (MacIntyre, McVeigh and Owen <xref rid="bib231" ref-type="bibr">1986</xref>). An improved LPS-based polyvalent vaccine (16 strains) was investigated in na&#239;ve CF patients. The vaccine failed to reduce the rate of PA colonization when compared with the non-vaccinated control group. The same vaccine was also tested in burn patients with inconclusive results (Jones, Roe and Gupta <xref rid="bib182" ref-type="bibr">1978</xref>; Langford and Hiller <xref rid="bib208" ref-type="bibr">1984</xref>). Possibly, the vaccine did not protect against a sufficient range of PA LPS serotypes (Doring and Pier <xref rid="bib95" ref-type="bibr">2008</xref>; Priebe and Goldberg <xref rid="bib294" ref-type="bibr">2014</xref>). Aerugen, an 8-valent vaccine from O-Ag conjugated to exotoxin A (EPA), was initially demonstrated safe and immunogenic in plasma donors, bone marrow transplant and non-colonized CF patients (Cryz <italic toggle="yes">et&#160;al.</italic><xref rid="bib74" ref-type="bibr">1987</xref>, <xref rid="bib76" ref-type="bibr">1989</xref>; Schaad <italic toggle="yes">et&#160;al.</italic><xref rid="bib323" ref-type="bibr">1991</xref>; Lang <italic toggle="yes">et&#160;al.</italic><xref rid="bib207" ref-type="bibr">2004</xref>). In a small open study involving 30 non-colonized CF, the vaccine was confirmed well tolerated and induced antibodies to the O-Ag promoting the opsonophagocytic killing which were maintained up to 3 years (Cryz <italic toggle="yes">et&#160;al.</italic><xref rid="bib77" ref-type="bibr">1994</xref>). In a cohort of 25 CF patients, yearly vaccinations over 10 years induced IgG levels lower than infection-induced IgG titers, but affinity and epitope specificity rather than the quantity of the antibodies was shown to mediate protection (Zuercher <italic toggle="yes">et&#160;al.</italic><xref rid="bib414" ref-type="bibr">2006</xref>). However, in a larger trial in European CF patients, Aerugen showed good safety but no significant differences from the placebo (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.biospace.com/News/crucell-n-v-announces-suspension-of-aerugenr/24447">http://www.biospace.com/News/crucell-n-v-announces-suspension-of-aerugenr/24447</ext-link>). In bronchiectasis patients, high titers of IgG2 specific for the O-Ag resulted in impaired PA serum-mediated killing (Wells <italic toggle="yes">et&#160;al.</italic><xref rid="bib387" ref-type="bibr">2014</xref>), which could explain the inconsistent results of LPS-based approaches.</p></sec><sec id="sec3-11"><title>
<italic toggle="yes">Salmonella</italic>
<roman toggle="no">species</roman>
</title><p>Due to the lack of CPS, the development of O-Ag based vaccines is in progress for <italic toggle="yes">S.</italic> Paratyphi A, and non-typhoid <italic toggle="yes">Salmonella</italic> (NTS). In Asia, a significant proportion of enteric fever is caused by <italic toggle="yes">S.</italic> Paratyphi A, while NTS, mainly <italic toggle="yes">S.</italic> Typhimurium and <italic toggle="yes">S.</italic> Enteritidis, is major cause of bloodstream infection in sub-Saharan Africa (MacLennan, Martin and Micoli <xref rid="bib234" ref-type="bibr">2014</xref>). O-Ag from three of the principal invasive serovars (namely, O:2 for <italic toggle="yes">S</italic>. Paratyphi A, and O:4,5 for <italic toggle="yes">S.</italic> Typhimurium and O:9 for <italic toggle="yes">S.</italic> Enteritidis) have been conjugated to carrier proteins and tested in animal models (MacLennan, Martin and Micoli <xref rid="bib234" ref-type="bibr">2014</xref>). Conjugation of <italic toggle="yes">S.</italic> Typhi O-Ag to rEPA has also been carried out to cover Vi-negative strains (Salman <italic toggle="yes">et&#160;al.</italic><xref rid="bib318" ref-type="bibr">2017</xref>). However, no vaccine is yet available against these diseases.</p></sec><sec id="sec3-12"><title>
<italic toggle="yes">Shigella</italic>
<roman toggle="no">species</roman>
</title><p>
<italic toggle="yes">Shigella</italic> species have recently been reviewed (Mani, Wierzba and Walker <xref rid="bib242" ref-type="bibr">2016</xref>). Shigellosis is caused by the ingestion of bacteria of the genus <italic toggle="yes">Shigella</italic>, of which three species are responsible for the majority of infections. <italic toggle="yes">Shigella flexneri</italic> is the most frequently isolated species worldwide, accounting for most cases in the least-developed countries; <italic toggle="yes">Sh. sonnei</italic> is more common in low- and middle-income countries; and <italic toggle="yes">Sh. dysenteriae</italic> has historically caused epidemics of dysentery, particularly in confined populations such as refugee camps (Mani, Wierzba and Walker <xref rid="bib242" ref-type="bibr">2016</xref>). Immunity to <italic toggle="yes">Shigella</italic> appears to be strain-specific, so an O-Ag-based vaccine covering the most commonly detected strains (i.e. <italic toggle="yes">Sh. flexneri</italic> 2a, 3a, 6 and <italic toggle="yes">Sh. sonnei</italic>) is desirable.</p><p>A conjugate vaccine composed of <italic toggle="yes">Sh. sonnei</italic> O-Ag bound to <italic toggle="yes">r</italic>EPA conferred type-specific protection against <italic toggle="yes">Sh. sonnei</italic> shigellosis when tested in Israeli army recruits (Cohen <italic toggle="yes">et&#160;al.</italic><xref rid="bib64" ref-type="bibr">1997</xref>). <italic toggle="yes">Shigella dysenteriae</italic> type 1 and <italic toggle="yes">Sh. flexneri</italic> 2a bioconjugates (of which the glycan component is depicted in Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) elicited significant LPS specific humoral responses in phase-1 studies (Hatz <italic toggle="yes">et&#160;al.</italic><xref rid="bib149" ref-type="bibr">2015</xref>; Riddle <italic toggle="yes">et&#160;al.</italic><xref rid="bib307" ref-type="bibr">2016</xref>). These promising studies support the use of O-Ag-based conjugates for human vaccination. Efforts have also been addressed to the synthesis of <italic toggle="yes">Sh. flexneri</italic> 2a and 3a O-Ag through rational investigation of minimal structural epitopes and impact of O-acetylation pattern in the structures (Boutet and Mulard <xref rid="bib26" ref-type="bibr">2008</xref>; Vulliez-Le Normand <italic toggle="yes">et&#160;al.</italic><xref rid="bib378" ref-type="bibr">2008</xref>; Phalipon <italic toggle="yes">et&#160;al.</italic><xref rid="bib287" ref-type="bibr">2009</xref>; Gauthier <italic toggle="yes">et&#160;al.</italic><xref rid="bib125" ref-type="bibr">2014</xref>). The conjugate of a synthetic pentadecasaccharide composed of three consecutive repeating units of <italic toggle="yes">Sh. flexneri</italic> 2a O-Ag, developed at the Pasteur Institute in France, has been recently tested in a phase-1 study (van der Put <italic toggle="yes">et&#160;al.</italic><xref rid="bib365" ref-type="bibr">2016</xref>).</p><sec id="sec3-12-1"><title>Vibrio cholerae</title><p>Cholera is a severe dehydrating diarrheal disease caused by toxigenic strains of Gram-negative <italic toggle="yes">V. cholerae</italic>. It represents a major international health concern: &#8764;3&#8211;5 million cases of cholera and 100 000&#8211;130 000 deaths due to cholera occur each year globally (WHO <xref rid="bib394" ref-type="bibr">2010</xref>). Children, especially younger than 5 years of age, are at particular risk in endemic areas.</p><p>There are more than 200 serogroups of <italic toggle="yes">V. cholerae</italic>, classified based on the O-Ag specificity. Among these serogroups, cholera is mainly caused by <italic toggle="yes">V. cholerae</italic> serogroup O1 and less commonly by serogroup O139. O1 can be classified into two serotypes, Ogawa and Inaba, whose O-Ags are linear homopolymers of <italic toggle="yes">&#945;</italic>-(1&#8594;2)-linked 3-deoxy-<italic toggle="yes">glycero</italic>-tetronamido-D-perosamine, differing for the non-reducing end terminal perosamine unit that is 2-O-methylated only in the Ogawa serotype (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) (Chatterjee and Chaudhuri <xref rid="bib53" ref-type="bibr">2003</xref>).</p><p>Killed oral cholera vaccines are increasingly becoming a standard cholera prevention and control tool. However, their use has been hampered by the requirement of two or three priming doses, relatively short-term protection and responses of lower magnitude and shorter duration in young children (Balakrishnan <xref rid="bib15" ref-type="bibr">2017</xref>).</p><p>Conjugates from detoxified Inaba LPS linked to cholera toxin (CT) variants CT-1 and CT-2 were shown safe in adult volunteers and induced anti-LPS vibrocidal antibodies (Gupta <italic toggle="yes">et&#160;al.</italic><xref rid="bib143" ref-type="bibr">1998</xref>). Recently, O1 Ogawa and Inaba O-Ags conjugated to recombinant tetanus toxoid heavy chain fragment (TThc) induced carbohydrate specific immune responses and resulted respectively in 95% and 55% protective efficacy in a mouse survival cholera challenge model (Alam <italic toggle="yes">et&#160;al.</italic><xref rid="bib8" ref-type="bibr">2014</xref>; Sayeed <italic toggle="yes">et&#160;al.</italic><xref rid="bib322" ref-type="bibr">2015</xref>). Likewise, O139 linked to TT induced specific antibodies that were vibriocidal and protective in the neonatal mouse model of cholera infection (Boutonnier <italic toggle="yes">et&#160;al.</italic><xref rid="bib27" ref-type="bibr">2001</xref>). To avoid LPS toxicity, synthetic oligosaccharides deriving from O1 and O139 O-Ag have also been produced for conjugation to carrier proteins (Saksena <italic toggle="yes">et&#160;al.</italic><xref rid="bib319a" ref-type="bibr">2006</xref>; Soliman and Kovac <xref rid="bib341" ref-type="bibr">2016</xref>). While a Ogawa type hexsaccharide bound to BSA induced antibodies that were protective in a challenge assay (Chernyak <italic toggle="yes">et&#160;al.</italic><xref rid="bib59" ref-type="bibr">2002</xref>; Rollenhagen <italic toggle="yes">et&#160;al.</italic><xref rid="bib309" ref-type="bibr">2009</xref>), the Inaba counterpart linked to <italic toggle="yes">r</italic>EPA induced specific antibodies which were neither vibriocidal nor protective in the infant mouse cholera model (Wade <italic toggle="yes">et&#160;al.</italic><xref rid="bib382" ref-type="bibr">2006</xref>). The elicited antibodies, regardless of serotype, were cross-reactive to heterologous LPS; however, anti-Ogawa serum did not kill Inaba bacteria, suggesting that immunodominant LPS epitopes differ between Ogawa and Inaba LPS.</p></sec></sec></sec><sec id="sec3-13"><title>Other surface carbohydrates</title><p>In addition to CPS or O-Ag, other carbohydrates decorating the surface of microbial pathogens have been targeted for the development of glycoconjugate vaccines.</p><p>A typical example is given by Gram-positive Group A <italic toggle="yes">Streptococcus</italic> (GAS), which is a major cause of pharyngitis in children across the world, with a high frequency of severe sequelae in low- and middle-income countries including acute rheumatic fever, rheumatic heart disease and post streptococcal glomerulo nephritis (Mitchell <xref rid="bib254" ref-type="bibr">2003</xref>). Native GAS capsule has the same structure as mammalian hyaluronic acid; thus, it is not a suitable target for a polysaccharide-based vaccine (MacLennan <xref rid="bib233" ref-type="bibr">1956</xref>). In contrast, the Lancefield group A carbohydrate (GAC), comprising a polyrhamnose backbone with an immunodominant GlcNAc side chain (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>), is a virulence factor, and conjugated to TT carrier protein elicited a protective immune response against systemic or nasal challenge with GAS (Sabharwal <italic toggle="yes">et&#160;al.</italic><xref rid="bib316" ref-type="bibr">2006</xref>). An inverse relationship between high Ab titers against GAS PS and the presence of GAS in the throat of Mexican children was observed (Sabharwal <italic toggle="yes">et&#160;al.</italic><xref rid="bib316" ref-type="bibr">2006</xref>). The epitope recognized by human antisera was identified in the hexamer composed by two repeating units (Michon <italic toggle="yes">et&#160;al.</italic><xref rid="bib251" ref-type="bibr">2005</xref>). Based on this observation, synthetic GAS oligosaccharides (2 or 4 repeats) conjugated to CRM<sub>197</sub> were demonstrated as efficacious as the conjugated PS in protecting mice from challenge with the pathogen (Kabanova <italic toggle="yes">et&#160;al.</italic><xref rid="bib184" ref-type="bibr">2010</xref>). Concerns about GlcNAc-containing vaccines have been raised due to a possible role of anti-GAS-PS antibodies in the development of GAS infection sequelae, like acute rheumatic fever or Sydenham's chorea (Shikhman, Greenspan and Cunningham <xref rid="bib335" ref-type="bibr">1993</xref>; Malkiel <italic toggle="yes">et&#160;al.</italic><xref rid="bib240" ref-type="bibr">2000</xref>; Kirvan <italic toggle="yes">et&#160;al.</italic><xref rid="bib192" ref-type="bibr">2006</xref>). GlcNAc-deficient GAS PS conjugated to recombinant pneumococcal protein SP0435 was also able to induce Abs promoting opsonophagocytic killing of multiple GAS serotypes and able to protect against GAS challenge after passive immunization (van Sorge <italic toggle="yes">et&#160;al.</italic><xref rid="bib366" ref-type="bibr">2014</xref>).</p><p>Polyrhamnan, besides being a component of GAS PS backbone, is constantly expressed as cell wall polysaccharide in <italic toggle="yes">St. pyogenes</italic> and <italic toggle="yes">St. agalactiae</italic> (van Sorge <italic toggle="yes">et&#160;al.</italic><xref rid="bib366" ref-type="bibr">2014</xref>).</p><p>The ubiquitous exo-polysaccharide PNAG (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) appears to play an important role in biofilm formation, immune evasion and pathogenesis in a variety of bacterial species including <italic toggle="yes">S. aureus</italic> (Cerca <italic toggle="yes">et&#160;al.</italic><xref rid="bib50" ref-type="bibr">2007</xref>), <italic toggle="yes">S. epidermidis</italic> (Mack <italic toggle="yes">et&#160;al.</italic><xref rid="bib232" ref-type="bibr">2004</xref>), <italic toggle="yes">Actinobacillus</italic> species (Kaplan and Mulks <xref rid="bib187" ref-type="bibr">2005</xref>) and <italic toggle="yes">E. coli</italic> (Wang, Preston and Romeo <xref rid="bib383" ref-type="bibr">2004</xref>; Cerca and Jefferson <xref rid="bib49" ref-type="bibr">2008</xref>).</p><p>When native PNAG from <italic toggle="yes">S. aureus</italic> (90% O-acetylated) was chemically treated to reduce acetylation to 15%, the resulting de-acetylated PNAG glycoform (dPNAG) elicited opsonic and protective antibodies against <italic toggle="yes">S. aureus</italic> (Maira-Litran <italic toggle="yes">et&#160;al.</italic><xref rid="bib237" ref-type="bibr">2002</xref>, <xref rid="bib239" ref-type="bibr">2005</xref>). In contrast, antibodies specific to the acetylated form were poorly opsonic and not protective (Maira-Litran <italic toggle="yes">et&#160;al.</italic><xref rid="bib238" ref-type="bibr">2004</xref>). Notably, most humans (95%) have high titers of natural antibody directed to the acetylated epitopes of native PNAG, and this antibody is poorly opsonic and not protective in animal models (Perez <italic toggle="yes">et&#160;al.</italic><xref rid="bib285" ref-type="bibr">2009</xref>). A synthetic dPNAG composed of nine repeating units conjugated to staphylococcal non-toxic mutant of alpha-hemolysin (Hla H35L) induced carbohydrate specific antibodies that reduced the bacterial burdens in animal models of <italic toggle="yes">S. aureus</italic> (skin abscesses, pneumonia and nasal colonization) (Pozzi <italic toggle="yes">et&#160;al.</italic><xref rid="bib292" ref-type="bibr">2012</xref>). Carrier-protein specific immunity was also shown to be effective in reducing bacterial levels in infected lungs and in nasal colonization. Rabbit antibodies induced against the synthetic oligosaccharide conjugated to TT induced complement mediated killing of <italic toggle="yes">A. baumannii</italic> S1, a high-PNAG-producing strain, but not its PNAG-negative mutant (Bentancor <italic toggle="yes">et&#160;al.</italic><xref rid="bib17" ref-type="bibr">2012</xref>). Immunization significantly reduced post infection levels of <italic toggle="yes">A. baumannii</italic> in the lungs or blood, compared to control groups, demonstrating that the PNAG conjugate could prevent pneumonia and pathogen caused bacteremia.</p><p>Another ubiquitous glycan is represented by the enterobacterial common antigen (ECA) (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) (M&#228;nnel and Mayer <xref rid="bib243" ref-type="bibr">1978</xref>). Monomer and dimer of this trisaccharide repeating unit have been synthesized and conjugated to BSA for the development of a specific mAb (SM250&#8211;1 A5), which recognized a variety of species, such as <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">Sh. sonnei</italic>, <italic toggle="yes">Sh. flexneri</italic>, <italic toggle="yes">Citrobacter freundii</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">Y. enterocolitica</italic>, <italic toggle="yes">Enterobacter aerogenes</italic>, <italic toggle="yes">S.</italic> Typhimurium, while it was not reactive to other Gram-negative bacteria (<italic toggle="yes">V. cholerae</italic>) and Gram-positive bacteria (<italic toggle="yes">Listeria monocytogenes</italic>) (Liu <italic toggle="yes">et&#160;al.</italic><xref rid="bib226" ref-type="bibr">2015</xref>) .</p><p>Alginate, a polysaccharide made by variable ratios of mannuronic to guluronic acids partially O-acetylated, was found in mucoid strains of PA (Pier <italic toggle="yes">et&#160;al.</italic><xref rid="bib290" ref-type="bibr">1994</xref>; Pier <xref rid="bib288" ref-type="bibr">2005</xref>; Sharma, Krause and Worgall <xref rid="bib332" ref-type="bibr">2011</xref>). Conjugated to a variety of carrier proteins, including EPA, TT, KLH, OMV (from <italic toggle="yes">N. meningitidis</italic> serogroup B) or synthetic peptide containing T- and B-cell epitopes, alginate was successful in inducing protective immunity in mice, mediated by opsonophagocityc antibodies at preclinical level, but has never been tested in human (Theilacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib352" ref-type="bibr">2003</xref>; Kashef <italic toggle="yes">et&#160;al.</italic><xref rid="bib189" ref-type="bibr">2006</xref>; Doring and Pier <xref rid="bib95" ref-type="bibr">2008</xref>; Farjah <italic toggle="yes">et&#160;al.</italic><xref rid="bib104" ref-type="bibr">2014</xref>, <xref rid="bib105" ref-type="bibr">2015</xref>). The structurally similar polymannuronic acid conjugated to type a flagellin also exhibited protective efficacy in a mouse lung infection model (Campodonico <italic toggle="yes">et&#160;al.</italic><xref rid="bib42" ref-type="bibr">2011</xref>).</p><p>Pel and Psl are other exopolysaccharides produced by PA (Ma <italic toggle="yes">et&#160;al.</italic><xref rid="bib227" ref-type="bibr">2006</xref>, <xref rid="bib228" ref-type="bibr">2007</xref>; Colvin <italic toggle="yes">et&#160;al.</italic><xref rid="bib66" ref-type="bibr">2012</xref>; Jennings <italic toggle="yes">et&#160;al.</italic><xref rid="bib178" ref-type="bibr">2015</xref>). Psl is found in 76% of analyzed clinical isolates, and its expression not only occurs in the primary infecting strains, but has also been implicated in establishing a persistent infection. Psl is responsible for the formation and maintenance of biofilms and an anti-Psl mAb exhibited opsonophagocytic killing of a number of strains and conferred significant protection in multiple animal models (DiGiandomenico <italic toggle="yes">et&#160;al.</italic><xref rid="bib93" ref-type="bibr">2012</xref>).</p><p>TAs have been explored as potential vaccine candidates for Gram-positive bacteria accounting for a large proportion of hospital-acquired antibiotic-resistant infections, such as staphylococci and enterococci (Theilacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib354" ref-type="bibr">2004</xref>). Immunization of mice with (poly)glycerolphosphate backbone induced in mice antibodies which mediated opsonophagocytic killing <italic toggle="yes">in vitro</italic> of <italic toggle="yes">S. epidermidis</italic> and <italic toggle="yes">S. aureus</italic> (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) and, upon passive transfer, reduced mortality in a murine <italic toggle="yes">S. aureus</italic> peritonitis model (Theilacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib353" ref-type="bibr">2006</xref>). Although LTA has been reported to be an TLR2 agonist, this activity might derive from contaminating lipoproteins/lipopeptides (Zahringer <italic toggle="yes">et&#160;al.</italic><xref rid="bib410" ref-type="bibr">2008</xref>). After conjugation to TT, a synthetic version of the (poly)glycerolphosphate backbone was also able to elicit murine-specific IgG enhancing opsonophagocytic killing of live <italic toggle="yes">S. aureus in vitro</italic>. Mice actively immunized with the (poly)glycerolphosphate conjugate vaccine showed a rapid clearance of staphylococcal bacteremia <italic toggle="yes">in vivo</italic> and, in contrast to purified LTA, did not exhibit detectable inflammatory activity (Chen <italic toggle="yes">et&#160;al.</italic><xref rid="bib55" ref-type="bibr">2013</xref>).</p><p>LTA substituted or not with alanine have been isolated and recognized by opsonic antibodies against enterococci (Theilacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib353" ref-type="bibr">2006</xref>; Sava <italic toggle="yes">et&#160;al.</italic><xref rid="bib321" ref-type="bibr">2010</xref>). The kojibiose&#8211;TA structure of one type of LTA (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) isolated from <italic toggle="yes">En. faecalis</italic> strains was very similar to the CPS (Wang <italic toggle="yes">et&#160;al.</italic><xref rid="bib384" ref-type="bibr">1999</xref>). To circumvent the polymer heterogeneity, various syntheses for the preparation of defined LTA antigens have been described, including automated solid-phase synthesis (Hogendorf <italic toggle="yes">et&#160;al.</italic><xref rid="bib157" ref-type="bibr">2010</xref>, <xref rid="bib159" ref-type="bibr">2011</xref>, <xref rid="bib158" ref-type="bibr">2012</xref>).</p><p>A short LTA hexamer with a single disaccharide substituent conjugated to BSA elicited the production of antibodies in rabbit that induced opsonic killing of enterococci and <italic toggle="yes">S. aureus</italic> strain MW2 (Laverde <italic toggle="yes">et&#160;al.</italic><xref rid="bib209" ref-type="bibr">2014</xref>). The LTA from <italic toggle="yes">E. faecalis</italic> strain 12030 was found identical to the CPS, except for the substitution at position C-2 with D-alanine (Theilacker <italic toggle="yes">et&#160;al.</italic><xref rid="bib353" ref-type="bibr">2006</xref>). Osponic serum recognized this polysaccharide similarly to LTA lacking of alanine (Sava <italic toggle="yes">et&#160;al.</italic><xref rid="bib321" ref-type="bibr">2010</xref>), indicating that anti-LTA antibodies are cross reactive irrespective of the different polysaccharide decorations.</p><p>In addition to TA, other classes of heteroglycans have been isolated from enterocci, including a heteroglycan composed of rhamnose, glucose, galactose, mannosamine and glucosamine (Hsu <italic toggle="yes">et&#160;al.</italic><xref rid="bib162" ref-type="bibr">2006</xref>). Two polysaccharides containing altruronic acid and legionaminic acid, respectively, and the fructose homopolymer levan have been isolated from <italic toggle="yes">En. faecium</italic>, in addition to a glucosylated LTA (Kodali <italic toggle="yes">et&#160;al.</italic><xref rid="bib199" ref-type="bibr">2015</xref>). Immunization of rabbits with CRM<sub>197</sub> conjugates of these polysaccharides showed that while antibodies raised against levan failed to mediate opsonophagocytic killing, the other two conjugated polysaccharides elicited antibodies with opsonic activity, which were also capable of reducing bacterial load in mouse liver or kidney tissue. Fragments of the capsule-like diheteroglycan (DHG) (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) were recently synthesized and characterized as a promising vaccine candidate (Krylov <italic toggle="yes">et&#160;al.</italic><xref rid="bib204" ref-type="bibr">2015</xref>).</p><p>
<italic toggle="yes">Clostridium difficile</italic> is a Gram-positive anaerobic spore-forming bacterium, the incidence and severity of which infection appears increased in the last decades, particularly in the USA and Canada (Warny <italic toggle="yes">et&#160;al.</italic><xref rid="bib386" ref-type="bibr">2005</xref>). An hypervirulent strain (NAP1/027/BI) with particularly severe antibiotic resistance was identified as the cause of these outbreaks.</p><p>Three surface polysaccharide structures, PSI, PSII and PSIII (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>), have been isolated (Ganeshapillai <italic toggle="yes">et&#160;al.</italic><xref rid="bib121" ref-type="bibr">2008</xref>). PSII was found the more abundant in the hypervirulent strain NAP1/027/BI and many other clinical isolates (Danieli <italic toggle="yes">et&#160;al.</italic><xref rid="bib83" ref-type="bibr">2011</xref>; Oberli <italic toggle="yes">et&#160;al.</italic><xref rid="bib271" ref-type="bibr">2011</xref>). Conjugates of the polysaccharide or the synthetic repeating unit with CRM<sub>197</sub>, recombinant bacterial toxins or ETEC proteins elicited carbohydrate specific antibodies (Adamo <italic toggle="yes">et&#160;al.</italic><xref rid="bib4" ref-type="bibr">2012</xref>; Bertolo <italic toggle="yes">et&#160;al.</italic><xref rid="bib19" ref-type="bibr">2012</xref>; Romano <italic toggle="yes">et&#160;al.</italic><xref rid="bib310" ref-type="bibr">2014</xref>). By microarray screening of synthetic structures, higher levels of IgA antibodies against PSI were found in patients with low or high severity of disease compared to asymptomatic control (Martin, Weishaupt and Seeberger <xref rid="bib247" ref-type="bibr">2011</xref>; Martin <italic toggle="yes">et&#160;al.</italic><xref rid="bib246" ref-type="bibr">2013b</xref>). Synthetic glycans selected by epitope mapping studies and displayed on a synthetic scaffold were shown to be immunogenic as larger fragment, demonstrating the candidacy of small structures for vaccine development (Broecker <italic toggle="yes">et&#160;al.</italic><xref rid="bib30" ref-type="bibr">2016a</xref>). PSIII is an LTA-like polymer, and anti-PSIII antibodies have also been detected in the blood of infected patients (Martin <italic toggle="yes">et&#160;al.</italic><xref rid="bib245" ref-type="bibr">2013a</xref>). Immunizations with conjugates of intact or de-O-acylated PSIII fractions raised IgG antibodies recognizing the polymer on <italic toggle="yes">C</italic>. <italic toggle="yes">difficile</italic> cellular surface (Cox <italic toggle="yes">et&#160;al.</italic><xref rid="bib70" ref-type="bibr">2013</xref>).</p><p>Serum, but not fecal, anti-PSIII IgG were found in hospitalized individuals, possibly due to pre-exposure to the pathogen (Broecker <italic toggle="yes">et&#160;al.</italic><xref rid="bib31" ref-type="bibr">2016b</xref>). A synthetic LTA fragment conjugated to CRM<sub>197</sub> elicited in mice antibodies that bound to the surface of a series of <italic toggle="yes">C. difficile</italic> strains. The alum-adjuvanted CRM<sub>197</sub> conjugate reduced the bacterial colonization in mice challenged with live <italic toggle="yes">C. difficile</italic> cells.</p></sec><sec id="sec3-14"><title>Mycobacterial and fungal surface carbohydrates</title><p>Although an anti-tuberculosis vaccine (BCG) is available, the overall effective rate of prevention is inferior to 50%. The emergence of antibiotic-resistant strains, particularly in HIV-infected individuals, is highlighting the need of improvement of the current preventive therapy. Lipoarabinomannan (LAM, Table&#160;<xref ref-type="table" rid="tbl2">2</xref>) is a major lipoglycan component of the outer cell wall of all mycobacterial species. LAM is an important immunomodulating compound, contributing to the pathogenesis of mycobacterial tubercolosis (MBT) infections. The derived AM, obtained by removal of the lipid in order to avoid any immunosuppressive effect, was covalently linked to the mycobacterial protein Ag85B or TT showing protective efficacy in mice and guinea pigs in terms of prolonged survival and reduced pathology, when administered with L3 adjuvant using a subcutaneous priming-intranasal boost regime (Hamasur <italic toggle="yes">et&#160;al.</italic><xref rid="bib146" ref-type="bibr">2003</xref>; Kallenius, Pawlowski and Hamasur <xref rid="bib186" ref-type="bibr">2008</xref>). Attempts to use conjugates of synthetic mannans (Leelayuwapan <italic toggle="yes">et&#160;al.</italic><xref rid="bib212" ref-type="bibr">2017</xref>), phosphatidylinositol mannosides (Boonyarattanakalin <italic toggle="yes">et&#160;al.</italic><xref rid="bib24" ref-type="bibr">2008</xref>) or rhamnans (Vignal <italic toggle="yes">et&#160;al.</italic><xref rid="bib373" ref-type="bibr">2003</xref>; Meng <italic toggle="yes">et&#160;al.</italic><xref rid="bib250" ref-type="bibr">2017</xref>) are in progress, although cross reactivity against MBT has not been so far elucidated.</p><p>
<italic toggle="yes">Candida</italic> species have become the fourth most common nosocomial bloodstream isolate in the USA and in most European countries, and a vaccine would be beneficial particularly for patients at high risk like those in intensive care units (Cutler <italic toggle="yes">et&#160;al.</italic><xref rid="bib81" ref-type="bibr">2007</xref>; Cassone <xref rid="bib45" ref-type="bibr">2008</xref>). Resistance to therapeutic treatment is increasing among <italic toggle="yes">Candida</italic> species and particular concern is being raised by the emergence of <italic toggle="yes">Candida auris</italic> in health care settings because this fungus is very resistant to drugs and can be easily spread from person to person. Branched &#946;-(1&#8594;3)-(1&#8594;6)-glucans have been considered to develop vaccines against infections caused by <italic toggle="yes">Candida</italic> species. &#946;-Glucans are component of most, if not all, fungi and therefore are attractive targets for fungal vaccines development. Conjugates based on &#946;-glucans and mannans (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>), either extracted from a natural source or chemically synthesized, have been proposed as possible vaccine candidates (Torosantucci <italic toggle="yes">et&#160;al.</italic><xref rid="bib358" ref-type="bibr">2005</xref>; Bromuro <italic toggle="yes">et&#160;al.</italic><xref rid="bib36" ref-type="bibr">2010</xref>; Adamo <italic toggle="yes">et&#160;al.</italic><xref rid="bib5" ref-type="bibr">2011</xref>, <xref rid="bib2" ref-type="bibr">2014</xref>; Hu <italic toggle="yes">et&#160;al.</italic><xref rid="bib163" ref-type="bibr">2013</xref>; Johnson and Bundle <xref rid="bib180" ref-type="bibr">2013</xref>; Lipinski <italic toggle="yes">et&#160;al.</italic><xref rid="bib220" ref-type="bibr">2013</xref>; Paulovicova <italic toggle="yes">et&#160;al.</italic><xref rid="bib278" ref-type="bibr">2013</xref>; Liao <italic toggle="yes">et&#160;al.</italic><xref rid="bib215" ref-type="bibr">2015</xref>, <xref rid="bib216" ref-type="bibr">2016</xref>). &#946;-Glucans are immunostimulator molecules through Dectin-1 activation (Donadei <italic toggle="yes">et&#160;al.</italic><xref rid="bib94" ref-type="bibr">2015</xref>); thus, bicomponent &#946;-glucan and &#946;-mannan conjugate has also been made (Lipinski <italic toggle="yes">et&#160;al.</italic><xref rid="bib220" ref-type="bibr">2013</xref>), showing enhanced immunoresponse against the latter antigen.</p><p>More recently, other species are emerging as targets for vaccination, such as <italic toggle="yes">Cr. neoformans</italic> and <italic toggle="yes">Aspergillus</italic>. <italic toggle="yes">Cryptococcus neoformans</italic> is an opportunistic encapsulated yeast that causes cryptococcal meningoencephalitis (cryptococcosis) in immunocompromised individuals, including AIDS patients and organ transplant recipients (Cogliati <xref rid="bib63" ref-type="bibr">2013</xref>). Invasive aspergillosis (IA), caused by <italic toggle="yes">Aspergillus</italic>, is the second most common cause of nosocomial, invasive fungal infections, with an incidence of approximately 5 per 100 000 population in the USA (Wilson <italic toggle="yes">et&#160;al.</italic><xref rid="bib399" ref-type="bibr">2002</xref>).</p><p>Similarly to <italic toggle="yes">Candida</italic>, these species are surrounded by &#946;-(1&#8594;3)-glucans (Maubon <italic toggle="yes">et&#160;al.</italic><xref rid="bib249" ref-type="bibr">2006</xref>), and capacity of anti &#946;-(1&#8594;3)-glucan antibodies to inhibit the cellular growth of acapsular <italic toggle="yes">Cryptococcus</italic> strains has been proven (Rachini <italic toggle="yes">et&#160;al.</italic><xref rid="bib295" ref-type="bibr">2007</xref>).</p><p>Both <italic toggle="yes">Cryptococcus</italic> and <italic toggle="yes">Aspergilli</italic> present at their surface &#945;-(1&#8594;3)-glucans (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>). In the first case, they anchor the polysaccharide capsule to the cell wall. In <italic toggle="yes">Aspergillus fumigatus</italic> (Fontaine <italic toggle="yes">et&#160;al.</italic><xref rid="bib117" ref-type="bibr">2010</xref>), &#945;-(1&#8594;3)-glucans induce the aggregation of germinating fungal conidia. Antibodies elicited in mice by conjugated synthetic &#945;-glucans recognize the cell wall of <italic toggle="yes">Aspergillus</italic> (Komarova <italic toggle="yes">et&#160;al.</italic><xref rid="bib200" ref-type="bibr">2015</xref>).</p><p>
<italic toggle="yes">Cryptococcus neoformans</italic> also exhibits a peculiar CPS<italic toggle="yes">.</italic> Four serotypes, A, B, C and D (Table&#160;<xref ref-type="table" rid="tbl2">2</xref>), are distinguished and they are composed for a large extent of mannose trimers with glucopyranosyluronate and xylopyranosyl substituents (GXM) creating the so called &#8216;triads&#8217; (Cherniak, Jones and Reiss <xref rid="bib57" ref-type="bibr">1988</xref>). Strains of serotype A and D are the most frequent cause of cryptococcosis in humans and thus the serotypes of primary interest for a human vaccine (Cherniak and Sundstrom <xref rid="bib58" ref-type="bibr">1994</xref>).</p><p>A glycoconjugate vaccine composed of unfractionated GXM polysaccharide conjugated to bovine gamma globulin was initially seen highly immunogenic, but protection from infection was not achieved (Goren and Middlebrook <xref rid="bib130" ref-type="bibr">1967</xref>). Fractionated GXM polysaccharide conjugated to TT was again highly immunogenic (Devi <italic toggle="yes">et&#160;al.</italic><xref rid="bib90" ref-type="bibr">1991</xref>), and both active and passive immunization of mice conferred protection against experimental cryptococcosis (Casadevall <italic toggle="yes">et&#160;al.</italic><xref rid="bib44" ref-type="bibr">1992</xref>; Devi <xref rid="bib89" ref-type="bibr">1996</xref>). However, using a library of mAbs it was later observed that the GXM-TT vaccine elicit protective, non-protective and even deleterious (disease-enhancing) antibodies (Mukherjee, Scharff and Casadevall <xref rid="bib259" ref-type="bibr">1992</xref>; Mukherjee <italic toggle="yes">et&#160;al.</italic><xref rid="bib258" ref-type="bibr">1995</xref>). The free unconjugated GXM polysaccharide would also have potent immunosuppressive properties (Vecchiarelli <xref rid="bib368" ref-type="bibr">2000</xref>).</p><p>These early findings led to the hypothesis that conjugated GXM could contain protective and non-protective epitopes, and a non-protective antibody response would prevent the action of formed protective antibodies (Nakouzi <italic toggle="yes">et&#160;al.</italic><xref rid="bib264" ref-type="bibr">2009</xref>). Efforts are currently ongoing to identify the protective and the non-protective epitopes present in the GXM through a library of synthetic oligosaccharides followed by conjugation to protein carrier and testing in mice (Oscarson <italic toggle="yes">et&#160;al.</italic><xref rid="bib272" ref-type="bibr">2005</xref>; Guazzelli, Ulc and Oscarson <xref rid="bib138" ref-type="bibr">2015</xref>; Guazzelli <italic toggle="yes">et&#160;al.</italic><xref rid="bib139" ref-type="bibr">2015</xref>; Guazzelli, McCabe and Oscarson <xref rid="bib137" ref-type="bibr">2016</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec4"><title>CONCLUSIONS</title><p>Glycans coating the bacterial surface are key antigens for the development of vaccines against bacterial and fungal diseases. Over the last decades, glycoconjugate vaccines licensed to combat <italic toggle="yes">N. meningitidis</italic>, <italic toggle="yes">H. influenzae</italic> and <italic toggle="yes">St. pneumoniae</italic> have proven to be safe, efficacious and cost effective (Sharma <italic toggle="yes">et&#160;al.</italic><xref rid="bib333" ref-type="bibr">2012</xref>; Delgleize <italic toggle="yes">et&#160;al.</italic><xref rid="bib85" ref-type="bibr">2016</xref>; Zarei, Almehdar and Redwan <xref rid="bib411" ref-type="bibr">2016</xref>; Delea <italic toggle="yes">et&#160;al.</italic><xref rid="bib84" ref-type="bibr">2017</xref>; Linares-Perez <italic toggle="yes">et&#160;al.</italic><xref rid="bib218" ref-type="bibr">2017</xref>).</p><p>Nevertheless, the continuously evolving epidemiology requires additional efforts to extend the coverage, as in the case of <italic toggle="yes">St. pneumoniae</italic>, while other pathogens request to be incessantly monitored to be prepared in case inclusion of emerging serotypes in the vaccine composition would be needed (i.e. <italic toggle="yes">N. meningitidis</italic> serogroup X or <italic toggle="yes">H. influenzae</italic> type a) (Micoli <italic toggle="yes">et al</italic>. <xref rid="bib253" ref-type="bibr">2013b</xref>; Cox <italic toggle="yes">et&#160;al.</italic><xref rid="bib71" ref-type="bibr">2017</xref>; LaForce <xref rid="bib206" ref-type="bibr">2017b</xref>)</p><p>Many diseases still remain to be controlled. Over the last years, alarming concern is emerging toward antibiotic-resistant bacteria, including, among others, the so-called ESKAPE pathogens, which are leading causes of nosocomial infections through the world (Boucher <italic toggle="yes">et&#160;al.</italic><xref rid="bib25" ref-type="bibr">2009</xref>; Garcia-Quintanilla <italic toggle="yes">et&#160;al.</italic><xref rid="bib124" ref-type="bibr">2016</xref>; Bloom, Black and Rappuoli <xref rid="bib20" ref-type="bibr">2017</xref>). Fungal infections are also becoming increasingly invasive for immunocompromised patients, such those with immune systems impaired by cancer chemotherapy, or hospitalized individuals (Spellberg <xref rid="bib343" ref-type="bibr">2011</xref>). Recent analyses have highlighted the need of novel therapeutic approaches to tackle these pathogens, and WHO and CDC have ranked and prioritized the relevance of these bacterial targets (CDC 2013; WHO <xref rid="bib396" ref-type="bibr">2017</xref>). Other emergencies could derive from bacteria which spread during environmental calamities (<italic toggle="yes">V. cholerae</italic>), particularly impacting poor countries, or which could be used as bioterrorism weapons (<italic toggle="yes">B. pseudomallei</italic> and <italic toggle="yes">mallei</italic>, <italic toggle="yes">F. tularensis</italic>).</p><p>Additional factors which will increase the need of preventative therapies are the changes in the age population composition, shifting toward a larger presence of elderly as consequence of the increased life expectation in the developed countries; the increased numbers of travelers, as well as the migration flows from the south to the north of the world; and even climatic changes which could play a role in selecting dangerous pathogens (Rappuoli <italic toggle="yes">et&#160;al.</italic><xref rid="bib298" ref-type="bibr">2011</xref>).</p><p>Nowadays different tools are available for the manufacturing of glycoconjugates, which could accelerate the development of novel carbohydrate-based vaccines. Semisynthetic conjugation is a well-established approach which delivered to patients efficacious vaccines against deadly pathogens. It requires a complex multistep manufacturing and quality control flow; however, it will continue to represent a reference approach, particularly for those structures difficult to express by glycoengineering methods and not promptly accessible by chemical synthesis.</p><p>The synthetic approach has been considered time demanding and expensive for vaccine manufacture compared to the use of bacterial-derived carbohydrates. Nonetheless, clear proofs of feasibility have been provided by the marketed synthetic Hib vaccine (Verez-Bencomo <italic toggle="yes">et&#160;al.</italic><xref rid="bib372" ref-type="bibr">2004</xref>) and the pentadecasaccharide <italic toggle="yes">Shigella</italic> conjugate recently entered phase-1 clinical trial (van der Put <italic toggle="yes">et&#160;al.</italic><xref rid="bib365" ref-type="bibr">2016</xref>). Additionally, synthesis of a number of challenging pneumococcal serotypes conjugates has been recently achieved (Geissner <italic toggle="yes">et&#160;al.</italic><xref rid="bib126" ref-type="bibr">2016</xref>; Parameswarappa <italic toggle="yes">et&#160;al.</italic><xref rid="bib276" ref-type="bibr">2016</xref>; Emmadi <italic toggle="yes">et&#160;al.</italic><xref rid="bib100" ref-type="bibr">2017</xref>; Lisboa <italic toggle="yes">et&#160;al.</italic><xref rid="bib222" ref-type="bibr">2017</xref>; Schumann <italic toggle="yes">et&#160;al.</italic><xref rid="bib325" ref-type="bibr">2017</xref>).</p><p>Synthetic carbohydrate chemistry can aid identification of the sugar target epitope, optimal carbohydrate density and attachment site to the carrier protein, supporting the rational design of vaccines with improved immunogenicity and preserved key protective protein epitopes.</p><p>Bioconjugation will play a pivotal role for faster and cheaper production of multicomponent vaccines. Bioconjugation has already provided candidates against <italic toggle="yes">Sh. dysenteriae</italic> O1 and <italic toggle="yes">Sh. flexneri</italic> 2a (Hatz <italic toggle="yes">et&#160;al.</italic><xref rid="bib149" ref-type="bibr">2015</xref>), and against ExPEC (Huttner <italic toggle="yes">et&#160;al.</italic><xref rid="bib172" ref-type="bibr">2017</xref>) tested in phase-1 clinical studies. <italic toggle="yes">Escherichia coli</italic> N-glycosylation so far applied is limited to the use of PglB for the transfer of the nascent polysaccharide chain with an end-terminal NAc hexosamine to the carrier protein. Directed enzyme evolution is applicable to increase the transferase promiscuity toward other sugar acceptors (Ihssen <italic toggle="yes">et&#160;al.</italic><xref rid="bib173" ref-type="bibr">2015</xref>). PglL, the <italic toggle="yes">O</italic>-transferase from <italic toggle="yes">N. meningitidis</italic> (Musumeci <italic toggle="yes">et&#160;al.</italic><xref rid="bib263" ref-type="bibr">2013</xref>), and NCT from <italic toggle="yes">Ac. pleuropneumoniae</italic> (Cuccui <italic toggle="yes">et&#160;al.</italic><xref rid="bib78" ref-type="bibr">2017</xref>) could also give access to a broader range of hexose ending polysaccharides.</p><p>Examples so far achieved of bioconjugate vaccines are related to polysaccharides assembled through group 1 and 4 CPS biochemical pathways. Other groups are more challenging and represent an opportunity to further progress this technology. The use of glycoengineered OMVs appears as a flexible but at a very early stage approach. Synthetic oligosaccharides and bioconjugation will aid the development of vaccines with higher standards in terms of product manufacturing and characterization compared to traditional conjugate vaccines.</p><p>The present analysis underscores how carbohydrate antigens will be key for the development of future vaccines against emerging pathogens, primarily the ESKAPE bacteria <italic toggle="yes">A. baumannii, En. faecium</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">P. aeruginosa</italic>, classified and critical targets by WHO and CDC, as well as <italic toggle="yes">C. difficile</italic> and GAS, categorized as serious threats. Vaccination for prevention of relevant targets, such as <italic toggle="yes">S. aureus</italic> and GBS infections, is progressing at clinical level. Fungal infections (<italic toggle="yes">Ca. albicans</italic>, <italic toggle="yes">Cr. neoformans</italic>) could also benefit of carbohydrate-based vaccination. Among the pathogens discussed in this review there are examples where a simple vaccine formulation with one or two antigens has the potential to ensure large coverage (e.g. <italic toggle="yes">F. tularensis</italic>, <italic toggle="yes">B. pseudomallei</italic> and <italic toggle="yes">mallei</italic>, <italic toggle="yes">V. cholerae, Haemophilus</italic> type a), and the development of a glycoconjugate vaccine appears feasible. For <italic toggle="yes">M. catarrhalis</italic>, <italic toggle="yes">N. gonorrhoeae</italic> and NTHi LOS, alone or in combination with protein antigens, could be key targets for vaccine design. In most of the other cases, a combination of multiple sugar components would be required. This is the case of <italic toggle="yes">Klebsiella</italic>, for which O-Ag could ensure a better coverage with a smaller number of antigens as compared to the CPS, or <italic toggle="yes">E. coli</italic>. In other cases, such as PA, the complexity of the bacterial mechanism of infection with transition from acute to chronic phase might render more challenging the identification of the optimal antigens. Use of pathogen-derived proteins as carrier for the glycan haptens could reduce the number of vaccine components, by broadening across strain protection and/or by tackling the pathogen on different virulence factors, provided that the key protective epitopes of the protein carrier are identified and preserved during conjugation (Broker <italic toggle="yes">et&#160;al.</italic><xref rid="bib33" ref-type="bibr">2017</xref>).</p><p>Recent advances in the field of glycoconjugate vaccines, synergy of the different technologies currently available and their appropriate selection will enable the tailored design of glycoconjugates of novel targets, expanding the number of available vaccines and tackling currently unmet medical needs.</p></sec></body><back><sec id="sec5"><title/><p>
<bold><italic toggle="yes">Conflict of interest.</italic></bold> FM, PC and RA are employees of GSK group of companies.</p></sec><ref-list><title>REFERENCES</title><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamo</surname><given-names>R</given-names></name></person-group><article-title>Advancing homogeneous antimicrobial glycoconjugate vaccines</article-title>. <source>Acc Chem Res</source><year>2017</year>;<volume>50</volume>:<fpage>1270</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28463499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.accounts.7b00106</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Q-Y</given-names></name>, <name name-style="western"><surname>Torosantucci</surname><given-names>A</given-names></name><etal/></person-group><article-title>Deciphering the structure&#8211;immunogenicity relationship of anti-<italic toggle="yes">Candida</italic> glycoconjugate vaccines</article-title>. <source>Chem Sci</source><year>2014</year>;<volume>5</volume>:<fpage>4302</fpage>&#8211;<lpage>11</lpage>.</mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nilo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Castagner</surname><given-names>B</given-names></name><etal/></person-group><article-title>Synthetically defined glycoprotein vaccines: current status and future directions</article-title>. <source>Chem Sci</source><year>2013</year>;<volume>4</volume>:<fpage>2995</fpage>&#8211;<lpage>3008</lpage>.<pub-id pub-id-type="pmid">25893089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c3sc50862e</pub-id><pub-id pub-id-type="pmcid">PMC4396375</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Romano</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Berti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Phosphorylation of the synthetic hexasaccharide repeating unit is essential for the induction of antibodies to <italic toggle="yes">Clostridium difficile</italic> PSII cell wall polysaccharide</article-title>. <source>ACS Chem Biol</source><year>2012</year>;<volume>7</volume>:<fpage>1420</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22620974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/cb300221f</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tontini</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brogioni</surname><given-names>G</given-names></name><etal/></person-group><article-title>Synthesis of laminarin fragments and evaluation of a &#946;-(1,3) glucan hexasaccharide-CRM 197 conjugate as vaccine candidate against <italic toggle="yes">Candida albicans</italic></article-title>. <source>J Carbohydr Chem</source><year>2011</year>;<volume>30</volume>:<fpage>249</fpage>&#8211;<lpage>80</lpage>.</mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>El-Sayed</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Haroun</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development of immunization trials against <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>Vaccine</source><year>2012a</year>;<volume>30</volume>:<fpage>2411</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">22100884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.11.027</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Haroun</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hussein</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Development of a new trend conjugate vaccine for the prevention of <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>Infect Dis Rep</source><year>2012b</year>;<volume>4</volume>:<fpage>e33</fpage>.<pub-id pub-id-type="pmid">24470947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4081/idr.2012.e33</pub-id><pub-id pub-id-type="pmcid">PMC3892636</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alam</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Bufano</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Evaluation in mice of a conjugate vaccine for cholera made from <italic toggle="yes">Vibrio cholerae</italic> O1 (Ogawa) O-specific polysaccharide</article-title>. <source>PLoS Neglect Trop D</source><year>2014</year>;<volume>8</volume>:<fpage>e2683</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0002683</pub-id><pub-id pub-id-type="pmcid">PMC3916310</pub-id><pub-id pub-id-type="pmid">24516685</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>MacMillan</surname><given-names>BG</given-names></name></person-group><article-title>Immunological control of <italic toggle="yes">Pseudomonas</italic> infection in burn patients: A clinical evaluation</article-title>. <source>Arch Surg</source><year>1971</year>;<volume>102</volume>:<fpage>31</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">4992359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archsurg.1971.01350010033008</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Insel</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Capsular antigens noncovalently or covalently associated with protein as vaccines to <italic toggle="yes">Haemophilus influenzae</italic> type b: comparison in two-year-old children</article-title>. <source>J Infect Dis</source><year>1985</year>;<volume>152</volume>:<fpage>634</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">3875668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/152.3.634</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Insel</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of <italic toggle="yes">Haemophilus influenzae</italic> type b coupled to protein carrier: structural and temporal a requirements for priming in the human infant</article-title>. <source>J Immunol</source><year>1986</year>;<volume>137</volume>:<fpage>1181</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">3016088</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arcuri</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Di Benedetto</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cunningham</surname><given-names>AF</given-names></name><etal/></person-group><article-title>The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against <italic toggle="yes">Salmonella</italic> Typhi</article-title>. <source>PLoS ONE</source><year>2017</year>;<volume>12</volume>:<fpage>e0189100</fpage>.<pub-id pub-id-type="pmid">29287062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0189100</pub-id><pub-id pub-id-type="pmcid">PMC5747453</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Baddiley</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Buchanan</surname><given-names>JG</given-names></name><etal/></person-group><article-title>882. Isolation and structure of ribitol phosphate derivatives (teichoic acids) from bacterial cell walls</article-title>. <source>J Chem Soc</source><year>1958</year>;<fpage>4344</fpage>&#8211;<lpage>54</lpage>.</mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashkenazi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Passwell</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Harlev</surname><given-names>E</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of <italic toggle="yes">Shigella sonnei</italic> and shigella flexneri 2a O-Specific polysaccharide conjugates in children</article-title>. <source>J Infect Dis</source><year>1999</year>;<volume>179</volume>:<fpage>1565</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10228084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/314759</pub-id></mixed-citation></ref><ref id="bib14a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>AuCoin</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Reed</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Marlenee</surname><given-names>NL</given-names></name><etal/></person-group><article-title>Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei</article-title>. <source>PLoS ONE</source><year>2012</year>;<volume>7</volume>:<fpage>e35386</fpage>.<pub-id pub-id-type="pmid">22530013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0035386</pub-id><pub-id pub-id-type="pmcid">PMC3328442</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balakrishnan</surname><given-names>VS</given-names></name></person-group><article-title>Cholera in Yemen</article-title>. <source>Lancet Infect Dis</source><year>2017</year>;<volume>17</volume>:<fpage>700</fpage>&#8211;<lpage>1</lpage>.<pub-id pub-id-type="pmid">28737493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(17)30352-3</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baumann</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Jansson</surname><given-names>P-E</given-names></name>, <name name-style="western"><surname>Kenne</surname><given-names>L</given-names></name><etal/></person-group><article-title>Structural studies of the <italic toggle="yes">Escherichia coli</italic> O1A O-polysaccharide, using the computer program CASPER</article-title>. <source>Carbohydr Res</source><year>1991</year>;<volume>211</volume>:<fpage>183</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">1773429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0008-6215(91)84159-c</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bentancor</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>O&#8217;Malley</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Bozkurt-Guzel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Poly- N -acetyl-beta-(1-6)-Glucosamine is a target for protective immunity against <italic toggle="yes">Acinetobacter baumannii</italic> infections</article-title>. <source>Infect Immun</source><year>2012</year>;<volume>80</volume>:<fpage>651</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">22104104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.05653-11</pub-id><pub-id pub-id-type="pmcid">PMC3264292</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berg</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kaur</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>M</given-names></name><etal/></person-group><article-title>The glycosyltransferases of <italic toggle="yes">Mycobacterium tuberculosis</italic>-roles in the synthesis of arabinogalactan, lipoarabinomannan, and other glycoconjugates</article-title>. <source>Glycobiology</source><year>2007</year>;<volume>17</volume>:<fpage>35R</fpage>&#8211;<lpage>56R</lpage>.<pub-id pub-id-type="pmid">17261566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/glycob/cwm010</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertolo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Boncheff</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Clostridium difficile</italic> carbohydrates: glucan in spores, PSII common antigen in cells, immunogenicity of PSII in swine and synthesis of a dual <italic toggle="yes">C. difficile</italic>-ETEC conjugate vaccine</article-title>. <source>Carbohydr Res</source><year>2012</year>;<volume>354</volume>:<fpage>79</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">22533919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2012.03.032</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloom</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name></person-group><article-title>Emerging infectious diseases: A proactive approach</article-title>. <source>Proc Natl Acad Sci USA</source><year>2017</year>;<volume>114</volume>:<fpage>4055</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28396438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1701410114</pub-id><pub-id pub-id-type="pmcid">PMC5402424</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boisier</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Nicolas</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Djibo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger</article-title>. <source>Clinical Infect Dis</source><year>2007</year>;<volume>44</volume>:<fpage>657</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">17278055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/511646</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boisvert</surname><given-names>A-A</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>DP</given-names></name></person-group><article-title>Invasive disease due to haemophilus influenzae type a in children in Canada's north: A priority for prevention</article-title>. <source>Can J Infect Dis Med</source><year>2015</year>;<volume>26</volume>:<fpage>291</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/613820</pub-id><pub-id pub-id-type="pmcid">PMC4692295</pub-id><pub-id pub-id-type="pmid">26744583</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boltje</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>J</given-names></name><etal/></person-group><article-title>Chemical synthesis and immunological evaluation of the inner core oligosaccharide of <italic toggle="yes">Francisella tularensis</italic></article-title>. <source>J Am Chem Soc</source><year>2012</year>;<volume>134</volume>:<fpage>14255</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">22867268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja306274v</pub-id><pub-id pub-id-type="pmcid">PMC3458509</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boonyarattanakalin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Michieletti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Chemical synthesis of all phosphatidylinositol mannoside (PIM) glycans from <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>J Am Chem Soc</source><year>2008</year>;<volume>130</volume>:<fpage>16791</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19049470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja806283e</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boucher</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Talbot</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Bradley</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America</article-title>. <source>Clin Infect Dis</source><year>2009</year>;<volume>48</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">19035777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/595011</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutet</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mulard</surname><given-names>LA</given-names></name></person-group><article-title>Synthesis of two Tetra- and four pentasaccharide fragments of <italic toggle="yes">Shigella flexneri</italic> serotypes 3a and X O-antigens from a common tetrasaccharide intermediate</article-title>. <source>Eur J Org Chem</source><year>2008</year>;<volume>2008</volume>:<fpage>5526</fpage>&#8211;<lpage>42</lpage>.</mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutonnier</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Villeneuve</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nato</surname><given-names>F</given-names></name><etal/></person-group><article-title>Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae o139 bound to tetanus toxoid</article-title>. <source>Infect Immun</source><year>2001</year>;<volume>69</volume>:<fpage>3488</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">11292781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.69.5.3488-3493.2001</pub-id><pub-id pub-id-type="pmcid">PMC98317</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brady</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cunney</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Murchan</surname><given-names>S</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Klebsiella pneumoniae</italic> bloodstream infection, antimicrobial resistance and consumption trends in Ireland: 2008 to 2013</article-title>. <source>Eur J Clin Microbiol</source><year>2016</year>;<volume>35</volume>:<fpage>1777</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10096-016-2727-4</pub-id><pub-id pub-id-type="pmid">27488438</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brett</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Burtnick</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Woods</surname><given-names>DE</given-names></name></person-group><article-title>The wbiA locus is required for the 2-O-acetylation of lipopolysaccharides expressed by <italic toggle="yes">Burkholderia pseudomallei</italic> and <italic toggle="yes">Burkholderia thailand</italic>ensis</article-title>. <source>FEMS Microbiol Lett</source><year>2003</year>;<volume>218</volume>:<fpage>323</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">12586411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-6968.2003.tb11536.x</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broecker</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hanske</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Multivalent display of minimal <italic toggle="yes">Clostridium difficile</italic> glycan epitopes mimics antigenic properties of larger glycans</article-title>. <source>Nat Commun</source><year>2016a</year>;<volume>7</volume>:<fpage>11224</fpage>.<pub-id pub-id-type="pmid">27091615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms11224</pub-id><pub-id pub-id-type="pmcid">PMC4838876</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broecker</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Wegner</surname><given-names>E</given-names></name><etal/></person-group><article-title>Synthetic lipoteichoic acid glycans are potential vaccine candidates to protect from <italic toggle="yes">Clostridium difficile</italic> infections</article-title>. <source>Cell Chem Biol</source><year>2016b</year>;<volume>23</volume>:<fpage>1014</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">27524293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2016.07.009</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Berti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Costantino</surname><given-names>P</given-names></name></person-group><article-title>Factors contributing to the immunogenicity of meningococcal conjugate vaccines</article-title>. <source>Hum Vacc Immunother</source><year>2016</year>;<volume>12</volume>:<fpage>1808</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2016.1153206</pub-id><pub-id pub-id-type="pmcid">PMC4964817</pub-id><pub-id pub-id-type="pmid">26934310</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Berti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>J</given-names></name><etal/></person-group><article-title>Polysaccharide conjugate vaccine protein carriers as a &#8220;neglected valency&#8221;&#8212;potential and limitations</article-title>. <source>Vaccine</source><year>2017</year>;<volume>35</volume>:<fpage>3286</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">28487056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.04.078</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Costantino</surname><given-names>P</given-names></name>, <name name-style="western"><surname>DeTora</surname><given-names>L</given-names></name><etal/></person-group><article-title>Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications</article-title>. <source>Biologicals</source><year>2011</year>;<volume>39</volume>:<fpage>195</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="pmid">21715186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biologicals.2011.05.004</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dull</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><etal/></person-group><article-title>Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages</article-title>. <source>Vaccine</source><year>2009</year>;<volume>27</volume>:<fpage>5574</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">19619500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.07.036</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bromuro</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Romano</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Chiani</surname><given-names>P</given-names></name><etal/></person-group><article-title>Beta-glucan-CRM<sub>197</sub> conjugates as candidates antifungal vaccines</article-title>. <source>Vaccine</source><year>2010</year>;<volume>28</volume>:<fpage>2615</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">20096763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.01.012</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Prados-Rosales</surname><given-names>R</given-names></name><etal/></person-group><article-title>Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi</article-title>. <source>Nat Rev Microbiol</source><year>2015</year>;<volume>13</volume>:<fpage>620</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">26324094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro3480</pub-id><pub-id pub-id-type="pmcid">PMC4860279</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Santa Maria</surname><given-names>JP</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Walker</surname><given-names>S</given-names></name></person-group><article-title>Wall teichoic acids of gram-positive bacteria</article-title>. <source>Annu Rev Microbiol</source><year>2013</year>;<volume>67</volume>:<fpage>313</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">24024634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-micro-092412-155620</pub-id><pub-id pub-id-type="pmcid">PMC3883102</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bundle</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>ICP</given-names></name>, <name name-style="western"><surname>Jennings</surname><given-names>HJ</given-names></name></person-group><article-title>Determination of the structure and conformation of bacterial polysaccharides by Carbon 13 Nuclear Magnetic Resonance</article-title>. <source>J Biol Chem</source><year>1974</year>;<volume>249</volume>:<fpage>2275</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">4206552</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrd</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Egan</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Summers</surname><given-names>MF</given-names></name><etal/></person-group><article-title>New n.m.r.-spectroscopic approaches for structural studies of polysaccharides: application to the <italic toggle="yes">Haemophilus influenzae</italic> type a capsular polysaccharide</article-title>. <source>Carbohydr Res</source><year>1987</year>;<volume>166</volume>:<fpage>47</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">3498535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0008-6215(87)80043-5</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campagnari</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Dudas</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Antigenic diversity of lipooligosaccharides of nontypable <italic toggle="yes">Haemophilus influenzae</italic></article-title>. <source>Infect Immun</source><year>1987</year>;<volume>55</volume>:<fpage>882</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">3549563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.55.4.882-887.1987</pub-id><pub-id pub-id-type="pmcid">PMC260433</pub-id></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campodonico</surname><given-names>VL</given-names></name>, <name name-style="western"><surname>Llosa</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Bentancor</surname><given-names>LV</given-names></name><etal/></person-group><article-title>Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental <italic toggle="yes">Pseudomonas aeruginosa</italic> lung infection in mice</article-title>. <source>Infect Immun</source><year>2011</year>;<volume>79</volume>:<fpage>3455</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">21628521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00157-11</pub-id><pub-id pub-id-type="pmcid">PMC3147594</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cartee</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Forsee</surname><given-names>WT</given-names></name>, <name name-style="western"><surname>Yother</surname><given-names>J</given-names></name></person-group><article-title>Initiation and synthesis of the <italic toggle="yes">Streptococcus pneumoniae</italic> type 3 capsule on a phosphatidylglycerol membrane anchor</article-title>. <source>J Bacteriol</source><year>2005</year>;<volume>187</volume>:<fpage>4470</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">15968057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JB.187.13.4470-4479.2005</pub-id><pub-id pub-id-type="pmcid">PMC1151773</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mukherjee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Devi</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Antibodies elicited by a <italic toggle="yes">Cryptococcus neoformans</italic>-Tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection</article-title>. <source>J Infect Dis</source><year>1992</year>;<volume>165</volume>:<fpage>1086</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">1583327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/165.6.1086</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassone</surname><given-names>A</given-names></name></person-group><article-title>Fungal vaccines: real progress from real challenges</article-title>. <source>Lancet Infect Dis</source><year>2008</year>;<volume>8</volume>:<fpage>114</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">18222162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(08)70016-1</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="other"><collab>CDC</collab>. <source>Antibiotic Resistance Threats in the United States</source>, <year>2013a</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-2508.pdf">https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-2508.pdf</ext-link></comment>.</mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="other"><collab>CDC</collab>. <source>Sexually Transmitted Diseases Surveillance</source>. <year>2013b</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cdc.gov/std/stats13/default.htm">http://www.cdc.gov/std/stats13/default.htm</ext-link> [last accessed 7 Mar 2014]</comment>.</mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal"><collab>CDC</collab>. <article-title>Food and drug administration approval for use of hiberix as a 3-Dose primary haemophilus influenzae Type b (Hib) vaccination series</article-title>. <source>MMWR Morb Mortal Wkly Rep</source><year>2016</year>;<volume>65</volume>:<fpage>418</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27124887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6516a3</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerca</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Jefferson</surname><given-names>KK</given-names></name></person-group><article-title>Effect of growth conditions on poly-N-acetylglucosamine expression and biofilm formation in <italic toggle="yes">Escherichia coli</italic></article-title>. <source>FEMS Microbiol Lett</source><year>2008</year>;<volume>283</volume>:<fpage>36</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">18445167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-6968.2008.01142.x</pub-id></mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerca</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Maira-Litran</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Jefferson</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Protection against <italic toggle="yes">Escherichia coli</italic> infection by antibody to the <italic toggle="yes">Staphylococcus aureus</italic> poly-N-acetylglucosamine surface polysaccharide</article-title>. <source>Proc Natl Acad Sci USA</source><year>2007</year>;<volume>104</volume>:<fpage>7528</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">17446272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0700630104</pub-id><pub-id pub-id-type="pmcid">PMC1863476</pub-id></mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerquetti</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Giufre</surname><given-names>M</given-names></name></person-group><article-title>Why we need a vaccine for non-typeable <italic toggle="yes">Haemophilus influenzae</italic></article-title>. <source>Hum Vacc Immunother</source><year>2016</year>;<volume>12</volume>:<fpage>2357</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2016.1174354</pub-id><pub-id pub-id-type="pmcid">PMC5027700</pub-id><pub-id pub-id-type="pmid">27171854</pub-id></mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Cox</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Phase-variable heptose I glycan extensions modulate efficacy of 2C7 vaccine antibody directed against neisseria gonorrhoeae lipooligosaccharide</article-title>. <source>J Immunol</source><year>2016</year>;<volume>196</volume>:<fpage>4576</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">27183633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1600374</pub-id><pub-id pub-id-type="pmcid">PMC4875794</pub-id></mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Chaudhuri</surname><given-names>K</given-names></name></person-group><article-title>Lipopolysaccharides of <italic toggle="yes">Vibrio cholerae</italic></article-title>. <source>BBA- Mol Basis Dis</source><year>2003</year>;<volume>1639</volume>:<fpage>65</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2003.08.004</pub-id><pub-id pub-id-type="pmid">14559113</pub-id></mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Valentine</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>C-J</given-names></name><etal/></person-group><article-title>Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies</article-title>. <source>Proc Natl Acad Sci USA</source><year>2016</year>;<volume>113</volume>:<fpage>E3609</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">27274048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1518311113</pub-id><pub-id pub-id-type="pmcid">PMC4932928</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Dintaman</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lees</surname><given-names>A</given-names></name><etal/></person-group><article-title>Novel synthetic (poly)glycerolphosphate-based antistaphylococcal conjugate vaccine</article-title>. <source>Infect Immun</source><year>2013</year>;<volume>81</volume>:<fpage>2554</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">23649092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00271-13</pub-id><pub-id pub-id-type="pmcid">PMC3697627</pub-id></mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Current advances and challenges in the development of <italic toggle="yes">Acinetobacter</italic> vaccines</article-title>. <source>Hum Vacc Immunother</source><year>2015</year>;<volume>11</volume>:<fpage>2495</fpage>&#8211;<lpage>500</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1052354</pub-id><pub-id pub-id-type="pmcid">PMC4635877</pub-id><pub-id pub-id-type="pmid">26158773</pub-id></mixed-citation></ref><ref id="bib57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherniak</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Reiss</surname><given-names>E</given-names></name></person-group><article-title>Structure determination of <italic toggle="yes">Cryptococcus neoformans</italic> serotype A-variant glucuronoxylomannan by 13C-n.m.r. spectroscopy</article-title>. <source>Carbohydr Res</source><year>1988</year>;<volume>172</volume>:<fpage>113</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">3280130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0008-6215(00)90846-2</pub-id></mixed-citation></ref><ref id="bib58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherniak</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sundstrom</surname><given-names>JB</given-names></name></person-group><article-title>Polysaccharide antigens of the capsule of <italic toggle="yes">Cryptococcus neoformans</italic></article-title>. <source>Infect Immun</source><year>1994</year>;<volume>62</volume>:<fpage>1507</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">8168912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.62.5.1507-1512.1994</pub-id><pub-id pub-id-type="pmcid">PMC186341</pub-id></mixed-citation></ref><ref id="bib59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chernyak</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kondo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wade</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Induction of protective immunity by synthetic <italic toggle="yes">Vibrio cholerae</italic> hexasaccharide derived from <italic toggle="yes">V. cholerae</italic> O1 Ogawa lipopolysaccharide bound to a protein carrier</article-title>. <source>J Infect Dis</source><year>2002</year>;<volume>185</volume>:<fpage>950</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">11920320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/339583</pub-id></mixed-citation></ref><ref id="bib60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chhibber</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bajaj</surname><given-names>J</given-names></name></person-group><article-title>Polysaccharide-iron-regulated cell surface protein conjugate vaccine: its role in protection against <italic toggle="yes">Klebsiella pneumoniae</italic>-induced lobar pneumonia</article-title>. <source>Vaccine</source><year>1995</year>;<volume>13</volume>:<fpage>179</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">7625113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0264-410x(95)93133-t</pub-id></mixed-citation></ref><ref id="bib61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chhibber</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rani</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vanashree</surname><given-names>Y</given-names></name></person-group><article-title>Immunoprotective potential of polysaccharide-tetanus toxoid conjugate in <italic toggle="yes">Klebsiella pneumoniae</italic> induced lobar pneumonia in rats</article-title>. <source>Indian J Exp Biol</source><year>2005</year>;<volume>43</volume>:<fpage>40</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">15691064</pub-id></mixed-citation></ref><ref id="bib62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chhibber</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wadhwa</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yadav</surname><given-names>V</given-names></name></person-group><article-title>Protective role of liposome incorporated lipopolysaccharide antigen of <italic toggle="yes">Klebsiella pneumoniae</italic> in a rat model of lobar pneumonia</article-title>. <source>Jpn J Infect Dis</source><year>2004</year>;<volume>57</volume>:<fpage>150</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">15329446</pub-id></mixed-citation></ref><ref id="bib63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cogliati</surname><given-names>M</given-names></name></person-group><article-title>Global molecular epidemiology of <italic toggle="yes">Cryptococcus neoformans</italic> and <italic toggle="yes">Cryptococcus gattii</italic>: an analysis of the molecular types</article-title>. <source>Scientifica (Cairo)</source><year>2013</year>;<volume>2013</volume>:<fpage>675213</fpage>.<pub-id pub-id-type="pmid">24278784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/675213</pub-id><pub-id pub-id-type="pmcid">PMC3820360</pub-id></mixed-citation></ref><ref id="bib64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ashkenazi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Double-blind vaccine-controlled randomised efficacy trial of an investigational <italic toggle="yes">Shigella sonnei</italic> conjugate vaccine in young adults</article-title>. <source>Lancet</source><year>1997</year>;<volume>349</volume>:<fpage>155</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9111538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(96)06255-1</pub-id></mixed-citation></ref><ref id="bib65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Kristian</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Weidenmaier</surname><given-names>C</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Staphylococcus aureus</italic> strains lacking D-Alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice</article-title>. <source>J Infect Dis</source><year>2002</year>;<volume>186</volume>:<fpage>214</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">12134257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/341454</pub-id></mixed-citation></ref><ref id="bib66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colvin</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Irie</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tart</surname><given-names>CS</given-names></name><etal/></person-group><article-title>The Pel and Psl polysaccharides provide <italic toggle="yes">Pseudomonas aeruginosa</italic> structural redundancy within the biofilm matrix</article-title>. <source>Environ Microbiol</source><year>2012</year>;<volume>14</volume>:<fpage>1913</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">22176658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1462-2920.2011.02657.x</pub-id><pub-id pub-id-type="pmcid">PMC3840794</pub-id></mixed-citation></ref><ref id="bib67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corsaro</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>De Castro</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Naldi</surname><given-names>T</given-names></name><etal/></person-group><article-title>1H and 13C NMR characterization and secondary structure of the K2 polysaccharide of <italic toggle="yes">Klebsiella pneumoniae</italic> strain 52145</article-title>. <source>Carbohydr Res</source><year>2005</year>;<volume>340</volume>:<fpage>2212</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">16054607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2005.07.006</pub-id></mixed-citation></ref><ref id="bib68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costantino</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Norelli</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Giannozzi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines</article-title>. <source>Vaccine</source><year>1999</year>;<volume>17</volume>:<fpage>1251</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">10195638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(98)00348-x</pub-id></mixed-citation></ref><ref id="bib69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costantino</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Berti</surname><given-names>F</given-names></name></person-group><article-title>The design of semi-synthetic and synthetic glycoconjugate vaccines</article-title>. <source>Expert Opin Drug Dis</source><year>2011</year>;<volume>6</volume>:<fpage>1045</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17460441.2011.609554</pub-id><pub-id pub-id-type="pmid">22646863</pub-id></mixed-citation></ref><ref id="bib70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>St Michael</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Aubry</surname><given-names>A</given-names></name><etal/></person-group><article-title>Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat <italic toggle="yes">Clostridium difficile</italic> infection</article-title>. <source>Glycoconj J</source><year>2013</year>;<volume>30</volume>:<fpage>843</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">23974722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10719-013-9489-3</pub-id></mixed-citation></ref><ref id="bib70a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>St Michael</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cairns</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera</article-title>. <source>Glycoconj j</source><year>2011</year>;<volume>28</volume>:<fpage>165</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">21590368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10719-011-9332-7</pub-id></mixed-citation></ref><ref id="bib71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cairns</surname><given-names>C</given-names></name><etal/></person-group><article-title>Investigating the candidacy of a capsular polysaccharide-based glycoconjugate as a vaccine to combat <italic toggle="yes">Haemophilus influenzae</italic> type a disease: a solution for an unmet public health need</article-title>. <source>Vaccine</source><year>2017</year>;<volume>35</volume>:<fpage>6129</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">28951087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.09.055</pub-id></mixed-citation></ref><ref id="bib72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Croxen</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Finlay</surname><given-names>BB</given-names></name></person-group><article-title>Molecular mechanisms of <italic toggle="yes">Escherichia coli</italic> pathogenicity</article-title>. <source>Nat Rev Microbiol</source><year>2009</year>;<volume>9</volume>:<fpage>26</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro2265</pub-id><pub-id pub-id-type="pmid">19966814</pub-id></mixed-citation></ref><ref id="bib73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names></name></person-group><article-title>Progress in immunization against <italic toggle="yes">Klebsiella</italic> infections</article-title>. <source>Eur J Clin Microbiol</source><year>1983</year>;<volume>2</volume>:<fpage>523</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">6365535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02016559</pub-id></mixed-citation></ref><ref id="bib74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Furer</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cross</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a <italic toggle="yes">Pseudomonas aeruginosa</italic> O-polysaccharide toxin A conjugate vaccine in humans.</article-title><source>J Clin Invest</source><year>1987</year>;<volume>80</volume>:<fpage>51</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">3110215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI113062</pub-id><pub-id pub-id-type="pmcid">PMC442200</pub-id></mixed-citation></ref><ref id="bib75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Furer</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Germanier</surname><given-names>R</given-names></name></person-group><article-title>Experimental <italic toggle="yes">Klebsiella pneumoniae</italic> burn wound sepsis: role of capsular polysaccharide</article-title>. <source>Infect Immun</source><year>1984</year>;<volume>43</volume>:<fpage>440</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">6360907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.43.1.440-441.1984</pub-id><pub-id pub-id-type="pmcid">PMC263459</pub-id></mixed-citation></ref><ref id="bib76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Sadojr</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Cross</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Octavalent pseudomonas aeruginosa O-polysaccharide-toxin a conjugate vaccine</article-title>. <source>Microb Pathogenesis</source><year>1989</year>;<volume>6</volume>:<fpage>75</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0882-4010(89)90010-7</pub-id><pub-id pub-id-type="pmid">2733597</pub-id></mixed-citation></ref><ref id="bib77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Wedgwood</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Immunization of noncolonized cystic fibrosis patients against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>J Infect Dis</source><year>1994</year>;<volume>169</volume>:<fpage>1159</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">8169414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/169.5.1159</pub-id></mixed-citation></ref><ref id="bib78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuccui</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Terra</surname><given-names>VS</given-names></name>, <name name-style="western"><surname>Bosse</surname><given-names>JT</given-names></name><etal/></person-group><article-title>The N -linking glycosylation system from <italic toggle="yes">Actinobacillus pleuropneumoniae</italic> is required for adhesion and has potential use in glycoengineering</article-title>. <source>Open Biol</source><year>2017</year>;<volume>7</volume>:<fpage>160212</fpage>.<pub-id pub-id-type="pmid">28077594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rsob.160212</pub-id><pub-id pub-id-type="pmcid">PMC5303269</pub-id></mixed-citation></ref><ref id="bib79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuccui</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Moule</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against <italic toggle="yes">Francisella tularensis</italic></article-title>. <source>Open Biol</source><year>2013</year>;<volume>3</volume>:<fpage>130002</fpage>.<pub-id pub-id-type="pmid">23697804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rsob.130002</pub-id><pub-id pub-id-type="pmcid">PMC3866875</pub-id></mixed-citation></ref><ref id="bib80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuthbertson</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kos</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Whitfield</surname><given-names>C</given-names></name></person-group><article-title>ABC transporters involved in export of cell surface glycoconjugates</article-title>. <source>Microbiol Mol Biol R</source><year>2010</year>;<volume>74</volume>:<fpage>341</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MMBR.00009-10</pub-id><pub-id pub-id-type="pmcid">PMC2937517</pub-id><pub-id pub-id-type="pmid">20805402</pub-id></mixed-citation></ref><ref id="bib81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutler</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Deepe</surname><given-names>GS</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Klein</surname><given-names>BS</given-names></name></person-group><article-title>Advances in combating fungal diseases: vaccines on the threshold</article-title>. <source>Nat Rev Microbiol</source><year>2007</year>;<volume>5</volume>:<fpage>13</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">17160002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro1537</pub-id><pub-id pub-id-type="pmcid">PMC2214303</pub-id></mixed-citation></ref><ref id="bib82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cywes-Bentley</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Skurnik</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zaidi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens</article-title>. <source>Proc Natl Acad Sci USA</source><year>2013</year>;<volume>110</volume>, <fpage>E2209</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">23716675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1303573110</pub-id><pub-id pub-id-type="pmcid">PMC3683766</pub-id></mixed-citation></ref><ref id="bib83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danieli</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lay</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Proietti</surname><given-names>D</given-names></name><etal/></person-group><article-title>First Synthesis of <italic toggle="yes">C. difficile</italic> PS-II cell wall polysaccharide repeating unit</article-title>. <source>Org Lett</source><year>2011</year>;<volume>13</volume>:<fpage>378</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">21190352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ol1026188</pub-id></mixed-citation></ref><ref id="bib84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delea</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Weycker</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Atwood</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada</article-title>. <source>PLoS ONE</source><year>2017</year>;<volume>12</volume>:<fpage>e0175721</fpage>.<pub-id pub-id-type="pmid">28472165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0175721</pub-id><pub-id pub-id-type="pmcid">PMC5417484</pub-id></mixed-citation></ref><ref id="bib85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delgleize</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Leeuwenkamp</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Theodorou</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model</article-title>. <source>BMJ Open</source><year>2016</year>;<volume>6</volume>:<fpage>e010776</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2015-010776</pub-id><pub-id pub-id-type="pmcid">PMC5168567</pub-id><pub-id pub-id-type="pmid">27903558</pub-id></mixed-citation></ref><ref id="bib86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dennis</surname><given-names>DT</given-names></name>, <name name-style="western"><surname>Inglesby</surname><given-names>TV</given-names></name>, <name name-style="western"><surname>Henderson</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Tularemia as a biological weapon</article-title>. <source>JAMA</source><year>2001</year>;<volume>285</volume>:<fpage>2763</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">11386933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.285.21.2763</pub-id></mixed-citation></ref><ref id="bib87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeShazer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Brett</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Woods</surname><given-names>DE</given-names></name></person-group><article-title>The type II O-antigenic polysaccharide moiety of <italic toggle="yes">Burkholderia pseudomallei</italic> lipopolysaccharide is required for serum resistance and virulence</article-title>. <source>Mol Microbiol</source><year>1998</year>;<volume>30</volume>:<fpage>1081</fpage>&#8211;<lpage>100</lpage>.<pub-id pub-id-type="pmid">9988483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2958.1998.01139.x</pub-id></mixed-citation></ref><ref id="bib88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeShazer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Waag</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Fritz</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Identification of a <italic toggle="yes">Burkholderia mallei</italic> polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant</article-title>. <source>Microb Pathogenesis</source><year>2001</year>;<volume>30</volume>:<fpage>253</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/mpat.2000.0430</pub-id><pub-id pub-id-type="pmid">11373120</pub-id></mixed-citation></ref><ref id="bib89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devi</surname><given-names>SJ</given-names></name></person-group><article-title>Preclinical efficacy of a Glucuronoxylomannan-Tetanus toxoid conjugate vaccine of <italic toggle="yes">Cryptococcus neoformans</italic> in a murine model</article-title>. <source>Vaccine</source><year>1996</year>;<volume>14</volume>:<fpage>841</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">8843625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0264-410x(95)00256-z</pub-id></mixed-citation></ref><ref id="bib90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devi</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Schneerson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Egan</surname><given-names>W</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Cryptococcus neoformans</italic> serotype a glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity</article-title>. <source>Infect Immun</source><year>1991</year>;<volume>59</volume>:<fpage>3700</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">1716613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.59.10.3700-3707.1991</pub-id><pub-id pub-id-type="pmcid">PMC258941</pub-id></mixed-citation></ref><ref id="bib91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhillon</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pace</surname><given-names>D</given-names></name></person-group><article-title>Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix&#174;): a review</article-title>. <source>Drugs</source><year>2017</year>;<volume>77</volume>:<fpage>1881</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">29094312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-017-0828-8</pub-id></mixed-citation></ref><ref id="bib92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diago-Navarro</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Passet</surname><given-names>V</given-names></name><etal/></person-group><article-title>Carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> exhibit variability in capsular polysaccharide and capsule associated virulence traits</article-title>. <source>J Infect Dis</source><year>2014</year>;<volume>210</volume>:<fpage>803</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">24634498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiu157</pub-id><pub-id pub-id-type="pmcid">PMC4432395</pub-id></mixed-citation></ref><ref id="bib93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiGiandomenico</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Warrener</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hamilton</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identification of broadly protective human antibodies to <italic toggle="yes">Pseudomonas aeruginosa</italic> exopolysaccharide Psl by phenotypic screening</article-title>. <source>J Exp Med</source><year>2012</year>;<volume>209</volume>:<fpage>1273</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">22734046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20120033</pub-id><pub-id pub-id-type="pmcid">PMC3405507</pub-id></mixed-citation></ref><ref id="bib94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donadei</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gallorini</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Berti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Rational design of adjuvant for skin delivery: conjugation of synthetic beta-Glucan Dectin-1 agonist to protein antigen</article-title>. <source>Mol Pharmaceutics</source><year>2015</year>;<volume>12</volume>:<fpage>1662</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.5b00072</pub-id><pub-id pub-id-type="pmid">25867449</pub-id></mixed-citation></ref><ref id="bib95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doring</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pier</surname><given-names>GB</given-names></name></person-group><article-title>Vaccines and immunotherapy against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>Vaccine</source><year>2008</year>;<volume>26</volume>:<fpage>1011</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">18242792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.12.007</pub-id></mixed-citation></ref><ref id="bib96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edebrink</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jansson</surname><given-names>P-E</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Structural studies of the O-polysaccharide from the lipopolysaccharide of <italic toggle="yes">Moraxella (Branhamella) catarrhalis</italic> serotype A (strain ATCC 25238)</article-title>. <source>Carbohydr Res</source><year>1994</year>;<volume>257</volume>:<fpage>269</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">7516823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0008-6215(94)80040-5</pub-id></mixed-citation></ref><ref id="bib97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edebrink</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jansson</surname><given-names>P-E</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Structural studies of the O-antigen oligosaccharides from two strains of <italic toggle="yes">Moraxella catarrhalis</italic> serotype C</article-title>. <source>Carbohydr Res</source><year>1995</year>;<volume>266</volume>:<fpage>237</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">7535189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0008-6215(94)00276-l</pub-id></mixed-citation></ref><ref id="bib98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edebrink</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jansson</surname><given-names>P-E</given-names></name>, <name name-style="western"><surname>Widmalm</surname><given-names>G</given-names></name><etal/></person-group><article-title>The structures of oligosaccharides isolated from the lipopolysaccharide of <italic toggle="yes">Moraxella catarrhalis</italic> serotype B, strain CCUG 3292</article-title>. <source>Carbohydr Res</source><year>1996</year>;<volume>295</volume>:<fpage>127</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">9002189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0008-6215(96)90132-9</pub-id></mixed-citation></ref><ref id="bib99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Jennings</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Apicella</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development</article-title>. <source>Crit Rev Microbiol</source><year>2016</year>;<volume>42</volume>:<fpage>928</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">26805040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/1040841X.2015.1105782</pub-id><pub-id pub-id-type="pmcid">PMC4958600</pub-id></mixed-citation></ref><ref id="bib100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emmadi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Lykke</surname><given-names>L</given-names></name><etal/></person-group><article-title>A <italic toggle="yes">Streptococcus pneumoniae</italic> Type 2 oligosaccharide glycoconjugate elicits opsonic antibodies and is protective in an animal model of invasive pneumococcal disease</article-title>. <source>J Am Chem Soc</source><year>2017</year>;<volume>139</volume>:<fpage>14783</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">28945368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.7b07836</pub-id></mixed-citation></ref><ref id="bib101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Endl</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Seidl</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Fiedler</surname><given-names>F</given-names></name><etal/></person-group><article-title>Chemical composition and structure of cell wall teichoic acids of staphylococci</article-title>. <source>Arch Microbiol</source><year>1983</year>;<volume>135</volume>:<fpage>215</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">6639273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00414483</pub-id></mixed-citation></ref><ref id="bib102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enright</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>McKenzie</surname><given-names>H</given-names></name></person-group><article-title><italic toggle="yes">Moraxella (Branhamella) catarrhalis</italic>&#8212;clinical and molecular aspects of a rediscovered pathogen</article-title>. <source>J Med Microbiol</source><year>1997</year>;<volume>46</volume>:<fpage>360</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">9152030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/00222615-46-5-360</pub-id></mixed-citation></ref><ref id="bib103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erbing</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kenne</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lindberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>Structural studies of the capsular polysaccharide from <italic toggle="yes">Klebsiella</italic> Type 1</article-title>. <source>Carbohydr Res</source><year>1976</year>;<volume>50</volume>:<fpage>115</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">975115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0008-6215(00)84088-4</pub-id></mixed-citation></ref><ref id="bib104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farjah</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Owlia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Siadat</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Conjugation of alginate to a synthetic peptide containing T- and B-cell epitopes as an induction for protective immunity against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>J Biotechnol</source><year>2014</year>;<volume>192</volume>:<fpage>240</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">25449544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbiotec.2014.10.025</pub-id></mixed-citation></ref><ref id="bib105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farjah</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Owlia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Siadat</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Immunological evaluation of an alginate-based conjugate as a vaccine candidate against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>APMIS</source><year>2015</year>;<volume>123</volume>:<fpage>175</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">25470757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apm.12337</pub-id></mixed-citation></ref><ref id="bib106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattom</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fuller</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Propst</surname><given-names>M</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a booster dose of <italic toggle="yes">Staphylococcus aureus</italic> types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX&#174;) in hemodialysis patients</article-title>. <source>Vaccine</source><year>2004a</year>;<volume>23</volume>:<fpage>656</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">15542186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2004.06.043</pub-id></mixed-citation></ref><ref id="bib107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattom</surname><given-names>AI</given-names></name>, <name name-style="western"><surname>Horwith</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Fuller</surname><given-names>S</given-names></name><etal/></person-group><article-title>Development of StaphVAX, a polysaccharide conjugate vaccine against <italic toggle="yes">S. aureus</italic> infection: from the lab bench to phase III clinical trials</article-title>. <source>Vaccine</source><year>2004b</year>;<volume>22</volume>:<fpage>880</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15040941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2003.11.034</pub-id></mixed-citation></ref><ref id="bib108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattom</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Matalon</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Buerkert</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy profile of a bivalent <italic toggle="yes">Staphylococcus aureus</italic> glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study</article-title>. <source>Hum Vacc Immunother</source><year>2015</year>;<volume>11</volume>:<fpage>632</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.34414</pub-id><pub-id pub-id-type="pmcid">PMC4514248</pub-id><pub-id pub-id-type="pmid">25483694</pub-id></mixed-citation></ref><ref id="bib109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Wacker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hernandez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in <italic toggle="yes">Escherichia coli</italic></article-title>. <source>Proc P Natl Acad Sci USA</source><year>2005</year>;<volume>102</volume>:<fpage>3016</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0500044102</pub-id><pub-id pub-id-type="pmcid">PMC549450</pub-id><pub-id pub-id-type="pmid">15703289</pub-id></mixed-citation></ref><ref id="bib110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiebig</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Litschko</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Freiberger</surname><given-names>F</given-names></name><etal/></person-group><article-title>Efficient solid-phase synthesis of meningococcal capsular oligosaccharides enables simple and fast chemoenzymatic vaccine production</article-title>. <source>J Biol Chem</source><year>2018</year>;<volume>293</volume>:<fpage>953</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">29187601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.RA117.000488</pub-id><pub-id pub-id-type="pmcid">PMC5777266</pub-id></mixed-citation></ref><ref id="bib111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiebig</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Romano</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Oldrini</surname><given-names>D</given-names></name><etal/></person-group><article-title>An efficient cell free enzyme-based total synthesis of a meningococcal vaccine candidate</article-title>. <source>NPJ Vaccines</source><year>2016</year>;<volume>1</volume>:<fpage>16017</fpage>.<pub-id pub-id-type="pmid">29263856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npjvaccines.2016.17</pub-id><pub-id pub-id-type="pmcid">PMC5707881</pub-id></mixed-citation></ref><ref id="bib112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filloux</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Whitfield</surname><given-names>C</given-names></name></person-group><article-title>Editorial: The many wonders of the bacterial cell surface</article-title>. <source>FEMS Microbiol Rev</source><year>2016</year>;<volume>40</volume>:<fpage>161</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">26684539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femsre/fuv047</pub-id></mixed-citation></ref><ref id="bib113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Behr</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hartma</surname><given-names>R</given-names></name><etal/></person-group><article-title>Teichoic acid and lipoteichoic acid of <italic toggle="yes">Streptococcus pneumoniae</italic> possess identical chain structures. A reinvestigation of teichoid acid (C polysaccharide)</article-title>. <source>Eur J Biochem</source><year>1993</year>;<volume>215</volume>:<fpage>851</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">8354290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1432-1033.1993.tb18102.x</pub-id></mixed-citation></ref><ref id="bib114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Koch</surname><given-names>HU</given-names></name>, <name name-style="western"><surname>Haas</surname><given-names>R</given-names></name></person-group><article-title>Improved preparation of lipoteichoic acids</article-title>. <source>Eur J Biochem</source><year>1983</year>;<volume>133</volume>:<fpage>523</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">6190649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1432-1033.1983.tb07495.x</pub-id></mixed-citation></ref><ref id="bib115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Follador</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Heinz</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Wyres</surname><given-names>KL</given-names></name><etal/></person-group><article-title>The diversity of <italic toggle="yes">Klebsiella pneumoniae</italic> surface polysaccharides</article-title>. <source>Microb Genom</source><year>2016</year>;<volume>2</volume>:<fpage>e000073</fpage>.<pub-id pub-id-type="pmid">28348868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/mgen.0.000073</pub-id><pub-id pub-id-type="pmcid">PMC5320592</pub-id></mixed-citation></ref><ref id="bib116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fomsgaard</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Fomsgaard</surname><given-names>A</given-names></name>, <name name-style="western"><surname>H&#248;iby</surname><given-names>N</given-names></name><etal/></person-group><article-title>Comparative immunochemistry of lipopolysaccharides from <italic toggle="yes">Branhamella catarrhalis</italic> strains</article-title>. <source>Infect Immun</source><year>1991</year>;<volume>59</volume>:<fpage>3346</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">1908833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.59.9.3346-3349.1991</pub-id><pub-id pub-id-type="pmcid">PMC258182</pub-id></mixed-citation></ref><ref id="bib117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fontaine</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Beauvais</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Loussert</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cell wall alpha1-3glucans induce the aggregation of germinating conidia of <italic toggle="yes">Aspergillus fumigatus</italic></article-title>. <source>Fungal Genet Biol</source><year>2010</year>;<volume>47</volume>:<fpage>707</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">20447463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fgb.2010.04.006</pub-id></mixed-citation></ref><ref id="bib118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Richet</surname><given-names>H</given-names></name></person-group><article-title>The epidemiology and control of <italic toggle="yes">Acinetobacter baumannii</italic> in health care facilities</article-title>. <source>Clin Infect Dis</source><year>2006</year>;<volume>42</volume>:<fpage>692</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">16447117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/500202</pub-id></mixed-citation></ref><ref id="bib119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frenck</surname><given-names>RW</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Creech</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Sheldon</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of a 4-antigen <italic toggle="yes">Staphylococcus aureus</italic> vaccine (SA4Ag): results from a first-in-human randomised, placebo-controlled phase 1/2 study</article-title>. <source>Vaccine</source><year>2017</year>;<volume>35</volume>:<fpage>375</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">27916408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.11.010</pub-id></mixed-citation></ref><ref id="bib120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganesh</surname><given-names>NV</given-names></name>, <name name-style="western"><surname>Fujikawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>YH</given-names></name><etal/></person-group><article-title>HPLC-assisted automated oligosaccharide synthesis</article-title>. <source>Org Lett</source><year>2012</year>;<volume>14</volume>:<fpage>3036</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22646669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ol301105y</pub-id><pub-id pub-id-type="pmcid">PMC3426652</pub-id></mixed-citation></ref><ref id="bib121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganeshapillai</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vinogradov</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rousseau</surname><given-names>J</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Clostridium difficile</italic> cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units</article-title>. <source>Carbohydr Res</source><year>2008</year>;<volume>343</volume>:<fpage>703</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">18237724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2008.01.002</pub-id></mixed-citation></ref><ref id="bib122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Tontini</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brogioni</surname><given-names>G</given-names></name><etal/></person-group><article-title>Immunoactivity of protein conjugates of carba analogues from <italic toggle="yes">Neisseria meningitidis</italic> a capsular polysaccharide</article-title>. <source>ACS Chem Biol</source><year>2013</year>;<volume>8</volume>:<fpage>2561</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">24000773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/cb400463u</pub-id></mixed-citation></ref><ref id="bib123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Quintanilla</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Iwashkiw</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>NL</given-names></name><etal/></person-group><article-title>Production of a recombinant vaccine candidate against <italic toggle="yes">Burkholderia pseudomallei</italic> exploiting the bacterial N-glycosylation machinery</article-title>. <source>Front Microbiol</source><year>2014</year>;<volume>5</volume>:<fpage>381</fpage>.<pub-id pub-id-type="pmid">25120536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2014.00381</pub-id><pub-id pub-id-type="pmcid">PMC4114197</pub-id></mixed-citation></ref><ref id="bib124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Quintanilla</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pulido</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Carretero-Ledesma</surname><given-names>M</given-names></name><etal/></person-group><article-title>Vaccines for antibiotic-resistant bacteria: possibility or pipe dream?</article-title><source>Trends Pharmacol Sci</source><year>2016</year>;<volume>37</volume>:<fpage>143</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">26574183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2015.10.003</pub-id></mixed-citation></ref><ref id="bib125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gauthier</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chassagne</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Theillet</surname><given-names>FX</given-names></name><etal/></person-group><article-title>Non-stoichiometric O-acetylation of <italic toggle="yes">Shigella flexneri</italic> 2a O-specific polysaccharide: synthesis and antigenicity</article-title>. <source>Org Biomol Chem</source><year>2014</year>;<volume>12</volume>:<fpage>4218</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">24836582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c3ob42586j</pub-id></mixed-citation></ref><ref id="bib126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geissner</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pereira</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Leddermann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Deciphering antigenic determinants of <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 4 capsular polysaccharide using synthetic oligosaccharides</article-title>. <source>ACS Chem Biol</source><year>2016</year>;<volume>11</volume>:<fpage>335</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">26674834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.5b00768</pub-id></mixed-citation></ref><ref id="bib82a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gening</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Maira-Litran</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kropec</surname><given-names>A</given-names></name><etal/></person-group><article-title>Synthetic b-(1-&gt;6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens</article-title>. <source>Infect Immun</source><year>2009</year>;<volume>78</volume>:<fpage>764</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">19948836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.01093-09</pub-id><pub-id pub-id-type="pmcid">PMC2812210</pub-id></mixed-citation></ref><ref id="bib127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geno</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Gilbert</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Pneumococcal capsules and their types: past, present, and future</article-title>. <source>Clin Microbiol Rev</source><year>2015</year>;<volume>28</volume>:<fpage>871</fpage>&#8211;<lpage>99</lpage>.<pub-id pub-id-type="pmid">26085553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00024-15</pub-id><pub-id pub-id-type="pmcid">PMC4475641</pub-id></mixed-citation></ref><ref id="bib129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gergova</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Iankov</surname><given-names>ID</given-names></name>, <name name-style="western"><surname>Haralambieva</surname><given-names>IH</given-names></name><etal/></person-group><article-title>Bactericidal monoclonal antibody against <italic toggle="yes">Moraxella catarrhalis</italic> lipooligosaccharide cross-reacts with <italic toggle="yes">Haemophilus</italic> spp</article-title>. <source>Curr Microbiol</source><year>2007</year>;<volume>54</volume>:<fpage>85</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">17211546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00284-005-0463-6</pub-id></mixed-citation></ref><ref id="bib130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goren</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Middlebrook</surname><given-names>GM</given-names></name></person-group><article-title>Protein conjugates of polysaccharide from <italic toggle="yes">Cryptococcus neoformans</italic></article-title>. <source>J Immunol</source><year>1967</year>;<volume>98</volume>:<fpage>901</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">4164846</pub-id></mixed-citation></ref><ref id="bib131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gow</surname><given-names>NAR</given-names></name>, <name name-style="western"><surname>Latge</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Munro</surname><given-names>CA</given-names></name></person-group><article-title>The fungal cell wall: structure, biosynthesis, and function</article-title>. <source>Microbiol Spectr</source><year>2017</year>;<volume>5</volume>, doi:<pub-id pub-id-type="doi">10.1128/microbiolspec.FUNK-0035-2016</pub-id>.<pub-id pub-id-type="pmcid">PMC11687499</pub-id><pub-id pub-id-type="pmid">28513415</pub-id></mixed-citation></ref><ref id="bib132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gowda</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Davidson</surname><given-names>EA</given-names></name></person-group><article-title>Glycosylphosphatidylinositol anchors represent the major carbohydrate modification in proteins of intraerythrocytic stage <italic toggle="yes">Plasmodium falciparum</italic></article-title>. <source>J Biol Chem</source><year>1997</year>;<volume>272</volume>:<fpage>6428</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">9045667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.272.10.6428</pub-id></mixed-citation></ref><ref id="bib133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenfield</surname><given-names>LK</given-names></name>, <name name-style="western"><surname>Whitfield</surname><given-names>C</given-names></name></person-group><article-title>Synthesis of lipopolysaccharide O-antigens by ABC transporter-dependent pathways</article-title>. <source>Carbohydr Res</source><year>2012</year>;<volume>356</volume>:<fpage>12</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">22475157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2012.02.027</pub-id></mixed-citation></ref><ref id="bib134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>X-X</given-names></name>, <name name-style="western"><surname>Chao-Ming</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ueyama</surname><given-names>T</given-names></name><etal/></person-group><article-title>Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from Nontypeable <italic toggle="yes">Haemophilus influenzae</italic> conjugated to proteins</article-title>. <source>Infect Immun</source><year>1996</year>;<volume>64</volume>:<fpage>4047</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">8926067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.64.10.4047-4053.1996</pub-id><pub-id pub-id-type="pmcid">PMC174335</pub-id></mixed-citation></ref><ref id="bib135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>X-X</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Barenkamp</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for <italic toggle="yes">Moraxella (Branhamella) catarrhalis</italic></article-title>. <source>Infect Immun</source><year>1998</year>;<volume>66</volume>:<fpage>1891</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">9573066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.66.5.1891-1897.1998</pub-id><pub-id pub-id-type="pmcid">PMC108140</pub-id></mixed-citation></ref><ref id="bib136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>XX</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Detoxified lipooligosaccharide from Nontypeable <italic toggle="yes">Haemophilus influenzae</italic> conjugated to proteins confers protection against otitis media in chinchillas</article-title>. <source>Infect Immun</source><year>1997</year>;<volume>65</volume>:<fpage>4488</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">9353024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.65.11.4488-4493.1997</pub-id><pub-id pub-id-type="pmcid">PMC175645</pub-id></mixed-citation></ref><ref id="bib137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guazzelli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>McCabe</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Oscarson</surname><given-names>S</given-names></name></person-group><article-title>Synthesis of part structures of <italic toggle="yes">Cryptococcus neoformans</italic> serotype C capsular polysaccharide</article-title>. <source>Carbohydr Res</source><year>2016</year>;<volume>433</volume>:<fpage>5</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">27423877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2016.06.012</pub-id></mixed-citation></ref><ref id="bib138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guazzelli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ulc</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Oscarson</surname><given-names>S</given-names></name></person-group><article-title>Synthesis of a glucuronic acid-containing thioglycoside trisaccharide building block and its use in the assembly of <italic toggle="yes">Cryptococcus neoformans</italic> capsular polysaccharide fragments</article-title>. <source>ChemistryOpen</source><year>2015</year>;<volume>4</volume>:<fpage>729</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">27308199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/open.201500143</pub-id><pub-id pub-id-type="pmcid">PMC4906494</pub-id></mixed-citation></ref><ref id="bib139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guazzelli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ulc</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rydner</surname><given-names>L</given-names></name><etal/></person-group><article-title>A synthetic strategy to xylose-containing thioglycoside tri- and tetrasaccharide building blocks corresponding to <italic toggle="yes">Cryptococcus neoformans</italic> capsular polysaccharide structures</article-title>. <source>Org Biomol Chem</source><year>2015</year>;<volume>13</volume>:<fpage>6598</fpage>&#8211;<lpage>610</lpage>.<pub-id pub-id-type="pmid">25986781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c5ob00766f</pub-id></mixed-citation></ref><ref id="bib140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulati</surname><given-names>S</given-names></name>, <name name-style="western"><surname>McQuillen</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Mandrell</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Immunogenicity of <italic toggle="yes">Neisseria gonorrhoeae</italic> lipooligosaccharide epitope 2C7, widely expressed in vivo with no immunochemical similarity to human glycosphingolipids</article-title>. <source>J Infect Dis</source><year>1996</year>;<volume>174</volume>:<fpage>1223</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">8940213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/174.6.1223</pub-id></mixed-citation></ref><ref id="bib141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulati</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Reed</surname><given-names>GW</given-names></name><etal/></person-group><article-title>Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection</article-title>. <source>PLoS Pathog</source><year>2013</year>;<volume>9</volume>:<fpage>e1003559</fpage>.<pub-id pub-id-type="pmid">24009500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1003559</pub-id><pub-id pub-id-type="pmcid">PMC3757034</pub-id></mixed-citation></ref><ref id="bib142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunn</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Ernst</surname><given-names>RK</given-names></name></person-group><article-title>The structure and function of Francisella lipopolysaccharide</article-title>. <source>Ann NY Acad Sci</source><year>2007</year>;<volume>1105</volume>:<fpage>202</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">17395723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1409.006</pub-id><pub-id pub-id-type="pmcid">PMC2742961</pub-id></mixed-citation></ref><ref id="bib143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Bryla</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Phase 1 evaluation of <italic toggle="yes">Vibrio cholerae</italic> O1, serotype inaba, polysaccharide-cholera toxin conjugates in adult volunteers</article-title>. <source>Infect Immun</source><year>1998</year>;<volume>66</volume>:<fpage>3095</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9632571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.66.7.3095-3099.1998</pub-id><pub-id pub-id-type="pmcid">PMC108318</pub-id></mixed-citation></ref><ref id="bib144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haghbin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>ML</given-names></name></person-group><article-title>Controlled prospective trial of <italic toggle="yes">Pseudomonas aeruginosa</italic> vaccine in children with acute leukemia</article-title>. <source>Cancer</source><year>1973</year>;<volume>32</volume>:<fpage>761</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">4201654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(197310)32:4&lt;761::aid-cncr2820320405&gt;3.0.co;2-h</pub-id></mixed-citation></ref><ref id="bib145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hahm</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Schlegel</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Hurevich</surname><given-names>M</given-names></name><etal/></person-group><article-title>Automated glycan assembly using the Glyconeer 2.1 synthesizer</article-title>. <source>Proc Natl Acad Sci USA</source><year>2017</year>;<volume>114</volume>:<fpage>E3385</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28396442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1700141114</pub-id><pub-id pub-id-type="pmcid">PMC5410834</pub-id></mixed-citation></ref><ref id="bib146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamasur</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Haile</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pawlowski</surname><given-names>A</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Mycobacterium tuberculosis</italic> arabinomannan-protein conjugates protect against tuberculosis</article-title>. <source>Vaccine</source><year>2003</year>;<volume>21</volume>:<fpage>4081</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">12922145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(03)00274-3</pub-id></mixed-citation></ref><ref id="bib147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hancock</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Gilmore</surname><given-names>MS</given-names></name></person-group><article-title>The capsular polysaccharide of <italic toggle="yes">Enterococcus faecalis</italic> and its relationship to other polysaccharides in the cell wall</article-title>. <source>Proc Natl Acad Sci USA</source><year>2002</year>;<volume>99</volume>:<fpage>1574</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">11830672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.032448299</pub-id><pub-id pub-id-type="pmcid">PMC122232</pub-id></mixed-citation></ref><ref id="bib148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harale</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Dumare</surname><given-names>NB</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>D</given-names></name><etal/></person-group><article-title>Synthesis of a tetrasaccharide and its glycoconjugate corresponding to the capsular polysaccharide of <italic toggle="yes">Neisseria meningitidis</italic> serogroup X and its immunochemical studies</article-title>. <source>RSC Adv</source><year>2015</year>;<volume>5</volume>:<fpage>41332</fpage>&#8211;<lpage>40</lpage>.</mixed-citation></ref><ref id="bib149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatz</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Bally</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rohrer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a candidate bioconjugate vaccine against <italic toggle="yes">Shigella dysenteriae</italic> type 1 administered to healthy adults: a single blind, partially randomized Phase I study</article-title>. <source>Vaccine</source><year>2015</year>;<volume>33</volume>:<fpage>4594</fpage>&#8211;<lpage>601</lpage>.<pub-id pub-id-type="pmid">26162850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.06.102</pub-id></mixed-citation></ref><ref id="bib150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heath</surname><given-names>PT</given-names></name></person-group><article-title>Status of vaccine research and development of vaccines for GBS</article-title>. <source>Vaccine</source><year>2016</year>;<volume>34</volume>:<fpage>2876</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26988258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.12.072</pub-id></mixed-citation></ref><ref id="bib151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heiss</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Burtnick</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Revised structures for the predominant O-polysaccharides expressed by <italic toggle="yes">Burkholderia pseudomallei</italic> and <italic toggle="yes">Burkholderia mallei</italic></article-title>. <source>Carbohydr Res</source><year>2013</year>;<volume>381</volume>:<fpage>6</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">24056008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2013.08.013</pub-id><pub-id pub-id-type="pmcid">PMC3923507</pub-id></mixed-citation></ref><ref id="bib152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendrickx</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Budzik</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Oh</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Architects at the bacterial surface - sortases and the assembly of pili with isopeptide bonds</article-title>. <source>Nat Rev Microbiol</source><year>2011</year>;<volume>9</volume>:<fpage>166</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">21326273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro2520</pub-id></mixed-citation></ref><ref id="bib153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hidron</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006&#8211;2007</article-title>. <source>Infect Control Hosp Epidemiol</source><year>2008</year>;<volume>29</volume>:<fpage>996</fpage>&#8211;<lpage>1011</lpage>.<pub-id pub-id-type="pmid">18947320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/591861</pub-id></mixed-citation></ref><ref id="bib154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirano</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Jiao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from nontypeable <italic toggle="yes">Haemophilus influenzae</italic> enhances bacterial clearance in mouse nasopharynx</article-title>. <source>FEMS Immunol Med Micr</source><year>2003</year>;<volume>35</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-695X.2003.tb00642.x</pub-id><pub-id pub-id-type="pmid">12589951</pub-id></mixed-citation></ref><ref id="bib155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hisatsune</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kondo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Isshiki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Occurrence of 2-O-methyl-N-(3-deoxy-L-glycero-tetronyl)-D-perosamine (4-amino-4,6-dideoxy-D-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 <italic toggle="yes">Vibrio cholerae</italic></article-title>. <source>Biochem Biophys Res Co</source><year>1993a</year>;<volume>190</volume>:<fpage>302</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/bbrc.1993.1046</pub-id><pub-id pub-id-type="pmid">8422256</pub-id></mixed-citation></ref><ref id="bib156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hisatsune</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kondo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Isshiki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>O-antigenic lipopolysaccharide of <italic toggle="yes">Vibrio cholerae</italic> O139 Bengal, a new epidemic strain for recent cholera in the Indian subcontinent</article-title>. <source>Biochem Bioph Res Co</source><year>1993b</year>;<volume>196</volume>:<fpage>1309</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/bbrc.1993.2395</pub-id><pub-id pub-id-type="pmid">7504475</pub-id></mixed-citation></ref><ref id="bib157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hogendorf</surname><given-names>WF</given-names></name>, <name name-style="western"><surname>Bos</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Overkleeft</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Synthesis of an alpha-kojibiosyl substituted glycerol teichoic acid hexamer</article-title>. <source>Bioorg Med Chem</source><year>2010</year>;<volume>18</volume>:<fpage>3668</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">20409722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmc.2010.03.071</pub-id></mixed-citation></ref><ref id="bib158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hogendorf</surname><given-names>WF</given-names></name>, <name name-style="western"><surname>Kropec</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Filippov</surname><given-names>DV</given-names></name><etal/></person-group><article-title>Light fluorous synthesis of glucosylated glycerol teichoic acids</article-title>. <source>Carbohydr Res</source><year>2012</year>;<volume>356</volume>:<fpage>142</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">22429772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2012.02.023</pub-id></mixed-citation></ref><ref id="bib159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hogendorf</surname><given-names>WF</given-names></name>, <name name-style="western"><surname>Meeuwenoord</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Overkleeft</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Automated solid phase synthesis of teichoic acids</article-title>. <source>Chem Commun</source><year>2011</year>;<volume>47</volume>:<fpage>8961</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c1cc13132j</pub-id><pub-id pub-id-type="pmid">21734985</pub-id></mixed-citation></ref><ref id="bib160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hortobagyi</surname><given-names>GN</given-names></name>, <name name-style="western"><surname>Gutterman</surname><given-names>JU</given-names></name>, <name name-style="western"><surname>Snyder</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Pseudomonas vaccine: a phase I evaluation for cancer research</article-title>. <source>Cancer Immunol Immunother</source><year>1978</year>;<volume>4</volume>:<fpage>201</fpage>&#8211;<lpage>7</lpage>.</mixed-citation></ref><ref id="bib161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>XX</given-names></name></person-group><article-title>Development of peptide mimotopes of lipooligosaccharide from Nontypeable <italic toggle="yes">Haemophilus influenzae</italic> as vaccine candidates</article-title>. <source>J Immunol</source><year>2003</year>;<volume>170</volume>:<fpage>4373</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">12682274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.170.8.4373</pub-id></mixed-citation></ref><ref id="bib162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Ganong</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Reinap</surname><given-names>B</given-names></name><etal/></person-group><article-title>Immunochemical characterization of polysaccharide antigens from six clinical strains of Enterococci</article-title>. <source>BMC Microbiol</source><year>2006</year>;<volume>6</volume>:<fpage>62</fpage>.<pub-id pub-id-type="pmid">16836754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2180-6-62</pub-id><pub-id pub-id-type="pmcid">PMC1538600</pub-id></mixed-citation></ref><ref id="bib163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Q-Y</given-names></name>, <name name-style="western"><surname>Allan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Adamo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Synthesis of a well-defined glycoconjugate vaccine by a tyrosine-selective conjugation strategy</article-title>. <source>Chem Sci</source><year>2013</year>;<volume>4</volume>:<fpage>3827</fpage>&#8211;<lpage>32</lpage>.</mixed-citation></ref><ref id="bib164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Q-Y</given-names></name>, <name name-style="western"><surname>Berti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Adamo</surname><given-names>R</given-names></name></person-group><article-title>Towards the next generation of biomedicines by site-selective conjugation</article-title>. <source>Chem Soc Rev</source><year>2016</year>;<volume>45</volume>:<fpage>1691</fpage>&#8211;<lpage>719</lpage>.<pub-id pub-id-type="pmid">26796469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c4cs00388h</pub-id></mixed-citation></ref><ref id="bib165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>WG</given-names></name>, <name name-style="western"><surname>Berry</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Exploration of <italic toggle="yes">Moraxella catarrhalis</italic> outer membrane proteins, CD and UspA, as new carriers for lipooligosaccharide-based conjugates</article-title>. <source>FEMS Immunol Med Micr</source><year>2004</year>;<volume>41</volume>:<fpage>109</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.femsim.2004.02.001</pub-id><pub-id pub-id-type="pmid">15145454</pub-id></mixed-citation></ref><ref id="bib166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>WG</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Battey</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from <italic toggle="yes">Moraxella catarrhalis</italic> conjugated to proteins</article-title>. <source>Infect Immun</source><year>2000</year>;<volume>68</volume>:<fpage>4980</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">10948114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.68.9.4980-4985.2000</pub-id><pub-id pub-id-type="pmcid">PMC101715</pub-id></mixed-citation></ref><ref id="bib167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Iterative one-pot synthesis of oligosaccharides</article-title>. <source>Angew Chem Int Ed</source><year>2004</year>;<volume>43</volume>:<fpage>5221</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.200460176</pub-id><pub-id pub-id-type="pmid">15455432</pub-id></mixed-citation></ref><ref id="bib167a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Krishna</surname><given-names>NR</given-names></name></person-group><article-title>Characterization of the group A streptococcal polysaccharide by two dimensional 1H-nuclear-magnetic-resonance spectroscopy</article-title>. <source>Carbohydr Res</source><year>1986</year>;<volume>155</volume>:<fpage>193</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">3539332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0008-6215(00)90145-9</pub-id></mixed-citation></ref><ref id="bib168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huebner</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Quaas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Krueger</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and -resistant Enterococci</article-title>. <source>Infect Immun</source><year>2000</year>;<volume>68</volume>:<fpage>4631</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">10899866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.68.8.4631-4636.2000</pub-id><pub-id pub-id-type="pmcid">PMC98395</pub-id></mixed-citation></ref><ref id="bib169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huebner</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Krueger</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of <italic toggle="yes">Enterococcus faecalis</italic> and vancomycin-resistant <italic toggle="yes">Enterococcus faecium</italic></article-title>. <source>Infect Immun</source><year>1999</year>;<volume>67</volume>:<fpage>1213</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10024563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.67.3.1213-1219.1999</pub-id><pub-id pub-id-type="pmcid">PMC96449</pub-id></mixed-citation></ref><ref id="bib170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hufnagel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Carey</surname><given-names>VJ</given-names></name>, <name name-style="western"><surname>Baldassarri</surname><given-names>L</given-names></name><etal/></person-group><article-title>Distribution of four capsular serotypes of <italic toggle="yes">Enterococcus faecalis</italic> among clinical isolates from different geographical origins and infection sites</article-title>. <source>Infection</source><year>2006</year>;<volume>34</volume>:<fpage>22</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">16501898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s15010-006-4100-5</pub-id></mixed-citation></ref><ref id="bib171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hufnagel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hancock</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Koch</surname><given-names>S</given-names></name><etal/></person-group><article-title>Serological and genetic diversity of capsular polysaccharides in <italic toggle="yes">Enterococcus faecalis</italic></article-title>. <source>J Clin Microbiol</source><year>2004</year>;<volume>42</volume>:<fpage>2548</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">15184433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JCM.42.6.2548-2557.2004</pub-id><pub-id pub-id-type="pmcid">PMC427887</pub-id></mixed-citation></ref><ref id="bib172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huttner</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hatz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>van den Dobbelsteen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic <italic toggle="yes">Escherichia coli</italic> in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial</article-title>. <source>Lancet Infect Dis</source><year>2017</year>;<volume>17</volume>:<fpage>528</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">28238601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(17)30108-1</pub-id></mixed-citation></ref><ref id="bib173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ihssen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Haas</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kowarik</surname><given-names>M</given-names></name><etal/></person-group><article-title>Increased efficiency of <italic toggle="yes">Campylobacter jejuni</italic> N-oligosaccharyltransferase PglB by structure-guided engineering</article-title>. <source>Open Biol</source><year>2015</year>;<volume>5</volume>:<fpage>140227</fpage>.<pub-id pub-id-type="pmid">25833378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rsob.140227</pub-id><pub-id pub-id-type="pmcid">PMC4422122</pub-id></mixed-citation></ref><ref id="bib174"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Janda</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Abbott</surname><given-names>SL</given-names></name></person-group><source>The Genera Klebsiella and Raoultella. The Enterobacteria</source>, <edition>2nd edn</edition>, <publisher-loc>Washington, USA</publisher-loc>: <publisher-name>ASM Press</publisher-name><year>2006</year>, pp. <fpage>115</fpage>&#8211;<lpage>29</lpage>.</mixed-citation></ref><ref id="bib175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jann</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Shashkov</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Kochanowski</surname><given-names>H</given-names></name><etal/></person-group><article-title>Structural comparison of the O6 specific polysaccharides from E. coli O6:K2:H1, <italic toggle="yes">E. coli</italic> O6:K13:H1, and <italic toggle="yes">E. coli</italic> O6:K54:H10</article-title>. <source>Carbohydr Res</source><year>1994</year>;<volume>263</volume>:<fpage>217</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">7528640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0008-6215(94)00167-7</pub-id></mixed-citation></ref><ref id="bib176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansson</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Lennholm</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Lindberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>Structural studies of the O-specific side-chains of the <italic toggle="yes">Escherichia coli</italic> O2 lipopolysaccharide</article-title>. <source>Carbohydr Res</source><year>1987</year>;<volume>161</volume>:<fpage>273</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">3555792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0008-6215(00)90084-3</pub-id></mixed-citation></ref><ref id="bib177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaurigue</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Seeberger</surname><given-names>PH</given-names></name></person-group><article-title>Parasite carbohydrate vaccines</article-title>. <source>Front Cell Infect Microbiol</source><year>2017</year>;<volume>7</volume>:<fpage>248</fpage>.<pub-id pub-id-type="pmid">28660174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2017.00248</pub-id><pub-id pub-id-type="pmcid">PMC5467010</pub-id></mixed-citation></ref><ref id="bib178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jennings</surname><given-names>LK</given-names></name>, <name name-style="western"><surname>Storek</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Ledvina</surname><given-names>HE</given-names></name><etal/></person-group><article-title>Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the <italic toggle="yes">Pseudomonas aeruginosa</italic> biofilm matrix</article-title>. <source>Proc Natl Acad Sci USA</source><year>2015</year>;<volume>112</volume>:<fpage>11353</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26311845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1503058112</pub-id><pub-id pub-id-type="pmcid">PMC4568648</pub-id></mixed-citation></ref><ref id="bib179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Romero-Steiner</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Carlone</surname><given-names>GM</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Haemophilus influenzae</italic> type a infection and its prevention</article-title>. <source>Infect Immun</source><year>2007</year>;<volume>75</volume>:<fpage>2650</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">17353280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.01774-06</pub-id><pub-id pub-id-type="pmcid">PMC1932902</pub-id></mixed-citation></ref><ref id="bib180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Bundle</surname><given-names>DR</given-names></name></person-group><article-title>Designing a new antifungal glycoconjugate vaccine</article-title>. <source>Chem Soc Rev</source><year>2013</year>;<volume>42</volume>:<fpage>4327</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">23232662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c2cs35382b</pub-id></mixed-citation></ref><ref id="bib181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>C</given-names></name></person-group><article-title>Revised structures for the capsular polysaccharides from <italic toggle="yes">Staphylococcus aureus</italic> Types 5 and 8, components of novel glycoconjugate vaccines</article-title>. <source>Carbohydr Res</source><year>2005</year>;<volume>340</volume>:<fpage>1097</fpage>&#8211;<lpage>106</lpage>.<pub-id pub-id-type="pmid">15797125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2005.02.001</pub-id></mixed-citation></ref><ref id="bib182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Roe</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>JL</given-names></name></person-group><article-title>Low mortality in burned patients in a <italic toggle="yes">Pseudomonas</italic> vaccine trial</article-title>. <source>Lancet</source><year>1978</year>:<fpage>401</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(78)91868-8</pub-id><pub-id pub-id-type="pmid">79764</pub-id></mixed-citation></ref><ref id="bib182a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nayerhoda</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comprehensive vaccine design for commensal disease progression</article-title>. <source>Sci Adv</source><year>2017</year>;<volume>3</volume>:<fpage>e1701797</fpage>.<pub-id pub-id-type="pmid">29057325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.1701797</pub-id><pub-id pub-id-type="pmcid">PMC5647123</pub-id></mixed-citation></ref><ref id="bib183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyce</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Abeygunawardana</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Isolation, structural characterization, and immunological evaluation of a high-molecular-weight exopolysaccharide from <italic toggle="yes">Staphylococcus aureus</italic></article-title>. <source>Carbohydr Res</source><year>2003</year>;<volume>338</volume>:<fpage>903</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">12681914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0008-6215(03)00045-4</pub-id></mixed-citation></ref><ref id="bib184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabanova</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Margarit</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Berti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Evaluation of a Group A Streptococcus synthetic oligosaccharide as vaccine candidate</article-title>. <source>Vaccine</source><year>2010</year>;<volume>29</volume>:<fpage>104</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">20870056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.09.018</pub-id></mixed-citation></ref><ref id="bib185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaieda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yano</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Okitsu</surname><given-names>N</given-names></name><etal/></person-group><article-title>In vitro investigation of the indirect pathogenicity of beta-lactamase-producing microorganisms in the nasopharyngeal microflora</article-title>. <source>Int J Pediat Otorhi</source><year>2005</year>;<volume>69</volume>:<fpage>479</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijporl.2004.11.013</pub-id><pub-id pub-id-type="pmid">15763284</pub-id></mixed-citation></ref><ref id="bib186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kallenius</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pawlowski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hamasur</surname><given-names>B</given-names></name></person-group><article-title>Mycobacterial glycoconjugates as vaccine candidates against tuberculosis</article-title>. <source>Trends Microbiol</source><year>2008</year>;<volume>16</volume>:<fpage>456</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">18774297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2008.07.007</pub-id></mixed-citation></ref><ref id="bib187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Mulks</surname><given-names>MH</given-names></name></person-group><article-title>Biofilm formation is prevalent among field isolates of <italic toggle="yes">Actinobacillus pleuropneumoniae</italic></article-title>. <source>Vet Microbiol</source><year>2005</year>;<volume>108</volume>:<fpage>89</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">15917136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2005.02.011</pub-id></mixed-citation></ref><ref id="bib188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapoor</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Vanjak</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Rozzelle</surname><given-names>J</given-names></name><etal/></person-group><article-title>Malaria derived glycosylphosphatidylinositol anchor enhances anti-Pfs25 functional antibodies that block malaria transmission</article-title>. <source>Biochemistry</source><year>2018</year>;<volume>57</volume>:<fpage>516</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29323879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biochem.7b01099</pub-id><pub-id pub-id-type="pmcid">PMC5803671</pub-id></mixed-citation></ref><ref id="bib189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashef</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Behzadian-Nejad</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Najar-Peerayeh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Synthesis and characterization of <italic toggle="yes">Pseudomonas aeruginosa</italic> alginate-tetanus toxoid conjugate</article-title>. <source>J Med Microbiol</source><year>2006</year>;<volume>55</volume>:<fpage>1441</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17005795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/jmm.0.46696-0</pub-id></mixed-citation></ref><ref id="bib190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenfack</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Mazur</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nualnoi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Deciphering minimal antigenic epitopes associated with <italic toggle="yes">Burkholderia pseudomallei</italic> and <italic toggle="yes">Burkholderia mallei</italic> lipopolysaccharide O-antigens</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>115</fpage>.<pub-id pub-id-type="pmid">28740137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-00173-8</pub-id><pub-id pub-id-type="pmcid">PMC5524647</pub-id></mixed-citation></ref><ref id="bib190a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenne</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lindberg</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Madden</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Structural studies of the Escherichia coli O-antigen 25</article-title>. <source>Carbohydr Res</source><year>1983</year>;<volume>122</volume>:<fpage>249</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">6200224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0008-6215(83)88336-0</pub-id></mixed-citation></ref><ref id="bib191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khatun</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Stephenson</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Toth</surname><given-names>I</given-names></name></person-group><article-title>An overview of structural features of antibacterial glycoconjugate vaccines that influence their immunogenicity</article-title>. <source>Chem Eur J</source><year>2017</year>;<volume>23</volume>:<fpage>4233</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">28097690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/chem.201603599</pub-id></mixed-citation></ref><ref id="bib192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirvan</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Swedo</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Snider</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Antibody-mediated neuronal cell signaling in behavior and movement disorders</article-title>. <source>J Neuroimmunol</source><year>2006</year>;<volume>179</volume>:<fpage>173</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">16875742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2006.06.017</pub-id></mixed-citation></ref><ref id="bib193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klevens</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Gaynes</surname><given-names>RP</given-names></name></person-group><article-title>The impact of antimicrobial-resistant, health care&#8211;associated infections on mortality in the United States</article-title>. <source>Clin Infect Dis</source><year>2008</year>;<volume>47</volume>:<fpage>927</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">18752440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/591698</pub-id></mixed-citation></ref><ref id="bib194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klompas</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kleinman</surname><given-names>K</given-names></name><etal/></person-group><article-title>Multicenter evaluation of a novel surveillance paradigm for complications of mechanical ventilation</article-title>. <source>PLoS One</source><year>2011</year>;<volume>6</volume>:<fpage>e18062</fpage>.<pub-id pub-id-type="pmid">21445364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0018062</pub-id><pub-id pub-id-type="pmcid">PMC3062570</pub-id></mixed-citation></ref><ref id="bib195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knirel</surname><given-names>YA</given-names></name>, <name name-style="western"><surname>Bystrova</surname><given-names>OV</given-names></name>, <name name-style="western"><surname>Kocharova</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Conserved and variable structural features in the lipopolysaccharide of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>J Endotoxin Res</source><year>2006</year>;<volume>12</volume>:<fpage>324</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">17254386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1179/096805106X118906</pub-id></mixed-citation></ref><ref id="bib196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knirel</surname><given-names>YA</given-names></name>, <name name-style="western"><surname>Bystrova</surname><given-names>OV</given-names></name>, <name name-style="western"><surname>Shashkov</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Structural analysis of the lipopolysaccharide core of a rough, cystic fibrosis isolate of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>Eur J Biochem</source><year>2001</year>;<volume>268</volume>:<fpage>4708</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">11532007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1432-1327.2001.02396.x</pub-id></mixed-citation></ref><ref id="bib197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knirel</surname><given-names>YA</given-names></name>, <name name-style="western"><surname>Paramonov</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Shashkov</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Structure of the polysaccharide chains of <italic toggle="yes">Pseudomonas pseudomallei</italic> lipopolysaccharides</article-title>. <source>Carbohydr Res</source><year>1992</year>;<volume>233</volume>:<fpage>185</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">1280183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0008-6215(00)90930-3</pub-id></mixed-citation></ref><ref id="bib198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schrag</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Alderson</surname><given-names>MR</given-names></name><etal/></person-group><article-title>WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016</article-title>. <source>Vaccine</source><year>2016</year>, doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.12.029</pub-id>.<pub-id pub-id-type="pmcid">PMC6892266</pub-id><pub-id pub-id-type="pmid">28017431</pub-id></mixed-citation></ref><ref id="bib199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kodali</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vinogradov</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Khoury</surname><given-names>N</given-names></name><etal/></person-group><article-title>A vaccine approach for the prevention of infections by multidrug-resistant <italic toggle="yes">Enterococcus faecium</italic></article-title>. <source>J Biol Chem</source><year>2015</year>;<volume>290</volume>:<fpage>19512</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">26109072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M115.655852</pub-id><pub-id pub-id-type="pmcid">PMC4528116</pub-id></mixed-citation></ref><ref id="bib200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komarova</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Orekhova</surname><given-names>MV</given-names></name>, <name name-style="western"><surname>Tsvetkov</surname><given-names>YE</given-names></name><etal/></person-group><article-title>Synthesis of a pentasaccharide and neoglycoconjugates related to fungal alpha-(1&#8594;3)-Glucan and their use in the generation of antibodies to trace <italic toggle="yes">Aspergillus fumigatus</italic> cell wall</article-title>. <source>Chem Eur J</source><year>2015</year>;<volume>21</volume>:<fpage>1029</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">25376936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/chem.201404770</pub-id></mixed-citation></ref><ref id="bib201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Vijayakrishnan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kowarik</surname><given-names>M</given-names></name><etal/></person-group><article-title>An antibacterial vaccination strategy based on a glycoconjugate containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2</article-title>. <source>Nat Chem</source><year>2016</year>;<volume>8</volume>:<fpage>242</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26892556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchem.2432</pub-id></mixed-citation></ref><ref id="bib202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowarik</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Numao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Definition of the bacterial N-glycosylation site consensus sequence</article-title>. <source>EMBO J</source><year>2006</year>;<volume>25</volume>:<fpage>1957</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">16619027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.emboj.7601087</pub-id><pub-id pub-id-type="pmcid">PMC1456941</pub-id></mixed-citation></ref><ref id="bib203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraemer</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Blum</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schibler</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis</article-title>. <source>Am J Resp Crit Care</source><year>2005</year>;<volume>171</volume>:<fpage>371</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.200407-948OC</pub-id><pub-id pub-id-type="pmid">15531750</pub-id></mixed-citation></ref><ref id="bib204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krylov</surname><given-names>VB</given-names></name>, <name name-style="western"><surname>Gerbst</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Argunov</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Definitive structural assessment of enterococcal diheteroglycan</article-title>. <source>Chem Eur J</source><year>2015</year>;<volume>21</volume>:<fpage>1749</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">25421964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/chem.201405857</pub-id></mixed-citation></ref><ref id="bib205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laferriere</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ravenscroft</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>S</given-names></name><etal/></person-group><article-title>Experimental design to optimize an <italic toggle="yes">Haemophilus influenzae</italic> type b conjugate vaccine made with hydrazide-derivatized tetanus toxoid</article-title>. <source>Glycoconjugate J</source><year>2011</year>;<volume>28</volume>:<fpage>463</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10719-011-9344-3</pub-id><pub-id pub-id-type="pmid">21850577</pub-id></mixed-citation></ref><ref id="bib206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaForce</surname><given-names>FM</given-names></name></person-group><article-title>Progress on MenACWYX vaccine: phase 1 trial results</article-title>. <source>Meningitis Research Foundation Conference</source><year>2017</year>, <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.meningitis.org/mrf-conference-2017">https://www.meningitis.org/mrf-conference-2017</ext-link> (26 March 2018, date last accessed)</comment>.</mixed-citation></ref><ref id="bib207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>R&#252;deberg</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sch&#246;ni</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Vaccination of cystic fibrosis patients against <italic toggle="yes">Pseudomonas aeruginosa</italic> reduces the proportion of patients infected and delays time to infection</article-title>. <source>Pediatr Infect Dis J</source><year>2004</year>;<volume>23</volume>:<fpage>504</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">15194830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.inf.0000129688.50588.ac</pub-id></mixed-citation></ref><ref id="bib208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langford</surname><given-names>DT</given-names></name>, <name name-style="western"><surname>Hiller</surname><given-names>J</given-names></name></person-group><article-title>Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis&#8211;three year results</article-title>. <source>Arch Dis Child</source><year>1984</year>;<volume>59</volume>:<fpage>1131</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">6441523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/adc.59.12.1131</pub-id><pub-id pub-id-type="pmcid">PMC1628912</pub-id></mixed-citation></ref><ref id="bib209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laverde</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wobser</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Romero-Saavedra</surname><given-names>F</given-names></name><etal/></person-group><article-title>Synthetic teichoic acid conjugate vaccine against nosocomial Gram-positive bacteria</article-title>. <source>PLoS ONE</source><year>2014</year>;<volume>9</volume>:<fpage>e110953</fpage>.<pub-id pub-id-type="pmid">25333799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0110953</pub-id><pub-id pub-id-type="pmcid">PMC4205086</pub-id></mixed-citation></ref><ref id="bib210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Doare</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Heath</surname><given-names>PT</given-names></name></person-group><article-title>An overview of global GBS epidemiology</article-title>. <source>Vaccine</source><year>2013</year>;<volume>31</volume>:<fpage>D7</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">23973349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.01.009</pub-id></mixed-citation></ref><ref id="bib211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebacq</surname><given-names>E</given-names></name></person-group><article-title>Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults</article-title>. <source>BioDrugs</source><year>2001</year>;<volume>15</volume>:<fpage>5</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">11754630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00063030-200115001-00002</pub-id></mixed-citation></ref><ref id="bib212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leelayuwapan</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kangwanrangsan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chawengkirttikul</surname><given-names>R</given-names></name><etal/></person-group><article-title>Synthesis and immunological studies of the lipomannan backbone glycans found on the surface of <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>J Org Chem</source><year>2017</year>;<volume>82</volume>:<fpage>7190</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28682637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.joc.7b00703</pub-id></mixed-citation></ref><ref id="bib213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Licini</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Haelterman</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Moris</surname><given-names>P</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an investigational 4-component <italic toggle="yes">Staphylococcus aureus</italic> vaccine with or without AS03 B adjuvant: results of a randomized phase I trial</article-title>. <source>Hum Vacc Immunother</source><year>2015</year>;<volume>11</volume>:<fpage>620</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1011021</pub-id><pub-id pub-id-type="pmcid">PMC4514337</pub-id><pub-id pub-id-type="pmid">25715157</pub-id></mixed-citation></ref><ref id="bib214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>LX</given-names></name></person-group><article-title>Endoglycosidases for the synthesis of polysaccharides and glycoconjugates</article-title>. <source>Adv Carbohydr Chem Biochem</source><year>2016</year>;<volume>73</volume>:<fpage>73</fpage>&#8211;<lpage>116</lpage>.<pub-id pub-id-type="pmid">27816108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.accb.2016.07.001</pub-id><pub-id pub-id-type="pmcid">PMC7327983</pub-id></mixed-citation></ref><ref id="bib215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Burgula</surname><given-names>S</given-names></name><etal/></person-group><article-title>Synthesis and immunological studies of linear oligosaccharides of beta-Glucan as antigens for antifungal vaccine development</article-title>. <source>Bioconjugate Chem</source><year>2015</year>;<volume>26</volume>:<fpage>466</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bc500575a</pub-id><pub-id pub-id-type="pmcid">PMC4664189</pub-id><pub-id pub-id-type="pmid">25671314</pub-id></mixed-citation></ref><ref id="bib216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>J</given-names></name><etal/></person-group><article-title>6-O-Branched Oligo-beta-Glucan-Based antifungal glycoconjugate vaccines</article-title>. <source>ACS Infect Dis</source><year>2016</year>;<volume>2</volume>:<fpage>123</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">27624963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsinfecdis.5b00104</pub-id><pub-id pub-id-type="pmcid">PMC5668869</pub-id></mixed-citation></ref><ref id="bib217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>FY</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>VA</given-names></name>, <name name-style="western"><surname>Khiem</surname><given-names>HB</given-names></name><etal/></person-group><article-title>The efficacy of a <italic toggle="yes">Salmonella</italic> typhi Vi conjugate vaccine in two-to-five-year-old children</article-title>. <source>N Engl J Med</source><year>2001</year>;<volume>344</volume>:<fpage>1263</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">11320385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM200104263441701</pub-id></mixed-citation></ref><ref id="bib218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linares-Perez</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Toledo-Romani</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Santana-Mederos</surname><given-names>D</given-names></name><etal/></person-group><article-title>From individual to herd protection with pneumococcal vaccines: the contribution of the Cuban pneumococcal conjugate vaccine implementation strategy</article-title>. <source>Int J Infect Dis</source><year>2017</year>;<volume>60</volume>:<fpage>98</fpage>&#8211;<lpage>102</lpage>.<pub-id pub-id-type="pmid">28457742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2017.03.011</pub-id></mixed-citation></ref><ref id="bib219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linnerborg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Widmalm</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Weintraub</surname><given-names>A</given-names></name><etal/></person-group><article-title>Structural elucidation of the O-Antigen lipopolysaccharide from two strains of plesiomonas shigelloides that share a type-specific antigen with <italic toggle="yes">Shigella flexneri</italic> 6, and the common group 1 antigen with <italic toggle="yes">Shigella flexneri</italic> spp and <italic toggle="yes">Shigella dysenteriae</italic> 1</article-title>. <source>Eur J Biochem</source><year>1995</year>;<volume>231</volume>:<fpage>839</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">7544287</pub-id></mixed-citation></ref><ref id="bib220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fitieh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>St Pierre</surname><given-names>J</given-names></name><etal/></person-group><article-title>Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating beta-Glucan</article-title>. <source>J Immunol</source><year>2013</year>; <volume>190</volume>:<fpage>4116</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">23514738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1202937</pub-id></mixed-citation></ref><ref id="bib221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Siber</surname><given-names>GR</given-names></name></person-group><article-title>How can vaccines contribute to solving the antimicrobial resistance problem?</article-title><source>mBio</source><year>2016</year>;<volume>7</volume>:<fpage>e00428</fpage>&#8211;<lpage>00416</lpage>.<pub-id pub-id-type="pmid">27273824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00428-16</pub-id><pub-id pub-id-type="pmcid">PMC4959668</pub-id></mixed-citation></ref><ref id="bib222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lisboa</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Semisynthetic glycoconjugate vaccine candidate against <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 5</article-title>. <source>Proc Natl Acad Sci USA</source><year>2017</year>;<volume>114</volume>:<fpage>11063</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">28973947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1706875114</pub-id><pub-id pub-id-type="pmcid">PMC5651752</pub-id></mixed-citation></ref><ref id="bib223"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lister</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Wolter</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Hanson</surname><given-names>ND</given-names></name></person-group><article-title>Antibacterial-resistant <italic toggle="yes">Pseudomonas aeruginosa</italic>: clinical impact and complex regulation of chromosomally encoded resistance mechanisms</article-title>. <source>Clin Microbiol Rev</source><year>2009</year>;<volume>22</volume>:<fpage>582</fpage>&#8211;<lpage>610</lpage>.<pub-id pub-id-type="pmid">19822890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00040-09</pub-id><pub-id pub-id-type="pmcid">PMC2772362</pub-id></mixed-citation></ref><ref id="bib224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liston</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Ovchinnikova</surname><given-names>OG</given-names></name>, <name name-style="western"><surname>Whitfield</surname><given-names>C</given-names></name></person-group><article-title>Unique lipid anchor attaches Vi antigen capsule to the surface of <italic toggle="yes">Salmonella</italic> enterica serovar Typhi</article-title>. <source>Proc Natl Acad Sci USA</source><year>2016</year>;<volume>113</volume>:<fpage>6719</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">27226298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1524665113</pub-id><pub-id pub-id-type="pmcid">PMC4914157</pub-id></mixed-citation></ref><ref id="bib225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Little</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ing</surname><given-names>C</given-names></name><etal/></person-group><article-title>Modification and periplasmic translocation of the biofilm exopolysaccharide poly-beta-1,6-N-acetyl-D-glucosamine</article-title>. <source>Proc Natl Acad Sci USA</source><year>2014</year>;<volume>111</volume>:<fpage>11013</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24994902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1406388111</pub-id><pub-id pub-id-type="pmcid">PMC4121833</pub-id></mixed-citation></ref><ref id="bib226"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zha</surname><given-names>J</given-names></name>, <name name-style="western"><surname>DiGiandomenico</surname><given-names>A</given-names></name><etal/></person-group><article-title>Synthetic enterobacterial common antigen (ECA) for the development of a universal immunotherapy for drug-resistant enterobacteriaceae</article-title>. <source>Angew Chem Int Ed</source><year>2015</year>;<volume>54</volume>:<fpage>10953</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201505420</pub-id><pub-id pub-id-type="pmcid">PMC4664081</pub-id><pub-id pub-id-type="pmid">26216389</pub-id></mixed-citation></ref><ref id="bib227"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Landry</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Analysis of <italic toggle="yes">Pseudomonas aeruginosa</italic> conditional psl variants reveals roles for the psl polysaccharide in adhesion and maintaining biofilm structure postattachment</article-title>. <source>J Bacteriol</source><year>2006</year>;<volume>188</volume>:<fpage>8213</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">16980452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JB.01202-06</pub-id><pub-id pub-id-type="pmcid">PMC1698210</pub-id></mixed-citation></ref><ref id="bib228"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sprinkle</surname><given-names>A</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Pseudomonas aeruginosa</italic> Psl is a galactose- and mannose-rich exopolysaccharide</article-title>. <source>J Bacteriol</source><year>2007</year>;<volume>189</volume>:<fpage>8353</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17631634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JB.00620-07</pub-id><pub-id pub-id-type="pmcid">PMC2168683</pub-id></mixed-citation></ref><ref id="bib229"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McFadden</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>De Jesus</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></name></person-group><article-title>The physical properties of the capsular polysaccharides from <italic toggle="yes">Cryptococcus neoformans</italic> suggest features for capsule construction</article-title>. <source>J Biol Chem</source><year>2006</year>;<volume>281</volume>:<fpage>1868</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">16278213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M509465200</pub-id></mixed-citation></ref><ref id="bib230"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McFetridge</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Meulen</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Folkerth</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults</article-title>. <source>Vaccine</source><year>2015</year>;<volume>33</volume>:<fpage>2793</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25913828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.04.025</pub-id></mixed-citation></ref><ref id="bib231"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacIntyre</surname><given-names>S</given-names></name>, <name name-style="western"><surname>McVeigh</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Owen</surname><given-names>P</given-names></name></person-group><article-title>Immunochemical and biochemical analysis of the polyvalent <italic toggle="yes">Pseudomonas aeruginosa</italic> vaccine PEV</article-title>. <source>Infect Immun</source><year>1986</year>;<volume>51</volume>:<fpage>675</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">3080373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.51.2.675-686.1986</pub-id><pub-id pub-id-type="pmcid">PMC262404</pub-id></mixed-citation></ref><ref id="bib232"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mack</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Chatterjee</surname><given-names>I</given-names></name><etal/></person-group><article-title>Mechanisms of biofilm formation in <italic toggle="yes">Staphylococcus epidermidis</italic> and <italic toggle="yes">Staphylococcus aureus</italic>: functional molecules, regulatory circuits, and adaptive responses</article-title>. <source>Int J Med Microbiol</source><year>2004</year>;<volume>294</volume>:<fpage>203</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">15493831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijmm.2004.06.015</pub-id></mixed-citation></ref><ref id="bib233"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacLennan</surname><given-names>AP</given-names></name></person-group><article-title>The production of capsules, hyaluronic acid and hyaluronidase by Group A and Group C Streptococci</article-title>. <source>J Gen Microbiol</source><year>1956</year>;<volume>14</volume>:<fpage>134</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">13306897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/00221287-14-1-134</pub-id></mixed-citation></ref><ref id="bib234"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacLennan</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Micoli</surname><given-names>F</given-names></name></person-group><article-title>Vaccines against invasive salmonella disease</article-title>. <source>Hum Vacc Immunother</source><year>2014</year>;<volume>10</volume>:<fpage>1478</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.29054</pub-id><pub-id pub-id-type="pmcid">PMC4185946</pub-id><pub-id pub-id-type="pmid">24804797</pub-id></mixed-citation></ref><ref id="bib235"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McVernon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nolan</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Richmond</surname><given-names>P</given-names></name><etal/></person-group><article-title>A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers</article-title>. <source>Pediatr Infect Dis J</source><year>2012</year>;<volume>31</volume>:<fpage>e15</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">22094636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/INF.0b013e31823e1e34</pub-id></mixed-citation></ref><ref id="bib236"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Dangor</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Heath</surname><given-names>PT</given-names></name><etal/></person-group><article-title>Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants</article-title>. <source>Vaccine</source><year>2013</year>;<volume>31</volume>:<fpage>D52</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23973347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.02.029</pub-id></mixed-citation></ref><ref id="bib237"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maira-Litran</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kropec</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Abeygunawardana</surname><given-names>C</given-names></name><etal/></person-group><article-title>Immunochemical properties of the staphylococcal Poly-N-Acetylglucosamine surface polysaccharide</article-title>. <source>Infect Immun</source><year>2002</year>;<volume>70</volume>:<fpage>4433</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">12117954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.70.8.4433-4440.2002</pub-id><pub-id pub-id-type="pmcid">PMC128161</pub-id></mixed-citation></ref><ref id="bib238"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maira-Litran</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kropec</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Goldmann</surname><given-names>D</given-names></name><etal/></person-group><article-title>Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide</article-title>. <source>Vaccine</source><year>2004</year>;<volume>22</volume>:<fpage>872</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">15040940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2003.11.033</pub-id></mixed-citation></ref><ref id="bib239"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maira-Litran</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kropec</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Goldmann</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Comparative opsonic and protective activities of <italic toggle="yes">Staphylococcus aureus</italic> conjugate vaccines containing native or deacetylated staphylococcal Poly-N-Acetyl-beta-(1-6)-Glucosamine</article-title>. <source>Infect Immun</source><year>2005</year>;<volume>73</volume>:<fpage>6752</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">16177353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.73.10.6752-6762.2005</pub-id><pub-id pub-id-type="pmcid">PMC1230901</pub-id></mixed-citation></ref><ref id="bib240"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malkiel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cunningham</surname><given-names>MW</given-names></name><etal/></person-group><article-title>T-Cell-dependent antibody response to the dominant epitope of streptococcal polysaccharide, N-Acetyl-Glucosamine, is cross-reactive with cardiac myosin</article-title>. <source>Infect Immun</source><year>2000</year>;<volume>68</volume>:<fpage>5803</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10992488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.68.10.5803-5808.2000</pub-id><pub-id pub-id-type="pmcid">PMC101540</pub-id></mixed-citation></ref><ref id="bib241"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malott</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Keller</surname><given-names>BO</given-names></name>, <name name-style="western"><surname>Gaudet</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Neisseria gonorrhoeae-derived heptose elicits an innate immune response and drives HIV-1 expression</article-title>. <source>Proc Natl Acad Sci USA</source><year>2013</year>;<volume>110</volume>:<fpage>10234</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23733950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1303738110</pub-id><pub-id pub-id-type="pmcid">PMC3690901</pub-id></mixed-citation></ref><ref id="bib242"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wierzba</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>RI</given-names></name></person-group><article-title>Status of vaccine research and development for shigella</article-title>. <source>Vaccine</source><year>2016</year>;<volume>34</volume>:<fpage>2887</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">26979135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.02.075</pub-id></mixed-citation></ref><ref id="bib243"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#228;nnel</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mayer</surname><given-names>H</given-names></name></person-group><article-title>Isolation and chemical characterization of the enterobacterial common antigen</article-title>. <source>Eur J Biochem</source><year>1978</year>;<volume>86</volume>:<fpage>361</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">658050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1432-1033.1978.tb12318.x</pub-id></mixed-citation></ref><ref id="bib244"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marburg</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jom</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tolman</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Bimolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with <italic toggle="yes">Neisseria meningitidis</italic> membrane protein</article-title>. <source>J Am Chem Soc</source><year>1986</year>;<volume>108</volume>:<fpage>5282</fpage>&#8211;<lpage>7</lpage>.</mixed-citation></ref><ref id="bib245"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Broecker</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Eller</surname><given-names>S</given-names></name><etal/></person-group><article-title>Glycan arrays containing synthetic <italic toggle="yes">Clostridium difficile</italic> lipoteichoic acid oligomers as tools toward a carbohydrate vaccine</article-title>. <source>Chem Commun</source><year>2013a</year>;<volume>49</volume>:<fpage>7159</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c3cc43545h</pub-id><pub-id pub-id-type="pmid">23836132</pub-id></mixed-citation></ref><ref id="bib246"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Broecker</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Oberli</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Immunological evaluation of a synthetic <italic toggle="yes">Clostridium difficile</italic> oligosaccharide conjugate vaccine candidate and identification of a minimal epitope</article-title>. <source>J Am Chem Soc</source><year>2013b</year>;<volume>135</volume>:<fpage>9713</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">23795894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja401410y</pub-id></mixed-citation></ref><ref id="bib247"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Weishaupt</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Seeberger</surname><given-names>PH</given-names></name></person-group><article-title>Progress toward developing a carbohydrate-conjugate vaccine against <italic toggle="yes">Clostridium difficile</italic> ribotype 027: synthesis of the cell-surface polysaccharide PS-I repeating unit</article-title>. <source>Chem Commun</source><year>2011</year>;<volume>47</volume>:<fpage>10260</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c1cc13614c</pub-id><pub-id pub-id-type="pmid">21998885</pub-id></mixed-citation></ref><ref id="bib248"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masuoka</surname><given-names>J</given-names></name></person-group><article-title>Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges</article-title>. <source>Clin Microbiol Rev</source><year>2004</year>;<volume>17</volume>:<fpage>281</fpage>&#8211;<lpage>310</lpage>.<pub-id pub-id-type="pmid">15084502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.17.2.281-310.2004</pub-id><pub-id pub-id-type="pmcid">PMC387410</pub-id></mixed-citation></ref><ref id="bib249"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maubon</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tanguy</surname><given-names>M</given-names></name><etal/></person-group><article-title>AGS3, an alpha(1-3)glucan synthase gene family member of <italic toggle="yes">Aspergillus fumigatus</italic>, modulates mycelium growth in the lung of experimentally infected mice</article-title>. <source>Fungal Genet Biol</source><year>2006</year>;<volume>43</volume>:<fpage>366</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">16531086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fgb.2006.01.006</pub-id></mixed-citation></ref><ref id="bib250"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>C</given-names></name><etal/></person-group><article-title>Synthesis and immunogenicity of PG-tb1 monovalent glycoconjugate</article-title>. <source>Eur J Med Chem</source><year>2017</year>;<volume>134</volume>:<fpage>140</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">28411454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2017.03.058</pub-id></mixed-citation></ref><ref id="bib251"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michon</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>Doubly branched hexasaccharide epitope on the cell wall polysaccharide of group A streptococci recognized by human and rabbit antisera</article-title>. <source>Infect Immun</source><year>2005</year>;<volume>73</volume>:<fpage>6383</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">16177309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.73.10.6383-6389.2005</pub-id><pub-id pub-id-type="pmcid">PMC1230941</pub-id></mixed-citation></ref><ref id="bib252"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Micoli</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Adamo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Proietti</surname><given-names>D</given-names></name><etal/></person-group><article-title>Meningococcal X polysaccharide quantification by high-performance anion-exchange chromatography using synthetic N-acetylglucosamine-4-phosphate as standard</article-title>. <source>Anal Biochem</source><year>2013a</year>;<volume>442</volume>:<fpage>259</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">23938776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ab.2013.08.001</pub-id></mixed-citation></ref><ref id="bib253"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Micoli</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Romano</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Tontini</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X</article-title>. <source>Proc Natl Acad Sci USA</source><year>2013b</year>;<volume>110</volume>:<fpage>19077</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">24191022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1314476110</pub-id><pub-id pub-id-type="pmcid">PMC3839747</pub-id></mixed-citation></ref><ref id="bib254"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>TJ</given-names></name></person-group><article-title>The pathogenesis of streptococcal infections: from tooth decay to meningitis</article-title>. <source>Nat Rev Microbiol</source><year>2003</year>;<volume>1</volume>:<fpage>219</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">15035026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro771</pub-id></mixed-citation></ref><ref id="bib255"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mogasale</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Maskery</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ochiai</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment</article-title>. <source>Lancet Gob Health</source><year>2014</year>;<volume>2</volume>:<fpage>e570</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(14)70301-8</pub-id><pub-id pub-id-type="pmid">25304633</pub-id></mixed-citation></ref><ref id="bib255a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morath</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Geye</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hartung</surname><given-names>T</given-names></name></person-group><article-title>Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus</article-title>. <source>J Exp Med</source><year>2001</year>;<volume>193</volume>:<fpage>393</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11157059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.193.3.393</pub-id><pub-id pub-id-type="pmcid">PMC2195914</pub-id></mixed-citation></ref><ref id="bib256"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morelli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cancogni</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tontini</surname><given-names>M</given-names></name><etal/></person-group><article-title>Synthesis and immunological evaluation of protein conjugates of <italic toggle="yes">Neisseria meningitidis</italic> X capsular polysaccharide fragments</article-title>. <source>Beilstein J Org Chem</source><year>2014</year>;<volume>10</volume>:<fpage>2367</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">25383107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3762/bjoc.10.247</pub-id><pub-id pub-id-type="pmcid">PMC4222376</pub-id></mixed-citation></ref><ref id="bib257"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morelli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Poletti</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lay</surname><given-names>L</given-names></name></person-group><article-title>Carbohydrates and immunology: synthetic oligosaccharide antigens for vaccine formulation</article-title>. <source>Eur J Org Chem</source><year>2011</year>;<volume>29</volume>:<fpage>5723</fpage>&#8211;<lpage>77</lpage>.</mixed-citation></ref><ref id="bib258"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nussbaum</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Scharff</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Protective and nonprotective monoclonal antibodies to <italic toggle="yes">Cryptococcus neoformans</italic> originating from one B Cell</article-title>. <source>J Exp Med</source><year>1995</year>;<volume>181</volume>:<fpage>405</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">7807020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.181.1.405</pub-id><pub-id pub-id-type="pmcid">PMC2191853</pub-id></mixed-citation></ref><ref id="bib259"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Scharff</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></name></person-group><article-title>Protective murine monoclonal antibodies to <italic toggle="yes">Cryptococcus neoformans</italic></article-title>. <source>Infect Immun</source><year>1992</year>;<volume>60</volume>:<fpage>4534</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">1398966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.60.11.4534-4541.1992</pub-id><pub-id pub-id-type="pmcid">PMC258199</pub-id></mixed-citation></ref><ref id="bib260"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>TF</given-names></name></person-group><article-title>Vaccines for Nontypeable <italic toggle="yes">Haemophilus influenzae</italic>: the future is now</article-title>. <source>Clin Vaccine Immunol</source><year>2015</year>;<volume>22</volume>:<fpage>459</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">25787137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CVI.00089-15</pub-id><pub-id pub-id-type="pmcid">PMC4412935</pub-id></mixed-citation></ref><ref id="bib261"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>TF</given-names></name>, <name name-style="western"><surname>Bakaletz</surname><given-names>LO</given-names></name>, <name name-style="western"><surname>Smeesters</surname><given-names>PR</given-names></name></person-group><article-title>Microbial interactions in the respiratory tract</article-title>. <source>Pediatr Infect Dis J</source><year>2009</year>;<volume>28</volume>:<fpage>S121</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">19918134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/INF.0b013e3181b6d7ec</pub-id></mixed-citation></ref><ref id="bib262"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>TF</given-names></name>, <name name-style="western"><surname>Brauer</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Aebi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Antigenic specificity of the mucosal antibody response to <italic toggle="yes">Moraxella catarrhalis</italic> in chronic obstructive pulmonary disease</article-title>. <source>Infect Immun</source><year>2005</year>;<volume>73</volume>:<fpage>8161</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">16299311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.73.12.8161-8166.2005</pub-id><pub-id pub-id-type="pmcid">PMC1307080</pub-id></mixed-citation></ref><ref id="bib263"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musumeci</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Hug</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>NE</given-names></name><etal/></person-group><article-title>In vitro activity of neisseria meningitidis PglL O -Oligosaccharyltransferase with diverse synthetic lipid donors and a UDP-activated sugar</article-title>. <source>J Biol Chem</source><year>2013</year>;<volume>288</volume>:<fpage>10578</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">23460642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M112.432815</pub-id><pub-id pub-id-type="pmcid">PMC3624439</pub-id></mixed-citation></ref><ref id="bib264"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakouzi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Oscarson</surname><given-names>S</given-names></name><etal/></person-group><article-title>The common <italic toggle="yes">Cryptococcus neoformans</italic> glucuronoxylomannan M2 motif elicits non-protective antibodies</article-title>. <source>Vaccine</source><year>2009</year>;<volume>27</volume>:<fpage>3513</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">19464529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.03.089</pub-id><pub-id pub-id-type="pmcid">PMC2932445</pub-id></mixed-citation></ref><ref id="bib265"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Prior</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Lever</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis</article-title>. <source>J Med Microbiol</source><year>2004</year>;<volume>53</volume>:<fpage>1177</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">15585494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/jmm.0.45766-0</pub-id></mixed-citation></ref><ref id="bib266"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuhaus</surname><given-names>FC</given-names></name>, <name name-style="western"><surname>Baddiley</surname><given-names>J</given-names></name></person-group><article-title>A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in Gram-Positive bacteria</article-title>. <source>Microbiol Mol Biol R</source><year>2003</year>;<volume>67</volume>:<fpage>686</fpage>&#8211;<lpage>723</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MMBR.67.4.686-723.2003</pub-id><pub-id pub-id-type="pmcid">PMC309049</pub-id><pub-id pub-id-type="pmid">14665680</pub-id></mixed-citation></ref><ref id="bib267"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neyra</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Paladino</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Le Borgne</surname><given-names>M</given-names></name></person-group><article-title>Mechanisms of depolymerization and activation of a polysialic acid and its tetramer by hydrogen peroxide</article-title>. <source>Carbohydr Polym</source><year>2015</year>;<volume>115</volume>:<fpage>494</fpage>&#8211;<lpage>501</lpage>.<pub-id pub-id-type="pmid">25439924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carbpol.2014.08.112</pub-id></mixed-citation></ref><ref id="bib268"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nilo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Morelli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Passalacqua</surname><given-names>I</given-names></name><etal/></person-group><article-title>Anti-Group B streptococcus glycan-conjugate vaccines using pilus protein GBS80 As carrier and antigen: comparing lysine and tyrosine-directed conjugation</article-title>. <source>ACS Chem Biol</source><year>2015</year>;<volume>10</volume>:<fpage>1737</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">25906283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.5b00247</pub-id></mixed-citation></ref><ref id="bib269"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nissen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Richmond</surname><given-names>P</given-names></name><etal/></person-group><article-title>A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen <italic toggle="yes">Staphylococcus aureus</italic> vaccine (SA3Ag) in healthy adults</article-title>. <source>Vaccine</source><year>2015</year>;<volume>33</volume>:<fpage>1846</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">25707693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.02.024</pub-id></mixed-citation></ref><ref id="bib270"><mixed-citation publication-type="journal"><collab>NNDSS</collab>. <source>National Notifiable Diseases Surveillance System</source>. <source>Australian Government Department of Health</source>. <year>2015</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www9.health.gov.au/cda/source/rpt_3_sel.cfm">http://www9.health.gov.au/cda/source/rpt_3_sel.cfm</ext-link> (last accessed 1 October 2015)</comment>.</mixed-citation></ref><ref id="bib271"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oberli</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Hecht</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Bindschadler</surname><given-names>P</given-names></name><etal/></person-group><article-title>A possible oligosaccharide-conjugate vaccine candidate for <italic toggle="yes">Clostridium difficile</italic> is antigenic and immunogenic</article-title>. <source>Chem Biol</source><year>2011</year>;<volume>18</volume>:<fpage>580</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21609839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2011.03.009</pub-id></mixed-citation></ref><ref id="bib272"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oscarson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Alpe</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Svahnberg</surname><given-names>P</given-names></name><etal/></person-group><article-title>Synthesis and immunological studies of glycoconjugates of <italic toggle="yes">Cryptococcus neoformans</italic> capsular glucuronoxylomannan oligosaccharide structures</article-title>. <source>Vaccine</source><year>2005</year>;<volume>23</volume>:<fpage>3961</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">15917118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2005.02.029</pub-id></mixed-citation></ref><ref id="bib274"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pace</surname><given-names>D</given-names></name></person-group><article-title>Glycoconjugate vaccines</article-title>. <source>Expert Opin Biol Ther</source><year>2013</year>;<volume>13</volume>:<fpage>11</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">22992106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2012.725718</pub-id></mixed-citation></ref><ref id="bib275"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pace</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name></person-group><article-title>Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines</article-title>. <source>Arch Dis Child</source><year>2007</year>;<volume>92</volume>:<fpage>909</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">17895339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/adc.2006.111500</pub-id><pub-id pub-id-type="pmcid">PMC2083216</pub-id></mixed-citation></ref><ref id="bib276"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parameswarappa</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Reppe</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Geissner</surname><given-names>A</given-names></name><etal/></person-group><article-title>A semi-synthetic oligosaccharide conjugate Vaccine candidate confers protection against <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 3 infection</article-title>. <source>Cell Chem Biol</source><year>2016</year>;<volume>23</volume>:<fpage>1407</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">27818299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2016.09.016</pub-id><pub-id pub-id-type="pmcid">PMC5234679</pub-id></mixed-citation></ref><ref id="bib277"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patrick</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Kimura</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Antigenic characterization of the oligosaccharide portion of the lipooligosaccharide of nontypable <italic toggle="yes">Haemophilus influenzae</italic></article-title>. <source>Infect Immun</source><year>1987</year>;<volume>55</volume>:<fpage>2902</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">2445682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.55.12.2902-2911.1987</pub-id><pub-id pub-id-type="pmcid">PMC260004</pub-id></mixed-citation></ref><ref id="bib278"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulovicova</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Paulovicova</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pilisiova</surname><given-names>R</given-names></name><etal/></person-group><article-title>Synthetically prepared glycooligosaccharides mimicking <italic toggle="yes">Candida albicans</italic> cell wall glycan antigens - novel tools to study host-pathogen interactions</article-title>. <source>FEMS Yeast Res</source><year>2013</year>;<volume>13</volume>:<fpage>659</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">23859640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1567-1364.12065</pub-id></mixed-citation></ref><ref id="bib279"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peacock</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Limmathurotsakul</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lubell</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes</article-title>. <source>PLoS Neglect Trop D</source><year>2012</year>; <volume>6</volume>:<fpage>e1488</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0001488</pub-id><pub-id pub-id-type="pmcid">PMC3269417</pub-id><pub-id pub-id-type="pmid">22303489</pub-id></mixed-citation></ref><ref id="bib280"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peleg</surname><given-names>AY</given-names></name>, <name name-style="western"><surname>Seifert</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Paterson</surname><given-names>DL</given-names></name></person-group><article-title><italic toggle="yes">Acinetobacter baumannii</italic>: emergence of a successful pathogen</article-title>. <source>Clin Microbiol Rev</source><year>2008</year>;<volume>21</volume>:<fpage>538</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">18625687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00058-07</pub-id><pub-id pub-id-type="pmcid">PMC2493088</pub-id></mixed-citation></ref><ref id="bib281"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peltola</surname><given-names>H</given-names></name>, <name name-style="western"><surname>K&#228;ythy</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sivonen</surname><given-names>A</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Haemophilus influenzae</italic> Type b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland</article-title>. <source>Pediatrics</source><year>1977a</year>;<volume>60</volume>:<fpage>727</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">335348</pub-id></mixed-citation></ref><ref id="bib282"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peltola</surname><given-names>H</given-names></name>, <name name-style="western"><surname>M&#228;kel&#228;</surname><given-names>H</given-names></name>, <name name-style="western"><surname>K&#228;yhty</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age</article-title>. <source>N Engl J Med</source><year>1977b</year>;<volume>297</volume>:<fpage>686</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">408682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM197709292971302</pub-id></mixed-citation></ref><ref id="bib283"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pennington</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Reynolds</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Wood</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Use of a <italic toggle="yes">Pseudomonas aeruginosa</italic> vaccine in patients with acute leukemia and cystic fibrosis</article-title>. <source>Am J Med</source><year>1975</year>;<volume>58</volume>:<fpage>629</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">805535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9343(75)90498-2</pub-id></mixed-citation></ref><ref id="bib284"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perepelov</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Shekht</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Shigella flexneri</italic> O-antigens revisited: final elucidation of the O-acetylation profiles and a survey of the O-antigen structure diversity</article-title>. <source>FEMS Immunol Med Micr</source><year>2012</year>;<volume>66</volume>:<fpage>201</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-695X.2012.01000.x</pub-id><pub-id pub-id-type="pmid">22724405</pub-id></mixed-citation></ref><ref id="bib285"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Prenafeta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Valle</surname><given-names>J</given-names></name><etal/></person-group><article-title>Protection from <italic toggle="yes">Staphylococcus aureus</italic> mastitis associated with poly-N-acetyl beta-1,6 glucosamine specific antibody production using biofilm-embedded bacteria</article-title>. <source>Vaccine</source><year>2009</year>;<volume>27</volume>:<fpage>2379</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">19428854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.02.005</pub-id><pub-id pub-id-type="pmcid">PMC3024585</pub-id></mixed-citation></ref><ref id="bib286"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Maclean</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Schollaardt</surname><given-names>T</given-names></name><etal/></person-group><article-title>Structural characterization of the lipopolysaccharide O-antigens of <italic toggle="yes">Burkholderia pseudomallei</italic></article-title>. <source>Infect Immun</source><year>1995</year>;<volume>63</volume>:<fpage>3348</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">7543882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.63.9.3348-3352.1995</pub-id><pub-id pub-id-type="pmcid">PMC173460</pub-id></mixed-citation></ref><ref id="bib287"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phalipon</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tanguy</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Grandjean</surname><given-names>C</given-names></name><etal/></person-group><article-title>A synthetic carbohydrate-protein conjugate vaccine candidate against <italic toggle="yes">Shigella flexneri</italic> 2a infection</article-title>. <source>J Immunol</source><year>2009</year>;<volume>182</volume>:<fpage>2241</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">19201878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0803141</pub-id></mixed-citation></ref><ref id="bib288"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pier</surname><given-names>DB</given-names></name></person-group><article-title>Application of vaccine technology to prevention of <italic toggle="yes">Pseudomonas aeruginosa</italic> infections</article-title>. <source>Expert Rev Vaccines</source><year>2005</year>;<volume>4</volume>:<fpage>645</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">16221066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.4.5.645</pub-id></mixed-citation></ref><ref id="bib289"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pier</surname><given-names>GB</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity</article-title>. <source>Int J Med Microbiol</source><year>2007</year>;<volume>297</volume>:<fpage>277</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">17466590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijmm.2007.03.012</pub-id><pub-id pub-id-type="pmcid">PMC1994162</pub-id></mixed-citation></ref><ref id="bib290"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pier</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>DesJardin</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Grout</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human immune response to <italic toggle="yes">Pseudomonas aeruginosa</italic> mucoid exopolysaccharide (alginate) vaccine</article-title>. <source>Infect Immun</source><year>1994</year>;<volume>62</volume>:<fpage>3972</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">8063415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.62.9.3972-3979.1994</pub-id><pub-id pub-id-type="pmcid">PMC303055</pub-id></mixed-citation></ref><ref id="bib291"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Podschun</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ullmann</surname><given-names>U</given-names></name></person-group><article-title><italic toggle="yes">Klebsiella</italic> spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors</article-title>. <source>Clin Microbiol Rev</source><year>1998</year>;<volume>11</volume>:<fpage>589</fpage>&#8211;<lpage>603</lpage>.<pub-id pub-id-type="pmid">9767057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/cmr.11.4.589</pub-id><pub-id pub-id-type="pmcid">PMC88898</pub-id></mixed-citation></ref><ref id="bib292"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pozzi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wilk</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six <italic toggle="yes">Staphylococcus aureus</italic> antigens</article-title>. <source>PLoS ONE</source><year>2012</year>;<volume>7</volume>:<fpage>e46648</fpage>.<pub-id pub-id-type="pmid">23077517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0046648</pub-id><pub-id pub-id-type="pmcid">PMC3471903</pub-id></mixed-citation></ref><ref id="bib293"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Goyette-Desjardins</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nothaft</surname><given-names>H</given-names></name><etal/></person-group><article-title>Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines</article-title>. <source>Sci Rep</source><year>2016</year>;<volume>6</volume>:<fpage>24931</fpage>.<pub-id pub-id-type="pmid">27103188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep24931</pub-id><pub-id pub-id-type="pmcid">PMC4840304</pub-id></mixed-citation></ref><ref id="bib294"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priebe</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Goldberg</surname><given-names>JB</given-names></name></person-group><article-title>Vaccines for <italic toggle="yes">Pseudomonas aeruginosa</italic>: a long and winding road</article-title>. <source>Expert Rev Vaccines</source><year>2014</year>;<volume>13</volume>:<fpage>507</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">24575895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2014.890053</pub-id><pub-id pub-id-type="pmcid">PMC4521563</pub-id></mixed-citation></ref><ref id="bib295"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rachini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pietrella</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lupo</surname><given-names>P</given-names></name><etal/></person-group><article-title>An Anti-beta-Glucan monoclonal antibody inhibits growth and capsule formation of <italic toggle="yes">Cryptococcus neoformans</italic> in vitro and exerts therapeutic, anticryptococcal activity in vivo</article-title>. <source>Infect Immun</source><year>2007</year>;<volume>75</volume>:<fpage>5085</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">17606600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00278-07</pub-id><pub-id pub-id-type="pmcid">PMC2168274</pub-id></mixed-citation></ref><ref id="bib296"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raetz</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Whitfield</surname><given-names>C</given-names></name></person-group><article-title>Lipopolysaccharide endotoxins</article-title>. <source>Annu Rev Biochem</source><year>2002</year>;<volume>71</volume>:<fpage>635</fpage>&#8211;<lpage>700</lpage>.<pub-id pub-id-type="pmid">12045108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.biochem.71.110601.135414</pub-id><pub-id pub-id-type="pmcid">PMC2569852</pub-id></mixed-citation></ref><ref id="bib297"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Holme</surname><given-names>T</given-names></name>, <name name-style="western"><surname>J&#246;nsson</surname><given-names>I</given-names></name><etal/></person-group><article-title>Lack of serotype-specific antibody response to lipopolysaccharide antigens of <italic toggle="yes">Moraxella catarrhalis</italic> during lower respiratory tract infection</article-title>. <source>Eur J Clin Microbiol Infect Dis</source><year>1995</year>;<volume>14</volume>:<fpage>297</fpage>&#8211;<lpage>304</lpage>.<pub-id pub-id-type="pmid">7649192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02116522</pub-id></mixed-citation></ref><ref id="bib297a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rana</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dalal</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>D</given-names></name><etal/></person-group><article-title>Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths</article-title>. <source>Vaccine</source><year>2015</year>;<volume>33</volume>:<fpage>2646</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">25907408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.04.031</pub-id></mixed-citation></ref><ref id="bib298"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mandl</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vaccines for the twenty-first century society</article-title>. <source>Nat Rev Immunol</source><year>2011</year>; <volume>11</volume>:<fpage>865</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">22051890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3085</pub-id><pub-id pub-id-type="pmcid">PMC7098427</pub-id></mixed-citation></ref><ref id="bib299"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Ravenscroft</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Costantino</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Talaga</surname><given-names>P</given-names></name><etal/></person-group><source>Glycoconjugate Vaccines. From Vaccine Analysis: Strategies, Principles, and Control</source>. <publisher-loc>Berlin Heidelberg</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2015</year>:<fpage>301</fpage>&#8211;<lpage>81</lpage>.</mixed-citation></ref><ref id="bib300"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravenscroft</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Serventi</surname><given-names>F</given-names></name><etal/></person-group><article-title>NMR characterization of pneumococcal bioconjugate vaccines</article-title>. <source>Abstract from 19th European Carbohydrate Symposium</source><year>2017</year>;<volume>697</volume>.</mixed-citation></ref><ref id="bib301"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravenscroft</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Wheeler</surname><given-names>JX</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>C</given-names></name></person-group><article-title>Bioanalysis of meningococcal vaccines</article-title>. <source>Bioanalysis</source><year>2010</year>;<volume>2</volume>:<fpage>343</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">21083312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/bio.09.181</pub-id></mixed-citation></ref><ref id="bib302"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reichmann</surname><given-names>NT</given-names></name>, <name name-style="western"><surname>Grundling</surname><given-names>A</given-names></name></person-group><article-title>Location, synthesis and function of glycolipids and polyglycerolphosphate lipoteichoic acid in Gram-positive bacteria of the phylum Firmicutes</article-title>. <source>FEMS Microbiol Lett</source><year>2011</year>;<volume>319</volume>:<fpage>97</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="pmid">21388439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-6968.2011.02260.x</pub-id><pub-id pub-id-type="pmcid">PMC3089915</pub-id></mixed-citation></ref><ref id="bib303"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reid</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Vinogradov</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Structural characterization of surface glycans from <italic toggle="yes">Clostridium difficile</italic></article-title>. <source>Carbohydr Res</source><year>2012</year>;<volume>354</volume>:<fpage>65</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">22560631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2012.02.002</pub-id></mixed-citation></ref><ref id="bib304"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reyes</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bardossy</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Zervos</surname><given-names>M</given-names></name></person-group><article-title>Vancomycin-resistant enterococci</article-title>. <source>Infect Dis Clin N Am</source><year>2016</year>;<volume>30</volume>:<fpage>953</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.idc.2016.07.009</pub-id><pub-id pub-id-type="pmid">27660091</pub-id></mixed-citation></ref><ref id="bib305"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Reis</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Cordeiro</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Prevention of <italic toggle="yes">Haemophilus influenzae</italic> Type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of hib immunization in Brazil</article-title>. <source>J Infect Dis</source><year>2003</year>;<volume>187</volume>:<fpage>109</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">12508153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/345863</pub-id></mixed-citation></ref><ref id="bib306"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Greening</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Enright</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Outbreak of <italic toggle="yes">Moraxella catarrhalis</italic> in a respiratory unit</article-title>. <source>Thorax</source><year>1993</year>;<volume>48</volume>:<fpage>91</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="pmid">8434362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/thx.48.1.91</pub-id><pub-id pub-id-type="pmcid">PMC464259</pub-id></mixed-citation></ref><ref id="bib307"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riddle</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Kaminski</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Di Paolo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a candidate bioconjugate vaccine against <italic toggle="yes">Shigella flexneri</italic> 2a administered to healthy adults: A single-blind, randomized Phase I Study</article-title>. <source>Clin Vaccine Immunol</source><year>2016</year>;<volume>23</volume>:<fpage>908</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">27581434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CVI.00224-16</pub-id><pub-id pub-id-type="pmcid">PMC5139601</pub-id></mixed-citation></ref><ref id="bib308"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robbins</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Schneerson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Horwith</surname><given-names>G</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Staphylococcus aureus</italic> types 5 and 8 capsular polysaccharide-protein conjugate vaccines</article-title>. <source>Am Heart J</source><year>2004</year>;<volume>147</volume>:<fpage>593</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15077073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2004.01.012</pub-id></mixed-citation></ref><ref id="bib309"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rollenhagen</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Kalsy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Saksena</surname><given-names>R</given-names></name><etal/></person-group><article-title>Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-<italic toggle="yes">Vibrio cholerae</italic> lipopolysaccharide responses in mice</article-title>. <source>Vaccine</source><year>2009</year>;<volume>27</volume>:<fpage>4917</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">19563890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.06.040</pub-id><pub-id pub-id-type="pmcid">PMC2761657</pub-id></mixed-citation></ref><ref id="bib310"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romano</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Leuzzi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cappelletti</surname><given-names>E</given-names></name><etal/></person-group><article-title>Recombinant <italic toggle="yes">Clostridium difficile</italic> toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity</article-title>. <source>Toxins</source><year>2014</year>;<volume>6</volume>:<fpage>1385</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">24759173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/toxins6041385</pub-id><pub-id pub-id-type="pmcid">PMC4014741</pub-id></mixed-citation></ref><ref id="bib311"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Huntley</surname><given-names>JF</given-names></name></person-group><article-title>From the outside-in: the <italic toggle="yes">Francisella tularensis</italic> envelope and virulence</article-title>. <source>Front Cell Infect Microbiol</source><year>2015</year>;<volume>5</volume>:<fpage>94</fpage>.<pub-id pub-id-type="pmid">26779445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2015.00094</pub-id><pub-id pub-id-type="pmcid">PMC4688374</pub-id></mixed-citation></ref><ref id="bib312"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rukavina</surname><given-names>T</given-names></name>, <name name-style="western"><surname>T&#237;cac</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Susa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Protective effect of antilipopolysaccharide monoclonal antibody in experimental <italic toggle="yes">Klebsiella</italic> infection</article-title>. <source>Infect Immun</source><year>1997</year>;<volume>65</volume>:<fpage>1754</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">9125558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.65.5.1754-1760.1997</pub-id><pub-id pub-id-type="pmcid">PMC175211</pub-id></mixed-citation></ref><ref id="bib313"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Beanan</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Olson</surname><given-names>R</given-names></name><etal/></person-group><article-title>The K1 Capsular polysaccharide from acinetobacter baumannii is a potential therapeutic target via passive immunization</article-title>. <source>Infect Immun</source><year>2013</year>;<volume>81</volume>:<fpage>915</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">23297385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.01184-12</pub-id><pub-id pub-id-type="pmcid">PMC3584894</pub-id></mixed-citation></ref><ref id="bib314"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>JR</given-names></name></person-group><article-title>Medical and economic impact of extraintestinal infections due to <italic toggle="yes">Escherichia coli</italic>: focus on an increasingly important endemic problem</article-title>. <source>Microbes Infect</source><year>2003</year>;<volume>5</volume>:<fpage>449</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">12738001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1286-4579(03)00049-2</pub-id></mixed-citation></ref><ref id="bib315"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryall</surname><given-names>RP</given-names></name></person-group><article-title>Multivalent meningococcal polysaccharide-proteinconjugate vaccine</article-title>. <source>European Patent</source><year>2003</year>, <comment>2003707551</comment>.</mixed-citation></ref><ref id="bib316"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabharwal</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Michon</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Group A Streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection</article-title>. <source>J Infect Dis</source><year>2006</year>;<volume>193</volume>:<fpage>129</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">16323141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/498618</pub-id></mixed-citation></ref><ref id="bib317"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saderson</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Strominger</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Nathenson</surname><given-names>SG</given-names></name></person-group><article-title>Chemical structure of teichoic acid from <italic toggle="yes">Staphylococcus aureus</italic>, strain copenhagen</article-title>. <source>J Chem Biol</source><year>1962</year>;<volume>237</volume>:<fpage>3603</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">13976222</pub-id></mixed-citation></ref><ref id="bib318"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>St. Michael</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>A</given-names></name><etal/></person-group><article-title>First characterization of immunogenic conjugates of Vi negative <italic toggle="yes">Salmonella</italic> Typhi O-specific polysaccharides with rEPA protein for vaccine development</article-title>. <source>J Immunol Methods</source><year>2017</year>;<volume>450</volume>:<fpage>27</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">28735760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jim.2017.07.005</pub-id></mixed-citation></ref><ref id="bib319"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandiumenge</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rello</surname><given-names>J</given-names></name></person-group><article-title>Ventilator-associated pneumonia caused by ESKAPE organisms</article-title>. <source>Curr Opin Pulm Med</source><year>2012</year>;<volume>18</volume>:<fpage>187</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">22366995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCP.0b013e328351f974</pub-id></mixed-citation></ref><ref id="bib319a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saksena</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wade</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Length of the linker and the interval between immunizations influences the efficacy of Vibrio cholerae O1, Ogawa hexasaccharide neoglycoconjugates</article-title>. <year>2006</year>;<volume>47</volume>:<fpage>116</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-695X.2006.00071.x</pub-id><pub-id pub-id-type="pmid">16706794</pub-id></mixed-citation></ref><ref id="bib320"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ulett</surname><given-names>GC</given-names></name>, <name name-style="western"><surname>Totsika</surname><given-names>M</given-names></name><etal/></person-group><article-title>Role of capsule and O antigen in the virulence of uropathogenic <italic toggle="yes">Escherichia coli</italic></article-title>. <source>PLoS One</source><year>2014</year>;<volume>9</volume>:<fpage>e94786</fpage>.<pub-id pub-id-type="pmid">24722484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0094786</pub-id><pub-id pub-id-type="pmcid">PMC3983267</pub-id></mixed-citation></ref><ref id="bib321"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sava</surname><given-names>IG</given-names></name>, <name name-style="western"><surname>Heikens</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kropec</surname><given-names>A</given-names></name><etal/></person-group><article-title>Enterococcal surface protein contributes to persistence in the host but is not a target of opsonic and protective antibodies in <italic toggle="yes">Enterococcus faecium</italic> infection</article-title>. <source>J Med Microbiol</source><year>2010</year>;<volume>59</volume>:<fpage>1001</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">20522627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/jmm.0.020578-0</pub-id></mixed-citation></ref><ref id="bib322"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayeed</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Bufano</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>P</given-names></name><etal/></person-group><article-title>A cholera conjugate vaccine containing o-specific polysaccharide (OSP) of V. cholerae O1 inaba and recombinant fragment of tetanus toxin heavy chain (OSP:rTTHc) induces serum, memory and lamina proprial responses against osp and is protective in mice</article-title>. <source>PLoS Neglect Trop D</source><year>2015</year>;<volume>9</volume>:<fpage>e0003881</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0003881</pub-id><pub-id pub-id-type="pmcid">PMC4495926</pub-id><pub-id pub-id-type="pmid">26154421</pub-id></mixed-citation></ref><ref id="bib323"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaad</surname><given-names>UB</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Ruedeberg</surname><given-names>A</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of <italic toggle="yes">Pseudomonas aeruginosa</italic> conjugate A vaccine in cystic fibrosis</article-title>. <source>Lancet</source><year>1991</year>;<volume>338</volume>:<fpage>1236</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">1682645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0140-6736(91)92103-9</pub-id></mixed-citation></ref><ref id="bib324"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneerson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Barrera</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Sutton</surname><given-names>A</given-names></name><etal/></person-group><article-title>Preparation, characterization, and immunogenicity of <italic toggle="yes">Haemophilus influenzae</italic> type b polysaccharide-protein conjugates</article-title>. <source>J Exp Med</source><year>1980</year>;<volume>152</volume>:<fpage>361</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">6967514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.152.2.361</pub-id><pub-id pub-id-type="pmcid">PMC2185954</pub-id></mixed-citation></ref><ref id="bib325"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schumann</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hahm</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Parameswarappa</surname><given-names>S</given-names></name><etal/></person-group><article-title>A semisynthetic <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 8 glycoconjugate vaccine</article-title>. <source>Sci Transl Med</source><year>2017</year>;<volume>9</volume>:<fpage>eaaf5347</fpage>.<pub-id pub-id-type="pmid">28275152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aaf5347</pub-id><pub-id pub-id-type="pmcid">PMC5573155</pub-id></mixed-citation></ref><ref id="bib326"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Burtnick</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Stokes</surname><given-names>MGM</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Burkholderia pseudomallei</italic> capsular polysaccharide conjugates provide protection against acute melioidosis</article-title>. <source>Infect Immun</source><year>2014</year>;<volume>82</volume>:<fpage>3206</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">24866807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.01847-14</pub-id><pub-id pub-id-type="pmcid">PMC4136211</pub-id></mixed-citation></ref><ref id="bib327"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Christ</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>George</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Protection against experimental melioidosis with a synthetic manno -Heptopyranose hexasaccharide glycoconjugate</article-title>. <source>Bioconjugate Chem</source><year>2016</year>;<volume>27</volume>:<fpage>1435</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.bioconjchem.5b00525</pub-id><pub-id pub-id-type="pmcid">PMC4911622</pub-id><pub-id pub-id-type="pmid">27124182</pub-id></mixed-citation></ref><ref id="bib328"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seeberger</surname><given-names>PH</given-names></name></person-group><article-title>The logic of automated glycan assembly</article-title>. <source>Acc Chem Res</source><year>2015</year>;<volume>48</volume>:<fpage>1450</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">25871824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ar5004362</pub-id></mixed-citation></ref><ref id="bib329"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seeberger</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Pereira</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>N</given-names></name><etal/></person-group><article-title>A semi-synthetic glycoconjugate vaccine candidate for carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>Angew Chem Int Ed</source><year>2017</year>;<volume>56</volume>:<fpage>13973</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201700964</pub-id><pub-id pub-id-type="pmcid">PMC5819008</pub-id><pub-id pub-id-type="pmid">28815890</pub-id></mixed-citation></ref><ref id="bib330"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sethi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>TF</given-names></name></person-group><article-title>Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review</article-title>. <source>Clin Microbiol Rev</source><year>2001</year>;<volume>14</volume>:<fpage>336</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">11292642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.14.2.336-363.2001</pub-id><pub-id pub-id-type="pmcid">PMC88978</pub-id></mixed-citation></ref><ref id="bib331"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sewell</surname><given-names>EW</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>ED</given-names></name></person-group><article-title>Taking aim at wall teichoic acid synthesis: new biology and new leads for antibiotics</article-title>. <source>J Antibiot</source><year>2014</year>;<volume>67</volume>:<fpage>43</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">24169797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ja.2013.100</pub-id></mixed-citation></ref><ref id="bib332"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Krause</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Worgall</surname><given-names>S</given-names></name></person-group><article-title>Recent developments for <italic toggle="yes">Pseudomonas</italic> vaccines</article-title>. <source>Hum Vaccines</source><year>2011</year>;<volume>7</volume>:<fpage>999</fpage>&#8211;<lpage>1011</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.7.10.16369</pub-id><pub-id pub-id-type="pmcid">PMC3360073</pub-id><pub-id pub-id-type="pmid">21941090</pub-id></mixed-citation></ref><ref id="bib333"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Patil</surname><given-names>VD</given-names></name>, <name name-style="western"><surname>Lalwani</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and <italic toggle="yes">Haemophilus influenzae</italic> type b vaccine manufactured using small and large scale manufacturing process</article-title>. <source>Vaccine</source><year>2012</year>;<volume>30</volume>:<fpage>510</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">22119927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.11.067</pub-id></mixed-citation></ref><ref id="bib334"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shibata</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tojo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Characterization of phosphomannan-protein complexes isolated from viable cells of yeast and mycelial forms of <italic toggle="yes">Candida albicans</italic> NIH B-792 strain by the action of Zymolyase-100T</article-title>. <source>Arch Biochem Biophys</source><year>1986</year>;<volume>251</volume>:<fpage>697</fpage>&#8211;<lpage>708</lpage>.<pub-id pub-id-type="pmid">3541789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0003-9861(86)90379-6</pub-id></mixed-citation></ref><ref id="bib335"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shikhman</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Greenspan</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Cunningham</surname><given-names>MW</given-names></name></person-group><article-title>A subset of mouse monoclonal antibodies cross-reactive with cytoskeletal proteins and group A streptococcal M proteins recognizes N-acetyl-beta-D-glucosamine</article-title>. <source>J Immunol</source><year>1993</year>;<volume>153</volume>:<fpage>3902</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">7690820</pub-id></mixed-citation></ref><ref id="bib336"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silhavy</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Kahne</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>S</given-names></name></person-group><article-title>The bacterial cell envelope</article-title>. <source>Cold Spring Harb Persp Biol</source><year>2010</year>;<volume>2</volume>:<fpage>a000414</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a000414</pub-id><pub-id pub-id-type="pmcid">PMC2857177</pub-id><pub-id pub-id-type="pmid">20452953</pub-id></mixed-citation></ref><ref id="bib337"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>EB</given-names></name>, <name name-style="western"><surname>Dow</surname><given-names>SW</given-names></name></person-group><article-title>Development of <italic toggle="yes">Burkholderia mallei</italic> and pseudomallei vaccines</article-title>. <source>Front Cell Infect Microbiol</source><year>2013</year>;<volume>3</volume>:<fpage>10</fpage>.<pub-id pub-id-type="pmid">23508691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2013.00010</pub-id><pub-id pub-id-type="pmcid">PMC3598006</pub-id></mixed-citation></ref><ref id="bib338"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cross</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tennant</surname><given-names>S</given-names></name></person-group><article-title>Broad spectrum conjugate vaccine to prevent <italic toggle="yes">Klebsiella pneumoniae</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic> infections</article-title>. <year>2016</year><comment>WO 2016044773 A1</comment>.</mixed-citation></ref><ref id="bib339"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skaare</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Anthonisen</surname><given-names>IL</given-names></name>, <name name-style="western"><surname>Kahlmeter</surname><given-names>G</given-names></name><etal/></person-group><article-title>Emergence of clonally related multidrug resistant <italic toggle="yes">Haemophilus influenzae</italic> with penicillin-binding protein 3-mediated resistance to extended-spectrum cephalosporins, Norway, 2006 to 2013</article-title>. <source>Euro Surveill</source><year>2014</year>;<volume>18</volume>:<fpage>20986</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.es2014.19.49.20986</pub-id><pub-id pub-id-type="pmid">25523969</pub-id></mixed-citation></ref><ref id="bib340"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smoot</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Demchenko</surname><given-names>AV</given-names></name></person-group><article-title>Chapter 5 Oligosaccharide synthesis: from conventional methods to modern expeditious strategies</article-title>. <source>Adv Carbohyd Chem Bi</source><year>2009</year>;<volume>62</volume>:<fpage>161</fpage>&#8211;<lpage>250</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0065-2318(09)00005-5</pub-id><pub-id pub-id-type="pmid">19501706</pub-id></mixed-citation></ref><ref id="bib341"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soliman</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Kovac</surname><given-names>P</given-names></name></person-group><article-title>Total synthesis of the complete protective antigen of <italic toggle="yes">Vibrio cholerae</italic> O139</article-title>. <source>Angew Chem Int Ed</source><year>2016</year>;<volume>55</volume>:<fpage>12850</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201606116</pub-id><pub-id pub-id-type="pmcid">PMC5165651</pub-id><pub-id pub-id-type="pmid">27623688</pub-id></mixed-citation></ref><ref id="bib342"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soriano</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Lamprecht</surname><given-names>B</given-names></name></person-group><article-title>Chronic obstructive pulmonary disease</article-title>. <source>Med Clin N Am</source><year>2012</year>;<volume>96</volume>:<fpage>671</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">22793937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcna.2012.02.005</pub-id></mixed-citation></ref><ref id="bib343"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spellberg</surname><given-names>B</given-names></name></person-group><article-title>Vaccines for invasive fungal infections</article-title>. <source>F1000 Med Rep</source><year>2011</year>;<volume>3</volume>:<fpage>13</fpage>.<pub-id pub-id-type="pmid">21876719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3410/M3-13</pub-id><pub-id pub-id-type="pmcid">PMC3155210</pub-id></mixed-citation></ref><ref id="bib344"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefanetti</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Q-Y</given-names></name>, <name name-style="western"><surname>Usera</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sugar-protein connectivity impacts on the immunogenicity of site-selective salmonella O-Antigen glycoconjugate vaccines</article-title>. <source>Angew Chem Int Ed</source><year>2015</year>;<volume>54</volume>:<fpage>13198</fpage>&#8211;<lpage>203</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201506112</pub-id><pub-id pub-id-type="pmcid">PMC4648054</pub-id><pub-id pub-id-type="pmid">26350581</pub-id></mixed-citation></ref><ref id="bib345"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Struve</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Roe</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Stegger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mapping the evolution of hypervirulent <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>mBio</source><year>2015</year>;<volume>6</volume>:<fpage>e00630</fpage>.<pub-id pub-id-type="pmid">26199326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00630-15</pub-id><pub-id pub-id-type="pmcid">PMC4513082</pub-id></mixed-citation></ref><ref id="bib346"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suetens</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hopkins</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kolman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Point prevalence survey of healthcare associated infections and antimicrobial use in European acute care hospitals</article-title>. <source>EDCPC</source><year>2013</year>, doi: <pub-id pub-id-type="doi">10.2900/86011</pub-id>.</mixed-citation></ref><ref id="bib347"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Biological activities of antibodies elicited by lipooligosaccharide based-conjugate vaccines of nontypeable <italic toggle="yes">Haemophilus influenzae</italic> in an otitis media model</article-title>. <source>Vaccine</source><year>2000</year>;<volume>18</volume>:<fpage>1264</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">10649628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(99)00381-3</pub-id></mixed-citation></ref><ref id="bib348"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szij&#225;rt&#243;</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Guachalla</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Hartl</surname><given-names>K</given-names></name><etal/></person-group><article-title>Both clades of the epidemic KPC-producing <italic toggle="yes">Klebsiella pneumoniae</italic> clone ST258 share a modified galactan O-antigen type</article-title>. <source>Int J Med Microbiol</source><year>2016</year>;<volume>306</volume>:<fpage>89</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">26723873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijmm.2015.12.002</pub-id></mixed-citation></ref><ref id="bib350"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talbot</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Bradley</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>JEJ</given-names></name><etal/></person-group><article-title>Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America</article-title>. <source>Clin Infect Dis</source><year>2006</year>;<volume>42</volume>:<fpage>657</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">16447111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/499819</pub-id></mixed-citation></ref><ref id="bib351"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thanawastien</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cartee</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Griffin</surname><given-names>TJIV</given-names></name><etal/></person-group><article-title>Conjugate-like immunogens produced as protein capsular matrix vaccines</article-title>. <source>Proc Natl Acad Sci USA</source><year>2015</year>;<volume>112</volume>:<fpage>E1143</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">25699685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1425005112</pub-id><pub-id pub-id-type="pmcid">PMC4364189</pub-id></mixed-citation></ref><ref id="bib352"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theilacker</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Coleman</surname><given-names>FT</given-names></name>, <name name-style="western"><surname>Mueschenborn</surname><given-names>S</given-names></name><etal/></person-group><article-title>Construction and characterization of a <italic toggle="yes">Pseudomonas aeruginosa</italic> mucoid exopolysaccharide-alginate conjugate vaccine</article-title>. <source>Infect Immun</source><year>2003</year>;<volume>71</volume>:<fpage>3875</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">12819072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.71.7.3875-3884.2003</pub-id><pub-id pub-id-type="pmcid">PMC162014</pub-id></mixed-citation></ref><ref id="bib353"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theilacker</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kaczynski</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Kropec</surname><given-names>A</given-names></name><etal/></person-group><article-title>Opsonic antibodies to <italic toggle="yes">Enterococcus faecalis</italic> strain 12030 are directed against lipoteichoic acid</article-title>. <source>Infect Immun</source><year>2006</year>;<volume>74</volume>:<fpage>5703</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">16988246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00570-06</pub-id><pub-id pub-id-type="pmcid">PMC1594888</pub-id></mixed-citation></ref><ref id="bib354"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theilacker</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Krueger</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Kropec</surname><given-names>A</given-names></name><etal/></person-group><article-title>Rationale for the development of immunotherapy regimens against enterococcal infections</article-title>. <source>Vaccine</source><year>2004</year>;<volume>22</volume>:<fpage>S31</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15576199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2004.08.014</pub-id></mixed-citation></ref><ref id="bib355"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thurlow</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>VC</given-names></name>, <name name-style="western"><surname>Fleming</surname><given-names>SD</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Enterococcus faecalis</italic> capsular polysaccharide serotypes C and D and their contributions to host innate immune evasion</article-title>. <source>Infect Immun</source><year>2009</year>;<volume>77</volume>:<fpage>5551</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">19805541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00576-09</pub-id><pub-id pub-id-type="pmcid">PMC2786471</pub-id></mixed-citation></ref><ref id="bib356"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiwary</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pathak</surname><given-names>RK</given-names></name><etal/></person-group><article-title>The Locus PgaABCD of <italic toggle="yes">Acinetobacter junii</italic> putatively responsible for poly-(1,6)-acetylglucosamine biosynthesis might be related to biofilm formation: a computational analysis</article-title>. <source>AiM</source><year>2016</year>;<volume>6</volume>:<fpage>222</fpage>&#8211;<lpage>32</lpage>.</mixed-citation></ref><ref id="bib357"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tom&#225;s</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Camprubi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Merino</surname><given-names>S</given-names></name><etal/></person-group><article-title>Surface exposure of O1 serotype lipopolysaccharide in <italic toggle="yes">Klebsiella pneumoniae</italic> strains expressing different K antigens</article-title>. <source>Infect Immun</source><year>1991</year>;<volume>59</volume>:<fpage>2006</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">1709919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.59.6.2006-2011.1991</pub-id><pub-id pub-id-type="pmcid">PMC257957</pub-id></mixed-citation></ref><ref id="bib358"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torosantucci</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bromuro</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chiani</surname><given-names>P</given-names></name><etal/></person-group><article-title>A novel glyco-conjugate vaccine against fungal pathogens</article-title>. <source>J Exp Med</source><year>2005</year>;<volume>202</volume>:<fpage>597</fpage>&#8211;<lpage>606</lpage>.<pub-id pub-id-type="pmid">16147975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20050749</pub-id><pub-id pub-id-type="pmcid">PMC2212864</pub-id></mixed-citation></ref><ref id="bib358a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trevi&#241;o</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Permenter</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>England</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Monoclonal antibodies passively protect BALB/c mice against Burkholderia mallei aerosol challenge</article-title>. <source>Infect Immun</source><year>2006</year>;<volume>74</volume>:<fpage>1958</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">16495574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.74.3.1958-1961.2006</pub-id><pub-id pub-id-type="pmcid">PMC1418687</pub-id></mixed-citation></ref><ref id="bib359"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>AEB</given-names></name>, <name name-style="western"><surname>Gerson</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>So</surname><given-names>HY</given-names></name><etal/></person-group><article-title>Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for <italic toggle="yes">S. pneumoniae</italic></article-title>. <source>Synth Syst Biotechnol</source><year>2017</year>;<volume>2</volume>:<fpage>49</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">29062961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.synbio.2016.12.002</pub-id><pub-id pub-id-type="pmcid">PMC5625727</pub-id></mixed-citation></ref><ref id="bib360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulanova</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tsang</surname><given-names>RSW</given-names></name></person-group><article-title>Haemophilus influenzae serotype a as a cause of serious invasive infections</article-title>. <source>Lancet Infect Dis</source><year>2014</year>;<volume>14</volume>:<fpage>70</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">24268829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(13)70170-1</pub-id></mixed-citation></ref><ref id="bib361"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulu-Kilic</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Doganay</surname><given-names>M</given-names></name></person-group><article-title>An overview: tularemia and travel medicine</article-title>. <source>Travel Med Infect Dis</source><year>2014</year>;<volume>12</volume>:<fpage>609</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">25457302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tmaid.2014.10.007</pub-id></mixed-citation></ref><ref id="bib362"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unemo</surname><given-names>M</given-names></name></person-group><article-title>Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving <italic toggle="yes">Neisseria gonorrhoeae</italic> continues to challenge</article-title>. <source>BMC Infect Dis</source><year>2015</year>;<volume>15</volume>:<fpage>364</fpage>.<pub-id pub-id-type="pmid">26293005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12879-015-1029-2</pub-id><pub-id pub-id-type="pmcid">PMC4546108</pub-id></mixed-citation></ref><ref id="bib363"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valguarnera</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Feldman</surname><given-names>MF</given-names></name></person-group><article-title>Glycoengineered outer membrane vesicles as a platform for vaccine development</article-title>. <source>Methods Enzymol</source><year>2017</year>;<volume>597</volume>:<fpage>285</fpage>&#8211;<lpage>310</lpage>.<pub-id pub-id-type="pmid">28935107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.mie.2017.06.032</pub-id></mixed-citation></ref><ref id="bib364"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Dobbelsteen</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Fae</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of a tetravalent <italic toggle="yes">E. coli</italic> O-antigen bioconjugate vaccine in animal models</article-title>. <source>Vaccine</source><year>2016</year>;<volume>34</volume>:<fpage>4152</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">27395567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.06.067</pub-id></mixed-citation></ref><ref id="bib365"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Put</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Guerreiro</surname><given-names>C</given-names></name><etal/></person-group><article-title>A synthetic carbohydrate conjugate vaccine candidate against Shigellosis: improved bioconjugation and impact of Alum on immunogenicity</article-title>. <source>Bioconjugate Chem</source><year>2016</year>;<volume>27</volume>:<fpage>883</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.bioconjchem.5b00617</pub-id><pub-id pub-id-type="pmid">26918643</pub-id></mixed-citation></ref><ref id="bib366"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Sorge</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Cole</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Kuipers</surname><given-names>K</given-names></name><etal/></person-group><article-title>The classical Lancefield antigen of group a <italic toggle="yes">Streptococcus</italic> is a virulence determinant with implications for vaccine design</article-title>. <source>Cell Host Microbe</source><year>2014</year>;<volume>15</volume>:<fpage>729</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">24922575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2014.05.009</pub-id><pub-id pub-id-type="pmcid">PMC4078075</pub-id></mixed-citation></ref><ref id="bib367"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaneechoutte</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Verschraegen</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Claeys</surname><given-names>G</given-names></name><etal/></person-group><article-title>Serological typing of <italic toggle="yes">Branhamella catarrhalis</italic> strains on the basis of lipopolysaccharide antigens</article-title>. <source>J Clin Microbiol</source><year>1990</year>;<volume>28</volume>:<fpage>182</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">2107197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jcm.28.2.182-187.1990</pub-id><pub-id pub-id-type="pmcid">PMC269572</pub-id></mixed-citation></ref><ref id="bib368"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vecchiarelli</surname><given-names>A</given-names></name></person-group><article-title>Immunoregulation by capsular components of <italic toggle="yes">Cryptococcus neoformans</italic></article-title>. <source>Med Mycol</source><year>2000</year>;<volume>38</volume>:<fpage>407</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">11204878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/mmy.38.6.407.417</pub-id></mixed-citation></ref><ref id="bib369"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veesenmeyer</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Hauser</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Lisboa</surname><given-names>T</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Pseudomonas aeruginosa</italic> virulence and therapy: evolving translational strategies</article-title>. <source>Crit Care Med</source><year>2009</year>;<volume>37</volume>:<fpage>1777</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">19325463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0b013e31819ff137</pub-id><pub-id pub-id-type="pmcid">PMC2749241</pub-id></mixed-citation></ref><ref id="bib370"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vella</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pace</surname><given-names>D</given-names></name></person-group><article-title>Glycoconjugate vaccines: an update</article-title>. <source>Expert Opin Biol Th</source><year>2015</year>;<volume>15</volume>:<fpage>529</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2015.993375</pub-id><pub-id pub-id-type="pmid">25496172</pub-id></mixed-citation></ref><ref id="bib371"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verduin</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Hol</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fleer</surname><given-names>A</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Moraxella catarrhalis</italic>: from emerging to established pathogen</article-title>. <source>Clin Microbiol Rev</source><year>2002</year>;<volume>15</volume>:<fpage>125</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">11781271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.15.1.125-144.2002</pub-id><pub-id pub-id-type="pmcid">PMC118065</pub-id></mixed-citation></ref><ref id="bib372"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verez-Bencomo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Fernandez-Santana</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Hardy</surname><given-names>E</given-names></name><etal/></person-group><article-title>A synthetic conjugate polysaccharide vaccine against <italic toggle="yes">Haemophilus influenzae</italic> type b</article-title>. <source>Science</source><year>2004</year>;<volume>305</volume>:<fpage>522</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">15273395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1095209</pub-id></mixed-citation></ref><ref id="bib373"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vignal</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Guerardel</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kremer</surname><given-names>L</given-names></name><etal/></person-group><article-title>Lipomannans, but not lipoarabinomannans, purified from <italic toggle="yes">Mycobacterium chelonae</italic> and <italic toggle="yes">Mycobacterium kansasii</italic> induce TNF- and IL-8 secretion by a CD14-toll-like receptor 2-dependent mechanism</article-title>. <source>J Immunol</source><year>2003</year>;<volume>171</volume>:<fpage>2014</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">12902506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.171.4.2014</pub-id></mixed-citation></ref><ref id="bib374"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinogradov</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Frirdich</surname><given-names>E</given-names></name>, <name name-style="western"><surname>MacLean</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Structures of lipopolysaccharides from <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>J Biol Chem</source><year>2002</year>;<volume>277</volume>:<fpage>25070</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">11986326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M202683200</pub-id></mixed-citation></ref><ref id="bib375"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinogradov</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sadovskaya</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Structural elucidation of the extracellular and cell-wall teichoic acids of <italic toggle="yes">Staphylococcus aureus</italic> MN8m, a biofilm forming strain</article-title>. <source>Carbohydr Res</source><year>2006</year>;<volume>341</volume>:<fpage>738</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">16458275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2006.01.012</pub-id></mixed-citation></ref><ref id="bib376"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinogradov</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>Shashkov</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Knirel</surname><given-names>YA</given-names></name><etal/></person-group><article-title>Structure of the O-antigen of <italic toggle="yes">Francisella tularensis</italic> strain 15</article-title>. <source>Carbohydr Res</source><year>1991</year>;<volume>214</volume>:<fpage>289</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">1769021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0008-6215(91)80036-m</pub-id></mixed-citation></ref><ref id="bib377"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vollmer</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Blanot</surname><given-names>D</given-names></name>, <name name-style="western"><surname>de Pedro</surname><given-names>MA</given-names></name></person-group><article-title>Peptidoglycan structure and architecture</article-title>. <source>FEMS Microbiol Rev</source><year>2008</year>;<volume>32</volume>:<fpage>149</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">18194336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-6976.2007.00094.x</pub-id></mixed-citation></ref><ref id="bib378"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vulliez-Le Normand</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Saul</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Phalipon</surname><given-names>A</given-names></name><etal/></person-group><article-title>Structures of synthetic O-antigen fragments from serotype 2a <italic toggle="yes">Shigella flexneri</italic> in complex with a protective monoclonal antibody</article-title>. <source>Proc Natl Acad Sci USA</source><year>2008</year>;<volume>105</volume>:<fpage>9976</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">18621718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0801711105</pub-id><pub-id pub-id-type="pmcid">PMC2481361</pub-id></mixed-citation></ref><ref id="bib379"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wacker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Feldman</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Callewaert</surname><given-names>N</given-names></name><etal/></person-group><article-title>Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems</article-title>. <source>Proc Natl Acad Sci USA</source><year>2006</year>;<volume>103</volume>:<fpage>7088</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">16641107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0509207103</pub-id><pub-id pub-id-type="pmcid">PMC1459022</pub-id></mixed-citation></ref><ref id="bib380"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wacker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Linton</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hitchen</surname><given-names>PG</given-names></name><etal/></person-group><article-title>N-linked glycosylation in <italic toggle="yes">Campylobacter jejuni</italic> and its functional transfer into <italic toggle="yes">E. coli</italic></article-title>. <source>Science</source><year>2002</year>;<volume>298</volume>:<fpage>1790</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">12459590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.298.5599.1790</pub-id></mixed-citation></ref><ref id="bib381"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wacker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kowarik</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevention of <italic toggle="yes">Staphylococcus aureus</italic> infections by glycoprotein vaccines synthesized in <italic toggle="yes">Escherichia coli</italic></article-title>. <source>J Infect Dis</source><year>2014</year>;<volume>209</volume>:<fpage>1551</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">24308931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jit800</pub-id><pub-id pub-id-type="pmcid">PMC3997581</pub-id></mixed-citation></ref><ref id="bib382"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wade</surname><given-names>TK</given-names></name>, <name name-style="western"><surname>Saksena</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Shiloach</surname><given-names>J</given-names></name><etal/></person-group><article-title>Immunogenicity of synthetic saccharide fragments of <italic toggle="yes">Vibrio cholerae</italic> O1 (Ogawa and Inaba) bound to Exotoxin A</article-title>. <source>FEMS Immunol Med Micr</source><year>2006</year>;<volume>48</volume>:<fpage>237</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-695X.2006.00143.x</pub-id><pub-id pub-id-type="pmid">17010106</pub-id></mixed-citation></ref><ref id="bib383"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Preston</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Romeo</surname><given-names>T</given-names></name></person-group><article-title>The pgaABCD locus of <italic toggle="yes">Escherichia coli</italic> promotes the synthesis of a polysaccharide adhesin required for biofilm formation</article-title>. <source>J Bacteriol</source><year>2004</year>;<volume>186</volume>:<fpage>2724</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">15090514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JB.186.9.2724-2734.2004</pub-id><pub-id pub-id-type="pmcid">PMC387819</pub-id></mixed-citation></ref><ref id="bib384"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Huebner</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tzianabos</surname><given-names>AO</given-names></name><etal/></person-group><article-title>Structure of an antigenic teichoic acid shared by clinical isolates of <italic toggle="yes">Enterococcus faecalis</italic> and vancomycin-resistant <italic toggle="yes">Enterococcus faecium</italic></article-title>. <source>Carbohydr Res</source><year>1999</year>;<volume>316</volume>:<fpage>155</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">10420594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0008-6215(99)00046-4</pub-id></mixed-citation></ref><ref id="bib385"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Chinoy</surname><given-names>ZS</given-names></name>, <name name-style="western"><surname>Ambre</surname><given-names>SG</given-names></name><etal/></person-group><article-title>A general strategy for the chemoenzymatic synthesis of asymmetrically branched N-glycans</article-title>. <source>Science</source><year>2013</year>;<volume>341</volume>:<fpage>379</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">23888036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1236231</pub-id><pub-id pub-id-type="pmcid">PMC3826785</pub-id></mixed-citation></ref><ref id="bib386"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warny</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pepin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Toxin production by an emerging strain of <italic toggle="yes">Clostridium difficile</italic> associated with outbreaks of severe disease in North America and Europe</article-title>. <source>Lancet</source><year>2005</year>;<volume>366</volume>:<fpage>1079</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">16182895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(05)67420-X</pub-id></mixed-citation></ref><ref id="bib387"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Whitters</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sevastsyanovich</surname><given-names>YR</given-names></name><etal/></person-group><article-title>Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing</article-title>. <source>J Exp Med</source><year>2014</year>;<volume>211</volume>:<fpage>1893</fpage>&#8211;<lpage>904</lpage>.<pub-id pub-id-type="pmid">25113975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20132444</pub-id><pub-id pub-id-type="pmcid">PMC4144740</pub-id></mixed-citation></ref><ref id="bib388"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werz</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Ranzinger</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Herget</surname><given-names>S</given-names></name><etal/></person-group><article-title>Exploring the structural diversity of mammalian carbohydrates (&#8220;Glycospace&#8221;) by statistical databank analysis</article-title>. <source>ACS Chem Biol</source><year>2007</year>;<volume>2</volume>:<fpage>685</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">18041818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/cb700178s</pub-id></mixed-citation></ref><ref id="bib389"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetter</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Goulding</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pickard</surname><given-names>D</given-names></name><etal/></person-group><article-title>Molecular characterization of the viaB locus encoding the biosynthetic machinery for Vi capsule formation in <italic toggle="yes">Salmonella</italic> Typhi</article-title>. <source>PLoS One</source><year>2012</year>;<volume>7</volume>:<fpage>e45609</fpage>.<pub-id pub-id-type="pmid">23029132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0045609</pub-id><pub-id pub-id-type="pmcid">PMC3448643</pub-id></mixed-citation></ref><ref id="bib390"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetter</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kowarik</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Steffen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Engineering, conjugation, and immunogenicity assessment of <italic toggle="yes">Escherichia coli</italic> O121 O antigen for its potential use as a typhoid vaccine component</article-title>. <source>Glycoconj J</source><year>2013</year>;<volume>30</volume>:<fpage>511</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">23053636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10719-012-9451-9</pub-id></mixed-citation></ref><ref id="bib391"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitfield</surname><given-names>C</given-names></name></person-group><article-title>Biosynthesis and assembly of capsular polysaccharides in <italic toggle="yes">Escherichia coli</italic></article-title>. <source>Annu Rev Biochem</source><year>2006</year>;<volume>75</volume>:<fpage>39</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">16756484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.biochem.75.103004.142545</pub-id></mixed-citation></ref><ref id="bib392"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitfield</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Perry</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Maclean</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Structural analysis of the O-antigen side chain polysaccharides in the lipopolysaccharides of <italic toggle="yes">Klebsiella</italic> serotypes O2(2a), O2(2a,2b), and O2(2a,2c)</article-title>. <source>Infect Immun</source><year>1992</year>;<volume>174</volume>:<fpage>4913</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jb.174.15.4913-4919.1992</pub-id><pub-id pub-id-type="pmcid">PMC206303</pub-id><pub-id pub-id-type="pmid">1378428</pub-id></mixed-citation></ref><ref id="bib393"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitfield</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Perry</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Expression of two structurally distinct D-galactan O antigens in the lipopolysaccharide of <italic toggle="yes">Klebsiella pneumoniae</italic> serotype O1</article-title>. <source>Infect Immun</source><year>1991</year>;<volume>173</volume>:<fpage>1420</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jb.173.4.1420-1431.1991</pub-id><pub-id pub-id-type="pmcid">PMC207279</pub-id><pub-id pub-id-type="pmid">1704883</pub-id></mixed-citation></ref><ref id="bib394"><mixed-citation publication-type="journal"><collab>WHO Cholera vaccines: WHO position paper</collab>. <article-title>Weekly epidemiological record</article-title>. <source>Relev&#233; &#233;pid&#233;miologique hebdomadaire</source><year>2010</year>;<volume>85</volume>:<fpage>117</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">20349546</pub-id></mixed-citation></ref><ref id="bib395"><mixed-citation publication-type="journal"><collab>WHO</collab>. <source>Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria Gonorrhoeae, on World Health Organization (WHO)</source>, <year>2012</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/">http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/</ext-link> (last accessed 7 March 2014)</comment>.</mixed-citation></ref><ref id="bib396"><mixed-citation publication-type="other"><collab>WHO</collab><source>Global Priority List of Antibiotic-Resistant Bacteria to Giude Research, Dicovery, and Development of New Antibiotics</source>. <year>2017</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf">http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf</ext-link> (26 March 2018, date last accessed)</comment>.</mixed-citation></ref><ref id="bib397"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willis</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Stupak</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>M</given-names></name><etal/></person-group><article-title>Conserved glycolipid termini in capsular polysaccharides synthesized by ATP-binding cassette transporter-dependent pathways in Gram-negative pathogens</article-title>. <source>Proc Natl Acad Sci USA</source><year>2013</year>;<volume>110</volume>:<fpage>7868</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">23610430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1222317110</pub-id><pub-id pub-id-type="pmcid">PMC3651472</pub-id></mixed-citation></ref><ref id="bib398"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willis</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Whitfield</surname><given-names>C</given-names></name></person-group><article-title>Structure, biosynthesis, and function of bacterial capsular polysaccharides synthesized by ABC transporter-dependent pathways</article-title>. <source>Carbohydr Res</source><year>2013</year>;<volume>378</volume>:<fpage>35</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">23746650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2013.05.007</pub-id></mixed-citation></ref><ref id="bib399"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Reyes</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Stolpman</surname><given-names>M</given-names></name><etal/></person-group><article-title>The direct cost and incidence of systemic fungal infections</article-title>. <source>Value Health</source><year>2002</year>;<volume>5</volume>:<fpage>26</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">11873380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1524-4733.2002.51108.x</pub-id></mixed-citation></ref><ref id="bib400"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Investigation of nontypeable <italic toggle="yes">Haemophilus influenzae</italic> outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines</article-title>. <source>Vaccine</source><year>2005</year>;<volume>23</volume>:<fpage>5177</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">16039021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2005.06.014</pub-id></mixed-citation></ref><ref id="bib401"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xiong</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Total synthesis of mycobacterial arabinogalactan containing 92 monosaccharide units</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>14851</fpage>.<pub-id pub-id-type="pmid">28300074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms14851</pub-id><pub-id pub-id-type="pmcid">PMC5357306</pub-id></mixed-citation></ref><ref id="bib402"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kohler</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Peschel</surname><given-names>A</given-names></name></person-group><article-title>The wall teichoic acid and lipoteichoic acid polymers of <italic toggle="yes">Staphylococcus aureus</italic></article-title>. <source>Int J Med Microbiol</source><year>2010</year>;<volume>300</volume>:<fpage>148</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">19896895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijmm.2009.10.001</pub-id></mixed-citation></ref><ref id="bib403"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Mueller</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Emergence of serogroup X meningococcal disease in Africa: need for a vaccine</article-title>. <source>Vaccine</source><year>2013</year>;<volume>31</volume>:<fpage>2852</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">23623866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.04.036</pub-id></mixed-citation></ref><ref id="bib404"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xin</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Dziadek</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bundle</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis</article-title>. <source>Proc Natl Acad Sci USA</source><year>2008</year>;<volume>105</volume>:<fpage>13526</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">18725625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0803195105</pub-id><pub-id pub-id-type="pmcid">PMC2533223</pub-id></mixed-citation></ref><ref id="bib405"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamasaki</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Yabe</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Kataoka</surname><given-names>C</given-names></name><etal/></person-group><article-title>The oligosaccharide of gonococcal lipooligosaccharide contains several epitopes that are recognized by human antibodies</article-title>. <source>Infect Immun</source><year>2010</year>;<volume>78</volume>:<fpage>3247</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">20479085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.01445-09</pub-id><pub-id pub-id-type="pmcid">PMC2897362</pub-id></mixed-citation></ref><ref id="bib406"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yother</surname><given-names>J</given-names></name></person-group><article-title>Capsules of <italic toggle="yes">Streptococcus pneumoniae</italic> and other bacteria: paradigms for polysaccharide biosynthesis and regulation</article-title>. <source>Annu Rev Microbiol</source><year>2011</year>;<volume>65</volume>:<fpage>563</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">21721938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.micro.62.081307.162944</pub-id></mixed-citation></ref><ref id="bib407"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Meyer</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>D</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> vaccine in cancer patients</article-title>. <source>Ann Intern Med</source><year>1973</year>;<volume>79</volume>:<fpage>518</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">4201225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-79-4-518</pub-id></mixed-citation></ref><ref id="bib408"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>XX</given-names></name></person-group><article-title>Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B <italic toggle="yes">Moraxella catarrhalis</italic></article-title>. <source>Infect Immun</source><year>2005</year>;<volume>73</volume>:<fpage>2790</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15845482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.73.5.2790-2796.2005</pub-id><pub-id pub-id-type="pmcid">PMC1087343</pub-id></mixed-citation></ref><ref id="bib409"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>XX</given-names></name></person-group><article-title>Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C <italic toggle="yes">Moraxella catarrhalis</italic></article-title>. <source>Infect Immun</source><year>2007</year>;<volume>75</volume>:<fpage>2974</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">17371852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.01915-06</pub-id><pub-id pub-id-type="pmcid">PMC1932890</pub-id></mixed-citation></ref><ref id="bib410"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahringer</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Lindner</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Inamura</surname><given-names>S</given-names></name><etal/></person-group><article-title>TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity</article-title>. <source>Immunobiology</source><year>2008</year>;<volume>213</volume>:<fpage>205</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">18406368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imbio.2008.02.005</pub-id></mixed-citation></ref><ref id="bib411"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarei</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Almehdar</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Redwan</surname><given-names>EM</given-names></name></person-group><article-title>Hib vaccines: past, present, and future perspectives</article-title>. <source>J Immunol Res</source><year>2016</year>;<volume>2016</volume>;<fpage>1</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/7203587</pub-id><pub-id pub-id-type="pmcid">PMC4745871</pub-id><pub-id pub-id-type="pmid">26904695</pub-id></mixed-citation></ref><ref id="bib411a"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>Y-J</given-names></name>, <name name-style="western"><surname>Malley</surname><given-names>R</given-names></name></person-group><article-title>Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity</article-title>. <source>Proc Natl Acad Sci USA</source><year>2013</year>;<volume>113</volume>:<fpage>13564</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1307228110</pub-id><pub-id pub-id-type="pmcid">PMC3746895</pub-id><pub-id pub-id-type="pmid">23898212</pub-id></mixed-citation></ref><ref id="bib412"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zilberberg</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Shorr</surname><given-names>AF</given-names></name></person-group><article-title>Secular trends in Gram-Negative resistance among urinary tract infection hospitalizations in the United States, 2000&#8211;2009</article-title>. <source>Infect Control Hosp Epidemiol</source><year>2013</year>;<volume>34</volume>:<fpage>940</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">23917908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/671740</pub-id></mixed-citation></ref><ref id="bib413"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jennings</surname><given-names>HJ</given-names></name></person-group><article-title>Preparation of glycoconjugate vaccines</article-title>. In: <source>Carbohydrate-Based Vaccines and Immunotherapies</source>. <person-group person-group-type="editor"><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Boons</surname><given-names>G-J</given-names></name></person-group> (eds.) <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>John Wiley &amp; Sons, Inc</publisher-name>, <year>2009</year>, <fpage>55</fpage>&#8211;<lpage>88</lpage>.</mixed-citation></ref><ref id="bib414"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuercher</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Horn</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Que</surname><given-names>JU</given-names></name><etal/></person-group><article-title>Antibody responses induced by long-term vaccination with an octovalent conjugate <italic toggle="yes">Pseudomonas aeruginosa</italic> vaccine in children with cystic fibrosis</article-title>. <source>FEMS Immunol Med Micr</source><year>2006</year>;<volume>47</volume>:<fpage>302</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-695X.2006.00103.x</pub-id><pub-id pub-id-type="pmid">16831219</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>